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Summary	
The	 Epstein-Barr	 virus	 (EBV)	 is	 a	 γ-herpesvirus	 that	 establishes	 lifelong	 infection	 in	 the	
majority	of	the	human	population.	Whilst	EBV	infection	is	asymptomatic	in	most	cases,	the	
global	 disease	 burden	 of	 EBV	 is	 substantial.	 EBV	 is	 the	 primary	 cause	 of	 infectious	
mononucleosis	 and	 approximately	 200,000	 cases	 of	 EBV-associated	 malignancies	 are	
annually	 diagnosed.	 EBV	 has	 multifaceted	 life	 cycle	 that	 comprises	 lytic	 replication	 and	
latency,	 with	 the	 establishment	 of	 latency	 enabling	 lifelong	 EBV	 carriage.	 The	majority	 of	
EBV	vaccine	candidates	have	previously	focused	on	the	major	glycoprotein	gp350.	However,	
the	interrogation	of	a	gp350	vaccine	in	a	phase	II	clinical	trial	showed	that	it	was	unable	to	
prevent	 EBV	 infection.	 Our	 laboratory	 has	 recently	 developed	 a	 vaccine	 candidate	 in	 the	
form	of	defective	EBV	particles.	These	defective	particles	lack	viral	DNA,	are	non-infectious	
and	 are	 composed	of	 several	 dozen	 EBV	 lytic	 proteins.	 In	 the	 present	work,	 the	 antigenic	
spectrum	 of	 defective	 EBV	 particles	 was	 enlarged	 to	 include	 immunodominant	 latent	
proteins.	 The	 introduction	 of	 latent	 proteins	 into	 the	 defective	 particles	 enabled	 the	
stimulation	of	several	lytic	protein-	and	latent	protein-specific	CD4+	T	cells.	Polyclonal	T	cells	
specific	for	the	modified	particles	were	shown	to	be	far	superior	to	gp350-specific	T	cells	at	
controlling	 EBV-infected	 B	 cells	 ex	 vivo.	 Furthermore,	 the	 modified	 particles	 afforded	
significant	 protection	 against	 EBV-infection	 in	 humanised	 mice.	 This	 suggests	 that	 EBV	
vaccines	can	be	enhanced	through	the	inclusion	of	additional	antigens.	By	incorporating	the	
most	 immunodominant	 EBV	 antigens	 into	 defective	 particles,	 it	would	 prime	 the	 immune	
system	against	EBV	antigens	that	are	expressed	at	all	stages	of	viral	infection	and	in	all	EBV-
associated	malignancies.	 Such	a	multipronged	approach	 is	 likely	 increase	 the	possibility	of	
achieving	sterile	immunity	after	prophylactic	vaccination.		
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Zusammenfasung	
Das	 Epstein-Barr-Virus	 (EBV)	 ist	 ein	 Gammaherpesvirus,	 mit	 dem	 die	 Mehrheit	 der	
Bevölkerung	 latent	 infiziert	 ist.	 Obwohl	 die	 EBV	 Infektion	 in	 den	 meisten	 Fällen	
asymptomatisch	verläuft	 ist	die	globale	Gesamtbelastung	durch	das	Virus	erheblich.	Durch	
die	 Erstinfektion	 mit	 EBV	 wird	 das	 Krankheitsbild	 der	 infektiösen	 Mononukleose	
hervorgerufen.	 Darüber	 hinaus	 verursacht	 das	 Virus	 200000	 EBV-assoziierte	 Krebsfälle	
jährlich.	 Der	 Lebenszyklus	 von	 EBV	 ist	 facettenreich	 und	 umfasst	 die	 lytische	 Vermehrung	
und	 die	 Latenz,	 welche	 zur	 Ausbildung	 einer	 lebenslangen	 latenten	 Infektion	 führt.	
Mehrheitlich	konzentrierten	sich	Vakzinierungen	bisher	auf	das	Glykoprotein	gp350.	Phase	II	
Studien	 zeigten	 jedoch,	dass	eine	Vakzinierung	gegen	dieses	Protein	nicht	 gegen	eine	EBV	
Infektion	 schützen	 kann.	 In	 unserem	 Labor	wurde	 ein	 Vakzinekanditat	 entwickelt,	 der	 auf	
defekten	Viruspartikeln	beruht.	Diese	defekten	Viruspartikel	 tragen	keine	virale	DNA	mehr	
und	sind	nicht	infektiös,	tragen	jedoch	einige	duzend	lytischer	Proteine.		In	der	dargelegten	
Arbeit	wurde	das	virale	Proteinspektrum	um	immundominante	latente	Proteine		erweitert.	
Das	 Einführen	 dieser	 latenten	 Proteine	 in	 die	 defekten	 EBV	 Partikel	 ermöglichte	 die	
Stimulation	 von	 spezifisch	 gegen	 diese	 Proteine	 gerichteten	 CD4+	 T	 Zellen.	 	 Die	 Kontrolle	
EBV	 infizierter	B	Zellen	ex	vivo	war	durch	polyklonale	T	Zellen,	die	gegen	die	modifizierten	
Partikel	 gerichtet	 waren,	 deutlich	 den	 herkömmlichen	 gp350	 spezifischen	 T	 Zellen	
überlegen.	 Darüber	 hinaus	 erzielten	 die	 modifizierten	 Partikel	 signifikanten	 Schutz	 gegen	
eine	 EBV-Infektion	 im	 Modell	 der	 	 humanisierten	 Maus.	 	 Die	 Ergebnisse	 lassen	 darauf	
schließen,	dass	die	Vakzinierung	gegen	EBV	durch	die	Integration	latenter	Proteine	deutlich	
verbessert	werden	kann.	Durch	die	Integration	der	immunodominanten	EBV	Antigene	kann	
eine	Immunantwort	hervorgerufen	werden,	die	gegen	EBV	Proteine	gerichtet	ist,	die	sich	in	
jedem	 Stadium	 der	 Infektion	 sowie	 EBV-assoziierten	 Malignomen	 zu	 finden	 ist.	 Dieser	
Vakzinierungsansatz	 erhöht	 die	Wahrscheinlichkeit	 eine	 sterile	 Immunität	 gegen	 EBV	nach	
Impfung	zu	entwickeln.		
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1.	Introduction		
1.1.	The	Epstein-Barr	Virus	
The	Epstein-Barr	Virus	(EBV)	is	a	member	of	the	Herpesviridae,	a	family	known	to	possess	a	
large	DNA	genome.	This	diverse	family	of	viruses	infect	many	mammals	and	vertebrates	and,	
rarely,	invertebrates	[1-3].	Despite	the	genetic	variation	within	the	Herpesviridae,	 it	 is	clear	
that	 herpesviruses	 from	 mammals	 and	 birds	 are	 more	 closely	 related;	 i.e.	 there	 is	 clear	
evidence	that	they	share	a	common	ancestor	[1].	
The	 Herpesviridae	 were	 initially	 divided	 into	 the	 Alpha-,	 Beta-	 and	 Gammaherpesvirinae	
following	 observations	 made	 about	 their	 biological	 properties.	 However,	 this	 subfamily	
classification	 has	 since	 been	 refined	 through	 the	 use	 of	molecular	 phylogenetics	 [4].	 EBV,	
also	known	as	human	herpes	virus	4,	has	been	placed	into	the	gammaherpesvirus	subfamily.	
The	 gammaherpesviruses,	 which	 branched	 off	 from	 the	 other	 herpesviruses	 around	 200	
million	 years	 ago,	 are	 typified	 by	 their	 lymphotropism	 and	 neoplastic	 associations	 [4].		
Furthermore,	 EBV	 is	 the	 type	 species	 of	 the	 gamma-1	 herpesviruses,	 a	 genus	 that	 is	 also	
know	 as	 the	 Lymphocrytoviruses	 (LCVs).	Members	 of	 this	 genus	 are	 known	 to	 exclusively	
infect	 primates	 and	 EBV	 is	 the	 only	 member	 of	 this	 genus	 that	 infects	 humans	 [5].	 In	
humans,	 EBV	 is	 transmitted	 orally	 and	 preferentially	 infects	 B	 cells.	 EBV	 can	 also	 infect	
epithelial	cells,	but	it	is	the	colonisation	of	the	B	cell	pool	that	enables	EBV	to	be	acquired	as	
a	lifelong	infection	[6].	
1.1.1.	The	structure	of	EBV	virions	
One	of	the	defining	features	of	the	herpesviruses	is	their	structure	(Fig.	1.1).	Just	like	other	
herpesviruses,	 EBV	 is	 rather	 large	 in	 size	 (∼180	 nm)	 and	 complex	 in	 structure	 [3,	 7].	 EBV	
virions	 contain	more	 than	 40	 different	 proteins	 [8].	 At	 the	 core	 of	 EBV	 virions	 is	 a	 highly	
ordered	T=16	icosahedral	capsid,	containing	a	linear	dsDNA	genome	(∼170	kb).	Immediately	
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outside	of	the	capsid	is	a	protein	matrix	that	has	been	termed	the	tegument.	The	outermost	
structure	of	the	EBV	virions	is	the	glycoprotein-rich	envelope	[2].	
A	 		B			 								
Figure	1.1:	The	structure	of	EBV.	An	electron	micrograph	(left)	and	a	schematic	representation	(right)	
of	EBV	virions	are	shown.	The	electron	micrograph	was	taken	of	B95-8	EBV	particles	pelleted	from	the	
supernatant	of	 induced	producer	cells.	The	schematic	representation	of	an	EBV	virion	highlights	the	
classic	 structural	 features	 of	 herpesviruses.	 The	 linear	 dsDNA	 genome	 is	 packaged	 within	 an	
icosahedral	 capsid.	 Beyond	 the	 capsid	 is	 a	 protein	matrix	 that	 is	 divided	 into	 the	 inner	 and	 outer	
tegument.	 The	 tegument	 is	 enclosed	 with	 a	 lipid	 bilayer	 rich	 in	 glycoproteins.	 The	 electron	
micrograph	was	taken	from	Pavlova	et	al.,	2013	[9].	
1.1.1.1.	The	EBV	capsid		
The	 icosahedral	 capsid	 of	 herpesviruses	 is	 formed	 through	 the	 assembly	 of	 150	hexamers	
and	12	pentamers;	 i.e.	 162	 capsomeres	 in	 total	 are	 required	 [10].	 The	 capsomeres,	which	
are	composed	of	the	major	capsid	protein	(MCP)	(BcLF1),	are	linked	to	each	other	through	a	
heterotrimeric	 triplex	 structure.	 The	 triplex	 structure	 is	 composed	 of	 triplex	 protein	 α	
(BORF1)	and	a	homodimer	of	triplex	protein	β	(BDLF1)	[10,	11].	The	structural	details	of	EBV	
icosahedral	 facets	 can	 be	 seen	 in	 Figure	 1.2.	 In	 total,	 there	 are	 320	 triplex	 structures	 per	
capsid	and	one	triplex	structure	is	found	at	the	interface	of	three	capsomeres.	Furthermore,	
there	is	the	small	capsid	protein	(SCP),	encoded	by	BFRF3,	which	interacts	with	the	MCP.	The	
role	of	the	SCP	has	been	shown	to	be	indispensible	for	gammaherpesvirus	capsid	assembly,	
but	this	is	not	the	case	for	alphaherpesviruses	[11,	12].	In	the	case	of	gammaherpesviruses	
SCP	has	been	suggested	to	crosslink	neighbouring	MCPs	to	ensure	capsid	stabilisation	[12].	
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Lastly,	there	are	the	scaffold	protein	(BdRF1)	and	maturation	protease	(BVRF2)	that	are	also	
required	 for	 capsid	 assembly.	 However,	 these	 proteins	 are	 more	 likely	 to	 play	 a	 role	 in	
assembly	and	maturation	of	the	icosahedral	capsid	rather	than	being	integral	structural	units	
[8,	11].	
							 		
Figure	1.2:	Structural	details	of	EBV	icosahedral	capsids.	The	3D-structure	was	derived	from	cryo-EM	
images	 that	 were	 taken	 of	 sucrose	 gradient-purified	 EBV	 capsids.	 (A)	 A	 single	 EBV	 facet	 showing	
hexamers	(blue)	and	pentamers	(blue)	and	triplex	structures	(red).	Pentamers	are	found	exclusively	at	
the	vertices	of	facets.	(B)	The	view	of	a	hexamer	(blue)	interacting	with	six	different	triplex	structures	
(red).	(C)	The	view	of	a	pentamer	(blue)	interacting	with	interacting	with	5	different	triplex	structures	
(red).	The	figure	was	taken	from	Germi	et	al.,	2012	[10].	
1.1.1.2.	The	EBV	Tegument	
The	tegument	is	the	protein	layer	that	is	sandwiched	between	the	capsid	and	viral	envelope.	
The	tegument	of	mature	virions	can	be	between	15	nm	and	50	nm	thick	and	is	divided	into	
the	 inner	 and	outer	 tegument.	 The	 inner	 tegument	proteins	engage	 in	 strong	 interactions	
with	the	capsid,	while	those	in	the	outer	tegument	associate	loosely	with	the	viral	envelope	
[13].	The	tegument	was	initially	thought	to	be	an	amorphous	protein	layer;	however,	recent	
studies	 have	 shown	 the	 tegument	 of	 herpesviruses	 to	 be	 an	 organised	 structure	 [14-17].		
Two	of	these	studies	involved	the	Human	Herpesvirus-8	(HHV-8)	and	Murine	herpesvirus-68	
(MHV-68),	both	gammaherpesviruses	and	close	relatives	of	EBV	[16,	18].	These	studies	allow	
inferences	to	be	made	with	regard	to	the	organisation	of	EBV	tegument.	This	is	important	as	
A	 B	 C	
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gammaherpesviruses	 encode	 tegument	 proteins	 that	 are	 not	 found	 in	 other	 herpesvirus	
subfamilies	[19].	
The	tegument	of	HHV-8,	also	known	as	Kaposi’s	sarcoma-associated	herpesvirus	(KSHV),	has	
been	studied	through	cryo-Electron	Microscopy	[18].	This	revealed	that	ORF19	and	ORF32,	
homologues	 of	 EBV	 BVRF1	 and	 BGLF1	 respectively,	 form	 a	 complex	 that	 simultaneously	
interacts	with	capsid	pentamers	and	nearby	triplex	structures.	This	interaction	is	thought	to	
act	as	an	anchoring	site	to	which	other	tegument	proteins	can	attach	(Fig.	1.3).	 In	another	
study,	the	large	tegument	protein	(LTP)	of	HHV-8	was	also	found	to	interact	with	the	capsid	
[16].	Through	the	use	of	yeast	two-hybrid	and	coimmunoprecipitation	(co-IP)	assays	the	LTP,	
a	homologue	of	 EBV	BPLF1,	was	 shown	 to	 interact	with	 the	MCP,	 triplex	α	 and	 triplex	β	
proteins.	Furthermore,	the	LTP	was	also	found	to	interact	with	itself	and	with	a	large	variety	
of	 tegument	proteins	 (e.g.	ORF33/BGLF2,	ORF45/BKRF4	ORF63/BOLF1,	 and	ORF75/BNRF1)	
and	membrane	proteins	 (e.g.	 gM,	 gB	and	gH)	 (Fig.	 1.3).	 This	 finding	 suggests	 that	 the	 LTP	
could	act	as	a	 scaffold	 for	other	 tegument	proteins.	Furthermore,	 the	ability	of	 the	LTP	 to	
interact	with	the	capsid	and	tegument	suggest	that	it	could	play	an	important	role	in	capsid	
positioning	prior	to	envelopment	[16,	20].		
BLRF2	is	another	tegument	protein	that	has	been	found	to	interact	strongly	with	the	capsid.	
Hence,	 BLRF2	 has	 also	 been	 implicated	 as	 an	 anchor	 for	 other	 tegument	 proteins.	 This	
reasoning	has	been	strengthened	by	the	observation	that	BLRF1/ORF52	from	EBV,	KSHV	and	
MHV-68	interacts	with	13	viral	proteins	[19].	One	of	these	interaction	partners	is	the	major	
tegument	protein	(MTP)	[21]	(Fig.	1.3).	The	EBV	MTP,	encoded	by	BNRF1,	has	been	found	to	
play	an	 important	 role	during	 infection.	Specifically,	BNRF1	has	been	 found	to	be	required	
for	 the	 transfer	 of	 virions	 from	 the	 endosomal	 compartment	 to	 the	 nucleus	 [22].	 In	 this	
manner,	 capsid-binding	 tegument	 proteins	 enable	 virion	 cargo	 to	 be	 delivered	 to	 newly	
infected	cells	[19].		
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Figure	 1.3:	 An	 overview	 of	 EBV	 tegument	 organisation.	 Confirmed	 interactions	 (solid	 arrows)	 and	
hypothetical	 interactions	 (dotted	 arrow)	 are	 indicated.	 Unknown	 infraction	 partners	 have	 been	
signified	with	 a	 question	mark	 (?).	Whilst	 specific	 envelope	 glycoproteins	 (gp)	 are	 not	 exemplified,	
BPLF1	is	known	to	interact	with	gB,	gM	and	gH.		
Tegument	 proteins	 that	 interact	 strongly	 with	 the	 capsid	 have	 also	 been	 shown	 to	 be	
important	 for	 viral	 egress.	 BLRF2/ORF52	enables	 the	 transport	 of	mature	 virions	 from	 the	
nucleus	to	the	extracellular	space	[23].	An	ORF52	deletion	mutant	of	MHV68	was	shown	to	
produce	mature	 capsids	 that	 contained	 some	 inner	 tegument	and	 lacked	outer	 tegument.	
These	 capsids	 failed	 to	 form	 mature	 virions	 and	 accumulated	 within	 the	 cytoplasm	 [24].	
Another	tegument	protein,	ORF45,	a	homologue	of	EBV	BKRF4,	has	also	been	implicated	in	
the	transport	of	capsid	during	viral	 lytic	replication	[25].	ORF45	was	found	to	 interact	with	
KIF3A,	a	subunit	of	kinesin-2.	The	ORF45-KIF3A	interaction	enables	the	transport	of	capsids	
along	microtubules	and	mediates	viral	egress.		
Lastly,	 it	 is	 important	 to	 note	 that	 host	 cellular	 proteins	 (e.g.	 actin,	 cofilin,	 tubulin	 and	
HSP70)	 have	 also	 been	 found	 to	 be	 abundant	 components	 of	 the	 EBV	 tegument	 [8].	 The	
occurrence	of	host	protein	within	enveloped	viruses	have	been	well	documented	in	recent	
years	[26].	However,	the	exact	role	of	these	host	proteins,	if	any,	has	not	been	well	defined.	
In	 the	 case	 of	 EBV,	 it	 is	 hypothesised	 that	 host	 proteins	 are	 accumulated	 during	
morphogenesis,	and	that	they	potentially	play	a	role	in	virion	stability	and/or	ingress	[8].		
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1.1.1.3.	The	EBV	Envelope	
EBV	 encodes	 an	 impressively	 high	 number	 of	 envelope	 glycoproteins.	 In	 total,	 11	
glycoproteins	have	been	found	to	associate	with	the	viral	envelope	[8].	Glycoproteins	were	
amongst	 the	 first	 proteins	 to	 be	 studied	 after	 EBV	was	 discovered	 in	 1964.	 The	 envelope	
glycoproteins	of	EBV	can	be	divided	into	two	groups,	those	that	are	involved	in	the	assembly	
of	virions	and	those	that	are	responsible	for	virus	entry	and	spread	[27].		
The	 most	 abundant	 glycoprotein	 in	 the	 EBV	 envelope	 is	 gp350/gp220	 (BLLF1).	 BLLF1	
encodes	two	alternatively	spliced	forms	that	have	a	mass	of	approximately	350	and	220	kDa	
[28].	It	is	known	that	gp350	is	a	907	residue	glycoprotein	that	has	a	short	cytoplasmic	tail	(18	
aa)	 at	 its	 C-terminus	 and	 a	 large	 extracellular	 ectodomain	 (860	 aa)	 at	 its	 N-terminus.	 The	
ligand-binding	 domain	 of	 gp350	 has	 been	 shown	 to	 comprise	 the	 first	 470	 aa	 [29].	 The	
principle	function	of	gp350	is	the	attachment	of	EBV	to	B	cells.	The	classical	ligand	partner	of	
gp350	on	B	cells	is	CD21.	It	is	known	that	gp350	binds	with	high	affinity	(10-8M)	to	a	protein	
surface	within	short	consensus	repeats	(SCR)	1	and	2	of	CD21	[28].	Additionally,	gp350	has	
been	shown	 to	 interact	with	CD35	 in	B	cells	 [30-32].	When	 it	 comes	 to	 the	attachment	of	
EBV	 to	 epithelial	 cells	 it	 is	 known	 that	 gp350	does	not	 play	 a	 role.	 EBV	 has	 recently	 been	
shown	to	interact	with	Ephrin	receptor	A	(EphA2)	expressed	on	epithelial	cells	through	the	
use	 of	 gH/gL	 [33,	 34].	 Furthermore,	 the	 glycoprotein	 BMRF2	 has	 been	 hypothesised	 to	
interact	 with	 integrins	 expressed	 on	 epithelial	 cells	 through	 the	 use	 its	 arginine-glycine-
alanine	(RGD)	motif	[35,	36].	
Once	EBV	attaches	to	host	cells	there	are	several	events	that	occur	in	order	for	membrane	
fusion	to	occur.	There	are	in	total	at	least	four	glycoproteins	that	are	required	for	membrane	
fusion	to	occur	once	virions	bind	to	host	cells,	viz.	gH	(gp85),	gL	(gp25),	gp42	and	gB	(gp110)	
(Fig.	 1.4).	Of	 these	glycoproteins,	 it	 is	 gH,	 gL	 and	gB	 that	 form	 the	 core	 fusion	machinery;	
with	gH	and	gL	playing	a	mediatory	 role	and	gB	executing	 the	 fusion	of	 the	viral	and	host	
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membranes.	The	importance	of	gB	in	membrane	fusion	was	first	shown	through	the	use	of	a	
gB	deletion	mutant	[37].	Mutant	virions	were	able	to	bind	to	cells	and	enter	endosomes,	but	
were	 unable	 to	 carry	 to	 out	 fusion.	Once	 virions	 bind	 to	 host	 cells,	 the	 gH/gL-HLA	 class	 II	
complex	 undergoes	 conformational	 changes,	 mediated	 by	 gp42,	 to	 bring	 apposing	
membranes	in	close	proximity.	Furthermore,	these	conformational	changes	enable	gH/gL	to	
be	positioned	such	that	gB	can	be	activated	and	initiate	membrane	fusion	[38].		
	
Figure	 1.4:	 Attachment	 and	 fusion	 of	 EBV	 with	 host	 cells.	 The	 viral	 membrane	 is	 represented	 in	
orange	while	the	host	cell	membrane	is	represented	in	dark	blue.	For	B	cell	entry,	the	attachment	of	
virus	occurs	through	the	gp350-CD21	interaction	(1).	The	gp42	protein,	which	associates	with	gH/gL	
via	a	high	affinity	 interaction,	 interacts	with	human	leukocyte	antigen	(HLA)	class	II	 (2).	This	triggers	
membrane	 fusion	 through	 the	 action	 of	 gH/gL	 and	 gB	 (3).	 The	 capsid	 of	 EBV	 is	 delivered	 into	 the	
cytoplasm	 after	 the	 viral	 envelope	 fuses	 with	 the	membrane	 of	 endosomes	 (4).	 For	 epithelial	 cell	
entry,	 the	 attachment	 of	 virus	 is	 mediated	 through	 the	 interaction	 of	 gH/gL	 with	 Ephrin	 receptor	
(EphA2)	(1)	and	BMRF2	with	integrins	(α3β1,	α5β1	or	αvβ1)	(2).	Membrane	fusion	is	triggered	via	the	
action	of	gB	 (3)	and	the	EBV	capsid	 is	directly	delivered	 in	 the	cytoplasm	of	epithelial	 cells	 (4).	This	
image	was	adapted	from	Longnecker	et	al.,	2013	[39].	
The	 EBV	 glycoproteins	 that	 are	 responsible	 for	 virus	 assembly	 have	 not	 been	 extensively	
studied.	 However,	 glycoproteins	 gM	 and	 gN	 have	 been	 implicated	 in	 exocytosis.	 For	
herpesviruses,	 the	 release	 of	 virions	 requires	 that	 tegumented	 capsids	 move	 from	 the	
cytoplasm	into	the	secretory	compartment	[27].	gM	is	a	large	multispan	membrane	protein,	
while	gN	is	a	small	single-pass	glycoprotein.	These	glycoproteins	associate	with	one	another	
to	carry	out	their	effector	functions.	Deletion	of	gN	was	shown	to	reduce	the	occurrence	of	
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mature	 gM	 [40].	 The	 lack	 of	 gN-gM	 was	 found	 have	 a	 deleterious	 effect	 on	 virion	
production;	i.e.	many	virions	were	found	to	be	incompletely	enveloped.	Additionally,	virions	
that	were	successfully	enveloped	were	trapped	in	vesicles.	
1.1.2.	The	Genome	structure	of	the	EBV	
The	 linear-double	 stranded	DNA	genome	 found	 in	 EBV	 capsids	 is	 approximately	 172	 kb	 in	
size	and	contains	at	 least	86	open	 reading	 frames	 [41,	42]	 (Fig.	1.5).	 The	 linear	genome	 is	
flanked	on	either	side	by	terminal	repeats,	which	mediate	circularisation	to	form	episomes	
within	 the	 nuclei	 of	 infected	 cells	 [43].	 The	 circular	 form	 of	 EBV,	 prevalent	 during	 viral	
latency,	 is	 maintained	 through	 the	 origin	 of	 plasmid	 replication	 (oriP).	 Conversely,	 lytic	
replication	 is	 initiated	 from	 the	 origin	 of	 lytic	 replication	 (orilyt)	 and	 yields	 head-to-tail	
concatemers	[44].	The	unique	long	region	of	the	EBV	genome	encodes	nine	latent	proteins	
and	 several	 non-coding	 RNAs.	 The	 latent	 proteins	 encoded	 by	 this	 region	 include	 the	
Epstein-Barr	nuclear	antigen	1	(EBNA1),	EBNA2,	EBNA3A,	EBNA3B,	EBNA3C,	EBNA-LP,	latent	
membrane	protein	1	(LMP1),	LMP2A	and	LMP2B.	The	non-coding	RNAs	include	the	Epstein-
Barr	virus-encoded	small	RNA	1	(EBER1)	and	2	(EBER2),	BART-derived	microRNAs	(miRNAs-
BARTs)	and	BHRF1	microRNAs	(miRNAs-BHRF1)	[42].		
	
Figure	1.5:	Organisation	of	 the	 linear	EBV	genome.	The	 linear	genome	 is	 flanked	by	0.5	kb	terminal	
direct	 repeats	 (TRs)	 and	 contains	 four	 internal	 repeat	 sequences	 (IRs).	 The	 unique	 short	 sequence	
(US)	region	comprises	the	unique	sequence	domain	1	(U1).	The	unique	long	sequences	(UL)	spans	the	
region	containing	U2	to	U5.	The	origin	of	replication	during	latency	(oriP)	contains	cis-acting	elements	
that	 ensure	 that	 episome	maintenance	occurs.	 The	 synthesis	 of	 EBV	DNA	during	 lytic	 replication	 is	
initiated	from	the	origins	of	lytic	replication	(orilyt).	An	11.8	kb	deletion	within	the	B95-8	strain,	the	
first	 herpesvirus	 to	 have	 its	 genome	 sequenced	 [41],	 is	 shown.	 The	 image	 was	 adapted	 from	
Longnecker	et	al.,	2013	[39].		
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1.1.3.	The	EBV	life	cycle	
1.1.3.1.	Latency	
The	 ability	 to	 establish	 latency	 in	 B	 cells	 is	 an	 essential	 characteristic	 of	 EBV.	 It	 is	 the	
colonisation	of	the	memory	B	cell	pool	that	enables	EBV	to	be	carried	 lifelong	[45].	During	
the	early	stages	of	primary	infection	EBV	infects	B	cells	found	at	oropharyngeal	mucosa	[46].	
Once	EBV	 infects	naïve	B	cell,	 there	are	a	host	of	events	 that	 lead	to	the	establishment	of	
true	 latency	 in	memory	B	 cells	 (Fig.	 1.6).	 EBV-infected	B	 cells	 display	different	patterns	of	
antigen	 expression,	 and	 depending	 on	 the	 antigens	 expressed,	 cells	 can	 be	 classified	 as	
having	 one	 of	 four	 latency	 programs	 [45,	 47].	 There	 are	 potentially	 6	 nuclear	 proteins	
(EBNA-1,	-2,	-3A,	-	3B,	-3C	and	-LP)	and	two	membrane	proteins	(LMP1	and	LMP2)	that	can	
be	expressed	during	latency.	
	
Figure	1.6:	The	latency	programs	in	EBV-infected	B	cells.	In	the	first	stage	of	infection	EBV	infects	host	
squamous	 epithelial	 cells	 and	 B	 cells	 in	 the	 oropharynx.	 In	 these	 cells	 the	 virus	 undergoes	 lytic	
replication	 and	 this	 leads	 to	 a	 rise	 of	 virus	 levels	 locally	 [45].	 Infected	 naïve	 B	 cells	 display	 type	 III	
latency	and	are	characterised	as	being	activated.	The	activated	B	cells	proliferate	and	ensure	that	the	
number	 of	 EBV	 infected	 cells	 rise.	 Some	 of	 these	 B	 cells	 enter	 the	 germinal	 centres	 of	 secondary	
lymphoid	tissues	and	display	type	II	 latency	[47].	These	B	cells	eventually	differentiate	 into	memory	
cells	B	cells	and	exit	the	germinal	centres.	Infected	memory	B	cells	circulate	freely	and	display	either	
type	 I	 or	 type	 0	 latency.	 Since	memory	 B	 cells	 express	 a	 limited	 number	 of	 antigens,	 they	 are	 not	
efficiently	recognised	by	immune	cells	[47].	When	memory	EBV-infected	B	cells	are	activated	they	can	
differentiate	 into	plasma	cells	and	this	can	 lead	to	 lytic	 replication	[48].	 It	 is	 important	 to	note	that	
irrespective	 of	 the	 type	 of	 latency,	 all	 EBV-infected	 cells	 express	 EBV-encoded	 small	 RNAs	 (EBERs)	
[47].	This	image	was	adapted	from	Heslop,	2009	[47].	
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Several	of	the	above	mentioned	latent	proteins	have	crucial	roles	in	B	cell	survival,	some	of	
which	will	 be	 considered	 here.	 EBNA1	 is	 expressed	 during	 all	 forms	 of	 latency,	 except	 for	
type	0,	and	is	a	DNA-binding	phosphoprotein	that	 is	necessary	for	viral	genome	replication	
and	maintenance	[46].	EBNA1	interacts	simultaneously	with	the	oriP	of	the	EBV	genome	and	
host	 chromosomes,	 ensuring	 that	 the	 EBV	 genome	 is	 tethered	 to	 the	 host	 chromosome	
during	mitosis	 [49].	 EBNA2	 is	 one	of	 the	 first	 viral	 genes	 to	be	 transcribed	after	 infection,	
and	once	translated,	 it	 is	able	 to	act	as	a	 transactivator	of	several	viral	 (e.g.	LMP1,	LMP2A	
and	LMP2B)	and	host	proteins	(e.g.	CD23	and	CD21)	[39,	50].	The	EBNA3	family	of	proteins,	
which	came	about	 through	gene	duplication	 [51],	act	as	 transcriptional	 regulators	 [52].	All	
members	 of	 the	 EBNA3	 family	 interact	 with	 the	 DNA-binding	 transcription	 factor	 RBPJ.	
Interestingly,	 EBNA2	 also	 interacts	 with	 this	 transcription	 factor	 and	 it	 is	 suggested	 that	
members	of	the	EBNA3	family	act	as	coactivators	of	EBNA2	[53].	Furthermore,	EBNA3A	and	
EBNA3C	 inhibit	pro-apoptotic	signals	 from	BIM	and	the	tumour	suppressor	p16INK4A	[54].	
LMP1	 is	 a	 multispan	 membrane	 protein	 that	 behaves	 like	 a	 constitutively	 active	 tumour	
necrosis	 factor	 (TNF)	 receptor.	 The	 signals	 generated	 by	 LMP1	 are	 very	 similar	 to	 that	 of	
CD40.	LMP1	also	upregulates	several	B	activation	markers	in	infected	cells	(viz.	CD21,	CD23,	
CD30	and	CD40)	and	antiapoptotic	markers	(e.g.	Bcl2	and	A20)	[55].	LMP2	is	also	a	multispan	
membrane	protein	that	plays	an	important	role	in	B	cell	survival	and	proliferation.	However,	
LMP2	can	be	transcribed	from	two	promoters	to	give	rise	to	LMP2A	or	LMP2B	[56].	LMP2A	
and	LMP2B	are	very	similar	except	that	LMP2B	lacks	a	tyrosine	kinase	signalling	domain.	The	
presence	of	this	domain	enables	LMP2A	to	mimic	B	cell	receptor	(BCR)	signals	[39].		
1.1.3.2.	Lytic	replication	
While	latency	is	important	for	EBV	to	survive	within	infected	individuals,	it	is	lytic	replication	
that	 ensures	 that	 EBV	 is	 transmitted	 from	 one	 host	 to	 another	 [57].	 Contrary	 to	 latency,	
characterised	 by	 the	 expression	 of	 a	 small	 subset	 of	 genes,	 lytic	 replication	 involves	 the	
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expression	of	around	80	viral	genes	[58].	The	exact	mechanism	that	 leads	 latently	 infected	
cells	 to	undergo	 reactivation	 in	 vivo	 is	 not	well	 understood.	However,	 it	 is	 know	 that	 lytic	
replication	occurs	in	memory	B	cells	associated	with	the	oropharyngeal	mucosa	[59,	60].		
During	 lytic	 replication	 a	 cascade	 of	 viral	 gene	 expression	 occurs	 that	 results	 in	 the	
production	 of	 immediate-early	 (IE),	 early	 (E)	 and	 late	 (L)	 gene	 products.	 This	 cascade	 is	
chiefly	mediated	by	the	activities	of	BZLF1;	a	DNA-binding,	d-zip	transcription	factor	[61-63].	
BZLF1	interacts	with	multiple	BZLF1	responsive	elements	(ZRE)	in	the	promoters	of	viral	and	
cellular	genes	and	the	EBV	orilyt	[58,	63,	64].		
During	 lytic	 replication	 the	 EBV	 genome	 is	 replicated	 by	 a	 rolling	 circle	 mechanism	 and	
results	in	the	generation	of	large	head-to-tail	concatemers	[60,	65].	In	order	for	this	process	
to	 be	 initiated	 several	 viral	 proteins	 are	 required;	 viz.	 DNA	 polymerase	 catalytic	 domain	
(BALF1),	 polymerase-associated	 processivity	 factor	 (BMRF1),	 single	 strand	 DNA-binding	
protein	 (BALF2),	 primase	 (BBLF4)	 and	 helicase/primase-associated	 protein	 (BBLF2/3)	 [65,	
66].	 Subsequent	 to	 DNA	 replication,	 the	 concatemers	 are	 cleaved	 within	 the	 TRs	 by	 a	
terminase	complex	(BALF3,	BGRF1/BDRF1	and	BFRF1A)	to	yield	individual	genomes	that	are	
packaged	into	viral	capsids	[9,	67,	68].		
1.2.	EBV-associated	diseases	and	malignancies	
Infection	 of	 human	 hosts	 by	 EBV	 is	 exceptionally	 common.	 Around	 95%	 of	 the	 human	
population	is	EBV	seropositive	once	they	reach	adulthood	[69].	In	the	majority	of	cases,	EBV	
is	 acquired	 early	 in	 life	 and	 infection	 is	 asymptomatic	 [69,	 70].	 However,	 when	 EBV	 is	
acquired	 during	 adolescence	 it	 can	 lead	 to	 the	 development	 of	 infectious	mononucleosis	
(IM),	 a	 disease	 that	 is	 usually	 self-limiting	 [70].	 During	 the	 acute	 phase	 of	 IM	 patients	
develop	cervical	lymphadenopathy,	fever	and	pharyngitis.	Subsequently,	a	small	proportion	
of	patients	(10-20%)	experience	fatigue	and	malaise	that	lasts	for	2-6	months	[69,	71,	72].	In	
addition	to	IM,	for	which	there	are	at	least	125,000	new	cases	each	year	in	the	USA,	there	is	
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also	a	wide	range	of	malignancies	that	are	associated	with	EBV.	Every	year	around	200,000	
new	cases	of	EBV-associated	malignancies	are	diagnosed	worldwide	[73].	Furthermore,	EBV	
is	also	considered	to	be	an	important	factor	in	the	development	of	Multiple	Sclerosis	[72].	
1.2.1.	EBV-associated	diseases	in	Immunocompromised	Individuals	
There	 are	 several	 EBV-related	 lymphoproliferative	 disorders	 that	 can	 occur	 in	 individuals	
with	genetic	or	acquired	immunosuppression	[74].	In	these	individuals,	their	immune	system	
fails	to	prevent	transformation	of	EBV-infected	cells	[75].		
A	 classic	 example	 of	 this	 is	 post-transplant	 lymphoproliferative	 disorder	 (PTLD),	 a	
heterogeneous	 group	 of	 lymphoproliferative	 diseases,	 often	 malignant,	 that	 involves	
lymphoid	 or	 plasmacytic	 proliferations	 [76,	 77].	 Since	 transplant	 patients	 are	 subjected	 to	
pharmacological	 immunosuppression,	 it	 is	 possible	 for	 EBV-positive	 cells	 to	 survive	 and	
proliferate	 despite	 the	 fact	 that	 they	 display	 type	 III	 latency	 [76].	 PTLD	 occurs	 in	 patients	
that	that	have	received	a	solid	organ	transplant	(SOT)	or	hematopoietic	stem	cell	transplant	
(HST).	 There	 are	 a	 several	 factors	 that	 influence	 ones	 likelihood	 of	 developing	 PTLD.	 One	
major	 factor	 is	 the	 serostatus	 of	 patients	 prior	 to	 receiving	 the	 transplant.	 Patients	 that	
experience	primary	 infection	during	or	after	transplantation	have	a	significantly	higher	risk	
than	those	that	are	already	EBV	positive	prior	to	transplantation	[77,	78].	Primary	infection	
can	 occur	 via	 the	 normal	 route	 or	 EBV	 can	 be	 acquired	 from	 the	 tissues/cells	 of	 the	
seropositive	donor.	Another	major	 risk	 factor	 is	 the	 level	 of	 immunosuppression	 received.	
Patients	 receiving	 higher	 levels	 of	 immunosuppressive	 drugs	 are	 more	 likely	 to	 develop	
PTLD.	 This	 is	 one	 of	 the	 reasons	 why	 a	 reduction	 in	 immunosuppression	 is	 a	 common	
treatment	 option	 for	 PTLD.	 Other	 treatment	 options	 include	 low-dose	 chemotherapy,	
adoptive	 immunotherapy	 and	 the	 use	 of	 the	 monoclonal	 anti-CD20	 (also	 known	 as	
rituximab)	[78].		
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1.2.2.	EBV-associated	malignancies	in	Immunocompetent	Individuals	
1.2.2.1.	Burkitt	lymphoma	
The	history	of	EBV	and	Burkitt	lymphoma	is	irrevocably	intertwined.	It	was	almost	60	years	
ago	when	Dennis	Burkitt	described	tumours	found	in	the	jaws	of	equatorial	African	children	
[79].	 Cell	 lines	 established	 from	 Burkitt	 lymphoma	 (BL)	 biopsies	 were	 analysed	 through	
electron	microscopy	 (EM)	 by	 Epstein	 et	 al.,	 1964	 [80]	 to	 reveal	 the	 presence	 of	 the	 EBV	
particles.		
The	clinical	variant	first	described	by	Dennis	Burkitt	is	now	known	as	endemic	BL	(eBL).	This	
variant	 occurs	 frequently	 in	 children	 from	 equatorial	 Africa	 and	 Papa	 New	 Guinea	 and	
displays	type	I	latency	[74].	Incidentally,	the	regions	affected	by	eBL	are	also	affected	by	the	
malarial	parasite	Plasmodium	falciparum.	This	led	to	a	hypothesis	that	coinfection	with	EBV	
and	P.falciparum	 promotes	 the	 development	 of	 eBL	 [81].	 It	 is	 thought	 that	 infection	with	
P.falciparum	 causes	 latently	 infected	 B	 cells	 to	 expand	 and	 undergo	 reactivation.	
Furthermore,	P.falciparum	infection	is	also	hypothesised	to	negatively	affect	EBV-specific	T-
cells,	enabling	EBV-infected	B	cells	to	proliferate	[77].	
In	addition	to	eBL,	there	are	two	other	clinical	variants	know	as	sporadic	BL	(sBL)	and	HIV-
associated	BL	[81].	Both	of	these	variants	do	not	associate	with	EBV	to	the	same	extent	as	
eBL,	where	nearly	every	malignant	cell	 is	EBV-positive.	However,	 irrespective	of	the	clinical	
variant	 displayed,	 all	 BLs	 are	 known	 to	 involve	 reciprocal	 chromosome	 translocations	
between	the	c-MYC	locus	on	chromosome	8	with	 immunoglobulin	heavy	or	 light	chain	 loci	
on	chromosome	14,	2	or	22	[82-84].			
1.2.2.2.	Hodgkin	lymphoma		
Hodgkin	 lymphoma	 is	 a	malignancy	 in	which	 a	 small	 number	 of	 neoplastic	Hodgkin	 Reed-
Sternberg	 (HRS)	 cells,	 displaying	 type	 II	 latency,	 are	 surrounded	 by	 an	 inflammatory	
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infiltrate;	comprised	of	granulocytes,	lymphocytes,	plasma	cells	and	histiocytes	[74,	81,	85].	
Hodgkin	 lymphoma	can	either	be	defined	as	 classical	Hodgkin	 lymphoma	 (cHL)	or	nodular	
lymphocyte-predominant	 lymphoma	 (NLPHL).	 Of	 these	 two	 groups,	 EBV	 has	 a	 stronger	
association	 with	 cHL	 [86].	 cHL	 most	 commonly	 affects	 the	 lymph	 nodes,	 spleen,	 bone	
marrow	 and	 liver.	 In	 these	 tissues,	 less	 than	 1%	 cellularity	 is	 due	 to	 the	 HRS	 cells.	 The	
majority	of	proliferations	in	the	affected	tissues	are	due	to	the	inflammatory	cells	[74].	Upon	
histological	 analysis,	 cHL	 can	 be	 further	 classified	 into	 lymphocyte	 predominance	 (LP),	
nodular	sclerosis	(NS),	mixed	cellularity	(MC)	and	lymphocyte	depletion	(LD)	subtypes	[77].	
Of	these	subtypes	EBV	associates	more	frequently	with	MC	and	LD	than	with	NS	and	LP	[81].		
The	origin	of	HL	has	been	a	topic	of	intense	debate	[77].	However,	it	is	now	widely	accepted	
that	in	the	majority	of	cases	HRS	cells	are	germinal	centre	(GC)	B	cells.	Through	analysing	the	
immunoglobulin	 genes	 of	 HRS	 cells,	 it	 was	 found	 that	 they	 had	 undergone	 somatic	
hypermutation	(SHM).	These	mutations	were	found	to	prevent	HRS	cells	from	expressing	a	
functional	BCR	 [74,	77].	Usually,	GC	B	cells	 that	 lack	a	BCR	die	by	apoptosis.	However,	 the	
expression	of	LMP2,	which	can	mimic	BCR	signals,	enables	the	HRS	cells	to	survive	[85].	
1.2.2.3.	Nasopharyngeal	Carcinoma	
Nasopharyngeal	 carcinoma	 (NPC)	 is	 an	 epithelial	 malignancy	 that	 occurs	 sporadically	
worldwide,	but	 is	 far	more	prevalent	 in	Southern	China	and	Southeast	Asia	 [42,	87,	88].	 In	
Southern	China	NPC	is	the	third	most	common	diagnosed	cancer	and	it	can	affect	up	to	50	
persons	 per	 100	 000	 [89].	 NPC	 can	 be	 divided	 into	 three	 types	 based	 on	 histological	
inspection;	i.e.	keratinising	squamous	cell	carcinoma	(type	I),	differentiated	non-keratinising	
squamous	 cell	 carcinoma	 (type	 I)	 and	 undifferentiated	 non-keratinising	 squamous	 cell	
carcinoma	 [90].	 The	 non-keratinising	 types	 are	 very	 common	 and	 account	 for	 more	 than	
80%	of	NPC	 cases	worldwide.	 Importantly,	 these	 two	 are	 almost	 always	 EBV	 positive	 [74,	
90].		
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EBV-positive	NPC	cells	display	gene	expression	that	is	intermediate	between	what	has	been	
observed	 for	BL	 (latency	 I)	and	HL	 (latency	 II).	NPC	cells	always	express	EBNA1	and	EBERs,	
however,	 in	 around	50%	of	 cases	 LMP1	and	 LMP2	proteins	 can	also	be	detected	 [74,	 89].	
EBNA1	 is	 known	 to	 be	 required	 for	 EBV	 episome	 maintenance,	 but	 in	 the	 case	 of	 NPC,	
EBNA1	 has	 also	 been	 shown	 to	 promote	 cell	 survival	 and	 proliferation	 [91].	 Furthermore,	
EBNA1	expression	has	also	been	shown	to	contribute	to	tumorigenicity	and	metastasis	[90,	
91].	LMP1	and	LMP2A	expression	in	NPC	has	been	shown	to	induce	epithelial-mesenchymal	
transition	 (EMT)	 through	 the	 action	 of	 Snail	 and	 Twist;	 both	 of	which	 negatively	 regulate	
epithelial	cadherin	(E-cadherin)	[92,	93].	
NPC	differs	 from	other	head	and	neck	cancers	 in	 terms	of	 its	unusually	high	propensity	 to	
metastasise	and	in	terms	of	the	treatment	modalities	used,	i.e.	radiotherapy,	in	combination	
with	chemotherapy,	is	preferentially	used	for	treatment	rather	than	surgery	[94,	95].	This	is	
due	 to	 the	 increased	 sensitivity	of	NPC	 to	 radiotherapy	and	 chemotherapy	 [95].	However,	
since	 patients	 are	 usually	 diagnosed	 at	 an	 advanced	 stage,	 it	 is	 common	 for	 patients	 to	
experience	relapse	after	treatment.	Additionally,	the	occurrence	of	secondary	malignancies	
after	 treatment	 is	 common	 [89].	 Considering	 these	 issues	 collectively,	 and	 the	 high	
association	 rates	 with	 EBV,	 there	 is	 a	 keen	 interest	 in	 developing	 therapeutic	 and	
prophylactic	vaccines	that	specifically	target	EBV	components	[96].		
1.3.	Immune	responses	against	EBV	
1.3.1.	Innate	Immune	Responses		
The	 innate	 immune	 response	 provides	 the	 first	 line	 of	 defence	 against	 pathogens.	
Components	of	 innate	 immunity	exist	prior	to	pathogen	exposure	and	are	able	to	respond	
within	 minutes	 of	 infection	 [97].	 Traditionally,	 the	 innate	 immune	 system	 is	 thought	 to	
provide	defence	prior	to	the	activities	of	the	adaptive	 immune	system.	However,	 in	recent	
years	new	evidence	has	emerged	that	suggests	that	the	innate	immune	system	modifies	and	
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regulates	 the	 adaptive	 immune	 response	 [98].	 Furthermore,	 components	 of	 the	 innate	
immune	have	also	been	found	to	exhibit	memory-like	features	[99].	
In	the	case	of	EBV,	the	innate	immune	response	has	been	found	to	play	an	important	role	in	
managing	 infection	 [100,	 101].	 During	 the	 early	 phase	 of	 infection,	 the	 innate	 immune	
system	 recognises	 EBV	 pathogen-associated	 molecular	 patters	 (PAMPs)	 through	 pattern	
recognition	 receptors	 (PRR)	 [45,	 100].	 Several	 APCs	 express	 Toll-like	 receptors	 (TLR),	 a	
specific	 class	 of	 PRRs,	 which	 are	 able	 to	 recognise	 different	 components	 of	 EBV.	
Plasmacytoid	dendritic	cells	(pDCs),	B	cells	and	monocytes	express	an	endosomal	receptor,	
known	as	TLR9,	which	allows	them	to	recognise	the	unmethylated	DNA	of	incoming	virions	
[45,	 102].	 Activation	 of	 TLR9	 stimulates	 NFκB	 to	 induce	 the	 production	 pro-inflammatory	
cytokines	 [98].	 TLR3,	 another	 endosomal	 receptor,	 is	 expressed	 by	 conventional	 dendritic	
cells	(cDCs)	and	enables	the	recognition	of	hairpin	structures	of	EBERs.	EBERs	interact	with	
the	EBER-binding	protein	known	as	La,	and	when	released	from	dead	cells,	can	be	taken	up	
and	 recognised	 by	 cDCs.	 Additionally,	 EBERs	 can	 also	 be	 recognised	 by	 the	 intracellular	
PAMP	known	as	retinoic	acid-inducible	gene	1	(RIG-1)	[102].	In	addition	to	being	sensed	by	
intracellular	TLRs,	EBV	can	also	be	recognised	by	a	TLR	expressed	on	the	surface	of	immune	
cells.	Specifically,	TLR2	is	expressed	on	the	surface	of	monocytes	and	its	interaction	with	EBV	
leads	to	the	release	of	monocyte	chemotactic	protein	1	(MCP-1)	[103].		
Natural	 killer	 (NK)	 cells	 are	 known	 to	 be	 an	 important	 component	 of	 the	 innate	 immune	
system	that	enables	protection	against	viruses	and	cancer	[101].	In	the	case	of	EBV,	NK	cells	
are	 the	 main	 effector	 cells	 of	 the	 innate	 immune	 response	 [97].	 NK	 cells	 carry	 out	 their	
effector	 functions	 through	 the	 secretion	 of	 cytokines,	 mediating	 the	 activity	 of	 other	
immune	cells,	or	through	cytotoxic	activity	[104].	 In	humans,	there	are	two	NK	cell	subsets	
that	 are	 responsible	 for	 carrying	out	 these	 functions.	 The	CD56brightCD16-KIR-	subset	is	 less	
mature	 and	 is	 commonly	 found	 within	 lymphoid	 organs.	 These	 cells	 are	 responsible	 for	
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secreting	 IFN-γ,	 tumour	 necrosis	 factor	 and	 granulocyte-macrophage	 colony-stimulating	
factor	 (GMSF).	 In	 contrast,	 the	 CD56dimCD16+KIR+	 subset	 is	 more	 differentiated	 and	 is	
commonly	 found	within	 the	blood.	 These	 cells	 contain	preformed	perforin	 and	granzymes	
and	are	poised	to	release	them	upon	stimulation	[45,	104,	105].	The	activities	of	NK	cells	in	
conjunction	with	APCs	are	summarised	in	Fig.	1.7.		
	
Figure	 1.7:	 An	 overview	 of	 the	 innate	 immune	 response	 against	 EBV.	 EBERs	 are	 expressed	 within	
infected	B	cells.	Upon	cell	death	EBERs,	along	with	their	binding	partner	La,	are	released	and	taken	up	
by	 cDCs.	 The	 endosomal	 TLR3	 becomes	 activated	 by	 the	 EBERs	 and	 results	 in	 the	 release	 of	 IL-12	
[102].	 CD56brightCD16-KIR-	NK	 cells	 (CD56b)	 in	 turn	 secrete	 IFN-γ	 and	 restrict	 B	 cell	 infection	 [100].	
Furthermore,	 IFN-γ	 is	also	known	to	 limit	B	cell	 transformation	 [45].	Unmethylated	DNA	within	EBV	
particles	 is	 able	 to	 stimulate	 TLR9	 in	 pCDs.	 This	 results	 in	 the	 secretion	 of	 IFN-α/β	 and	 the	
concomitant	activation	of	CD56dimCD16+KIR+	NK	cells	 (CD56a).	These	cells	destroy	EBV	 infected	cells	
through	the	release	of	cytotoxic	molecules	[102].		
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1.3.2.	Adaptive	Immune	Responses	
1.3.2.1.	Antibody	Response	
Lytic	 and	 latent	 antigens	 are	 both	 targeted	 by	 the	 antibodies	 of	 infected	 hosts	 [106]	 (Fig.	
1.8).	 Viral	 capsid	 antigen	 (VCA)-specific	 IgM	 is	 one	 of	 the	 first	 antibodies	 that	 can	 be	
detected	 after	 the	 onset	 of	 IM	 [75].	 The	 VCA-IgM	 response	 last	 for	 2-3	 months	 and	 this	
enables	 it	to	be	used	as	an	 indicator	of	primary	 infection	[107].	Conversely,	VCA-IgG	is	not	
very	 useful	 for	 the	 diagnosis	 of	 IM.	 VCA-IgG	 appears	 several	 weeks	 after	 the	 onset	 of	
symptoms	and	persists	 lifelong	 [106].	 EBNA1-IgG	appears	 in	 the	blood	of	most	 individuals	
three	months	 after	 primary	 infection,	 but	 once	 they	 appear	 they	 can	be	detected	 lifelong	
[75].		
	
Figure	1.8:	 EBV	 load	and	EBV-specific	 antibodies	during	 symptomatic	primary	EBV	 infection.	During	
the	initial	phase	of	primary	infection,	the	level	of	EBV	is	relatively	high	within	the	oral	cavity.	For	this	
reason,	EBV	can	usually	be	detected	in	the	oral	cavity	with	quantitative	PCR	before	it	detected	in	the	
blood.	Moreover,	EBV	is	cleared	much	faster	from	the	blood	than	in	the	oral	compartment.	Shedding	
of	virions	from	the	oral	cavity	generally	persists	for	several	months	after	primary	infection.	However,	
shedding	can	also	occur	sporadically	 in	healthy	carriers.	VCA-IgM	and	VCA-IgG	 levels	rise	during	the	
early	 stages	 of	 primary	 infection,	 while	 EBNA1-IgG	 is	 only	 detected	 months	 later.	 This	 figure	 was	
taken	from	Odumade	et	al.,	2011	[75].		
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1.3.2.2.	Cellular	immune	response		
The	activities	of	CD4+	and	CD8+	T	cells	are	fundamental	to	the	control	of	acute	and	persistent	
EBV	infection	[108].		Both	CD8+	and	CD4+	T-cell	populations	have	been	studied	in	the	context	
of	IM	(Fig.	9A),	with	the	former	receiving	more	attention	thus	far.		During	the	acute	phase	of	
IM	 there	 is	 a	 dramatic	 expansion	 of	 the	 CD8+	 compartment.	 The	 large	 majority	 of	 the	
expanded	 CD8+	 T	 cells	 are	 virus-specific	 [45,	 105,	 109].	 The	 CD4+	 compartment	 expands	
significantly	 less	 when	 compared	 to	 the	 CD8+	 compartment.	 However,	 when	 specificities	
against	 individual	 epitopes	 are	 considered	 collectively,	 they	 comprise	 a	 much	 larger	
proportion	of	the	total	T-cell	pool	[45,	110].	Despite	this	discrepancy	between	the	CD8+	and	
CD4+	responses	to	EBV	infection,	it	is	thought	that	both	CD8+	and	CD4+	T	cells	are	required	to	
control	 EBV	 infection.	 Immunocompromised	 transplant	 patients	 suffering	 from	 PTLD	 are	
usually	 treated	 with	 preparations	 containing	 CD4+	 and	 CD8+	 components	 [108].	
Furthermore,	 better	 clinical	 outcomes	 are	 observed	 when	 the	 T-cell	 preparations	 have	
broader	specificity	and	when	they	contain	higher	proportions	of	CD4+	T	cells	[111,	112].		
The	response	of	healthy	seropositive	individuals	has	also	been	studied	with	regards	to	their	
immunodominance	 hierarchies	 (Fig.	 9B).	 Unsurprisingly,	 memory	 responses	 in	 healthy	
individuals	reflect	the	immunodominance	hierarchies	observed	in	IM	patients.	Memory	CD8+	
T	 cells	 respond	 readily	 to	 lytic	 cycle	 antigens.	 In	 particular,	 the	 CD8+	 memory	 response	
shows	a	marked	hierarchy	towards	IE	and	E	antigens	[110].	In	addition	to	lytic	proteins,	CD8+	
T	cells	from	healthy	donors	also	respond	frequently	to	members	of	the	EBNA3	family	[113].	
Memory	CD4+	T	cells			respond				broadly	to	lytic	and	latent	antigens.	CD4+	responses	against	
lytic	cycle	antigens	(e.g.	gp110	(BALF)	and	gp350	(BLLF1))	can	frequently	be	detected,	while	
CD8+	responses	against	these	antigens	are	rarely	detected	[108,	110].	Interestingly,	work	by	
Adhikary		et		al.,		2006	[108]		have	shown		that		gp350-		and		gp110-specific		CD4+		T		cells		are		
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Figure	1.9:	Cellular	immune	responses	to	EBV.	(A)	Response	kinetics	during	primary	symptomatic	EBV	
infection.	 	 The	blue	 shaded	 area	 represents	 the	 first	 4-6	weeks	 after	 primary	 infection.	During	 this	
time	signs	and	symptoms	are	apparent	but	it	is	difficult	to	perform	detailed	diagnostics.	Dotted	lines	
during	 this	period	 signify	uncertainty	about	a	particular	parameter.	 	 (i)	 CD8+	T	 cells	 specific	 against	
lytic	antigens	expand	massively	during	the	initial	phase	of	IM.	Conversely,	CD8+	T	cells	specific	against	
latent	antigens	are	far	 less	abundant.	As	signs	and	symptoms	disappear,	the	number	of	CD8+	T	cells	
specific	for	latent	and	lytic	antigens	in	blood	decreases.	This	observation	is	more	pronounced	for	lytic	
antigen-specific	CD8+	T	cells.	(ii)	EBV-specific	CD4+	T	cells	are	significantly	less	numerous	compared	to	
EBV-specific	 CD8+	 T	 cells.	 Furthermore,	 CD4+	 responses	 decline	 much	 faster	 than	 CD8+	 responses.	
Latent	 epitope-specific	 responses	 are	 usually	 more	 dominant	 than	 those	 of	 lytic	 antigen-specific	
responses.	 Unique	 amongst	 latent	 epitope	 CD4+	 T-cell	 responses,	 EBNA1-specific	 CD4+	 T	 cells	 only	
appear	 months	 after	 IM.	 (B)	 EBV	 antigens	 recognised	 by	 memory	 CD4+	 and	 CD8+	 T	 cells.	 Healthy	
seropositive	donors	contain	T	cells	that	are	specific	against	latent	and	immediate-early	(IE),	early	(E)	
and	 late	 (L)	 antigens.	 The	 data	 displayed	was	 obtained	 primarily	 through	 IFN-γ	 ELISPOT	 analysis	 of	
CD4+	 or	 CD8+	 depleted	 PBMCs.	 The	 frequency	 and	 intensity	 of	 each	 response	 is	 illustrated.	 ‘Not	
tested’	(n.t.)	is	indicated	for	antigens	that	were	not	analysed.	The	image	was	adapted	from	Hislop	et	
al.,	2007	[110]	and	Taylor	et	al.,	2015	[45].		
cytotoxic	in	character;	i.e.		they		control	the		outgrowth		of			EBV-infected			cells		through		the		
release		of	granzyme	B	and	perforin.	CD4+	cytolytic	T-cell	(CTL)	responses	are	known	to	occur	
when	individuals	suffer	from	chronic	viral	 infections.	CD4+	CTLs	have	also	been	reported	to				
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respond	to	human	cytomegalovirus	 (HCMV),	hepatitis	virus,	and	human	 immunodeficiency	
virus	1	infections	[114].	Responses	of	CD4+	T	cells	to	latent	proteins	have	been	well	studied	
and	healthy	donors	have	been	found	to	respond	frequently	to	a	number	of	 latent	proteins	
[110,	115].	Many	 individuals	develop	CD4+	T-cell	 responses	against	 latent	antigens	despite	
the	fact	that	latent	antigens	are	endogenously	derived.	It	is	thought	that	DCs	or	B	cells	take	
up	latent	antigens	released	from	infected	cells	and	present	them	on	MHC	class	II	molecules	
[115].	 In	the	case	of	EBNA1,	there	 is	a	more	 intriguing	explanation	for	the	development	of	
CD4+	T-cell	responses.	Loading	of	cytosolic	EBNA1	peptides	onto	MHC	class	II	molecules	have	
been	 shown	 to	 occur	 after	 autophagy.	 Specifically,	 EBNA1	 is	 taken-up	 by	 autophagocytic	
vesicles,	 transported	 to	 lysosomes,	 processed	 and	 loaded	 onto	 MHC	 class	 II	 molecules.		
Considering	that	EBNA1	is	expressed	during	almost	all	forms	of	latency	(viz.	type	I,	II	and	III),	
it	might	suggest	an	important	role	for	EBNA1-specific	CD4+	T	cells	in	healthy	hosts	[116].		
1.3.3.	Immune	Evasion		
EBV	has	evolved	a	plethora	of	immune	evasion	mechanisms	that	target	innate	and	adaptive	
immune	 components	 [117].	 In	 fact,	 EBV	 encodes	 a	 lytic	 cycle	 protein	 that	 is	 capable	 of	
targeting	 the	 innate,	 CD4+	 and	 CD8+	 responses.	 This	 protein	 is	 an	 alkaline	 exonuclease	
(BGLF5)	that	has	RNase	activity	[118].	The	RNase	activity	of	BGLF5	enables	it	to	mediate	host	
shutoff;	 i.e.	destabilise	host	 cell	mRNA	such	 that	host	protein	 synthesis	 is	down	 regulated	
[119].	Some	of	the	genes	that	are	targeted	in	this	manner	include	those	that	encode	TLR2,	
TLR9,	 HLA	 I	 and	 HLA	 II	 molecules.	 Two	 additional	 proteins	 are	 produced	 during	 lytic	
replication	 that	 contributes	 to	 immune	 evasion;	 viz.	 BNLF2a	 and	 BCRF1	 [120].	 BCRF1	 is	 a	
viral	 homologue	 of	 the	 anti-inflammatory	 IL-10,	 which	 is	 known	 to	 negatively	 affect	 the	
priming	of	CD4+	cells	and	 their	effector	 functions	 [117].	BNLF2a	 is	a	protein	 that	has	been	
found	 to	 integrate	 into	 ER	membranes	 and	 interfere	with	 the	 TAP	 transporter	 associated	
with	HLA	class	I	presentation	[110].		
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EBV	also	encodes	 immune	evasion	proteins	 that	 form	part	of	virions.	The	major	 tegument	
protein	BNRF1	and	 the	 large	 tegument	protein	BPLF1	have	both	been	 identified	as	having	
immune	evasive	properties	[121,	122].	BNRF1	has	been	shown	to	disrupt	the	functioning	of	
promyelocytic	leukemia	nuclear	bodies	(PML-NBs).	PML-NBs	carry	out	antiviral	activities	by	
suppressing	the	expression	of	viral	DNA	[123].	The	disruption	of	PML-NBs	by	BNRF1	ensures	
the	occurrence	of	viral	 latency	and	cellular	 immortalisation	post-infection	[124].	BPLF1	 is	a	
deubiquitinase	(DUB)	and	it	uses	this	activity	to	interfere	with	intermediates	of	TLR	signaling	
pathways.	 By	 interfering	 with	 TLR	 signaling,	 BPLF1	 is	 able	 to	 inhibit	 the	 production	 of	
cytokines	in	the	presence	of	TLR	stimulation	[117].		
1.4.	Vaccination	against	EBV	
The	 first	 virus	 that	was	 shown	 to	be	oncogenic	 in	humans	 is	 EBV	 [48].	 Subsequent	 to	 this	
paradigm-shifting	discovery,	vaccination	against	EBV	has	been	touted	as	a	possible	means	of	
limiting	 EBV-associated	 diseases	 and	 cancers.	 Epstein	 and	 Achong	 suggested	 vaccination	
against	 EBV	 as	 early	 as	 1973	 [125].	 Unfortunately,	 despite	 decades	 of	 research,	 no	 EBV	
vaccine	has	made	it	onto	the	market.		
The	struggle	towards	a	prophylactic	vaccine	is	not	exclusive	to	EBV,	but	it	has	also	been	the	
case	for	the	majority	of	human	herpesviruses.	The	only	human	herpesvirus	for	which	there	is	
currently	 a	 licensed	 vaccine	 is	 the	 varicella-zoster	 virus	 (VZV).	 VZV,	 also	 known	 as	 human	
herpesvirus	 3	 (HHV-3),	 is	 an	 alphaherpesvirus	 that	 is	 responsible	 for	 the	 development	 of	
varicella	(or	chickenpox)	and	zoster	(or	shingles)	[126,	127].	Varicella	is	a	self-limiting	disease	
that	occurs	during	primary	 infection,	usually	 in	childhood,	and	is	characterised	by	a	diffuse	
vesicular	rash	[127,	128].	As	with	EBV,	VZV	establishes	a	life-long	latent	infection	subsequent	
to	 primary	 infection	 [126].	 	 VZV	 is	 able	 to	 reactivate,	 usually	 in	 older	 individuals	 or	 the	
immunocompromised,	and	results	 in	a	painful	vesicular	rash	that	can	be	followed	by	post-
herpetic	 neuralgia	 (PHN)	 [129].	 Vaccines	 have	 been	 developed	 that	 prevent	 varicella	 and	
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zoster.	Both	vaccines	are	based	on	the	 live	attenuated	Oka	strain	 that	was	 first	 isolated	 in	
Japan	[126].	The	only	difference	between	the	two	is	that	the	zoster	vaccine	is	given	at	a	dose	
14	 times	 higher	 than	 the	 varicella	 vaccine	 [130].	 Once	 individuals	 are	 vaccinated,	 the	
attenuated	Oka	 strain	 is	 able	 to	 carry	out	 latent	 infection	 in	a	 similar	 fashion	 to	wild-type	
VZV	 strains	 [126].	 Furthermore,	 vaccinated	 individuals	 are	not	protected	 from	 subsequent	
VZV	 infection	 [131].	 Despite	 the	 inability	 to	 achieve	 sterile	 immunity,	 vaccination	 still	
manages	to	prevent	up	to	85%	of	varicella	cases	and	69.8%	of	zoster	cases	[127].		
Vaccination	 against	 herpesviruses	 has	 also	 successfully	 been	 carried	 out	 in	 animals.	 An	
excellent	 example	 is	 that	Marek’s	disease	 (MD),	 a	 lymphoproliferative	disease	 that	 afflicts	
poultry.	MD	 is	 caused	 by	 the	 highly	 oncogenic	 alphaherpesvirus	 know	 as	Marek’s	 disease	
virus	(MDV)	or	Gallid	herpesvirus	2	(GaHV-2)	[132,	133].	Fowls	that	acquire	MD	suffer	from	
paralysis,	 blindness	 and	 develop	 lymphomas	 within	 visceral	 organs	 [132].	 As	 with	 VZV,	
vaccination	against	MDV	is	achieved	through	the	use	of	a	live	attenuated	vaccine.	The	most	
widely	used	vaccine	 is	a	high	passage	clone	of	 the	CVI988	strain	 that	was	 first	used	 in	 the	
Netherlands	[134,	135].	Vaccinated	fowls	are	protected	from	mortality	and	the	development	
of	 MD.	 Vaccination	 against	 MD	 was	 the	 first	 instance	 in	 which	 a	 cancer	 was	 prevented	
through	the	use	of	antiviral	vaccination.	It	is	important	to	note	that	vaccination	against	MD	
does	not	prevent	infection	with	MDV	[135].		
The	majority	 of	 prophylactic	 EBV	 vaccines	 that	 have	 been	 investigated	 have	 targeted	 the	
envelope	 glycoprotein	 gp350	 [131,	 136].	 This	 glycoprotein	 was	 selected	 due	 to	 its	
abundance	 within	 viral	 membranes	 and	 the	 membranes	 of	 infected	 cells.	 Furthermore,	
gp350	 is	 a	 frequent	 target	 of	 neutralising	 antibodies	 [73].	 gp350	 based	 vaccines	 initially	
showed	great	promise	when	 tested	 in	non-human	primates;	 i.e.	 cotton-top	 tamarins	 [137,	
138],	 common	 marmosets	 [139]and	 rhesus	 macaques	 [140].	 In	 all	 of	 these	 studies,	
vaccination	was	shown	to	offer	some	form	of	protection,	e.g.	a	reduction	in	seroconversion,	
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EBV	 viral	 load	 or	 the	 development	 of	 lymphomas.	 In	 contrast,	 results	 obtained	 from	 a	
handful	 of	 clinical	 trials	 in	 humans	 have	 been	 less	 impressive.	 The	 largest	 of	 these	was	 a	
phase	II,	double-blind,	randomised,	placebo	controlled	trial	[71].	 In	total,	181	EBV	negative	
young	adults	(aged	16	to	25)	were	given	three	doses	of	a	recombinant	gp350	vaccine	or	the	
placebo.	 The	 vaccine	 was	 well	 tolerated	 and	 almost	 all	 vaccinated	 individuals	 (99%)	
developed	anti-gp350	responses.	Nineteen	months	after	vaccination,	it	was	established	that	
the	 vaccine	 did	 not	 protect	 individuals	 from	 EBV	 infection.	 However,	 it	 was	 found	 that	
vaccination	greatly	reduced	the	incidence	(78%)	of	IM	over	a	2-year	observation	period.		
Our	group	recently	developed	a	vaccine	candidate	in	the	form	of	EBV	virus-like	particles	and	
light	 particles	 (VLPs/LPs),	 herein	 referred	 to	 as	 DNA-free	 EBV	 (DFEBV)	 [9].	 Deletion	 of	 the	
BFLF1/BFRF1A-coding	sequence	from	wtEBV	(B95-8	strain)	produced	a	mutant	incapable	of	
packaging	 viral	 genomes.	 Since	 BFRF1A	 is	 an	 integral	 part	 of	 the	 terminase	 complex,	 a	
collection	 of	 proteins	 that	 cleave	 DNA	 concatemers	 into	 individual	 genomes	 prior	 to	
packaging	 into	 capsids,	 its	 deletion	 prevented	 packaging	 of	 viral	 DNA.	 Importantly,	 the	
mutant	EBV	particles	were	shown	to	be	as	immunogenic	as	wtEBV,	with	both	tegument-	and	
envelope-specific	 T	 cells	 being	 stimulated	 by	 DFEBV.	Whilst	 the	 absence	 of	 DNA	 rendered	
DFEBV	non-infectious,	the	deletion	of	gp110	has	recently	been	shown	necessary	to	abrogate	
the	toxic	potential	of	EBV	structural	proteins	 [141].	This	suggests	 that	deletion	of	gp110	 is	
necessary	for	DFEBV	to	be	considered	as	a	suitable	prophylactic	vaccine	candidate.		
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2.	Aims	and	objectives	
DFEBV	that	lacks	gp110,	hereafter	simply	referred	to	as	DFEBV,	is	highly	immunogenic,	devoid	
of	 viral	 DNA,	 incapable	 of	 infection	 and	 non-toxic	 [9,	 141].	 Whilst	 these	 characteristics	
indicate	that	DFEBV	has	potential	as	a	prophylactic	vaccine	candidate,	it	is	completely	devoid	
of	 latent	 proteins.	 Latency	 is	 a	 major	 aspect	 of	 the	 EBV	 life	 cycle,	 and	 vaccination	 with	
lytic/structural	 proteins	 would	 not	 afford	 protection	 if	 a	 subset	 of	 infected	 cells	 are	 left	
untargeted	and	latency	is	established.		
To	address	the	aforementioned	shortcoming	of	DFEBV,	the	primary	aim	of	the	present	thesis	
was	 to	 enlarge	 the	 antigenic	 spectrum	 of	 DFEBV	 to	 include	 latent	 proteins.	 Ideally,	 the	
incorporated	 latent	 proteins	 should	 not	 compromise	 the	 antigenicity	 of	 preexisting	
structural	proteins.	Thus,	enabling	the	stimulation	of	latent	protein-	and	structural	protein-
specific	 T	 cells	 (Fig.	 2.1).	 A	 secondary	 aim	 of	 this	 thesis	 was	 to	 extensively	 examine	 the	
antigenicity	of	DFEBV	containing	latent	proteins.	The	following	objectives	were	established	to	
determine	whether	DFEBV	containing	latent	protein	moieties	has	potential	as	a	prophylactic	
vaccine	candidate:		
(i) Design	a	strategy	to	introduce	latent	antigens	into	DFEBV.		
(ii) Develop	a	method	of	quantifying	DFEBV.	
(iii) Comprehensively	interrogate	the	antigenicity	of	DFEBV	containing	latent	antigens	
in	vitro	and	ex	vivo.	
(iv) Evaluate	 the	 performance	 of	 DFEBV	 containing	 latent	 antigens	 in	 an	 in	 vivo	
model.		
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Figure	 2.1:	 The	 introduction	 of	 latent	 proteins	 into	 DFEBV	 is	 proposed	 to	 enlarge	 its	 antigenic	
spectrum.	(A)	Enlarging	the	antigenic	spectrum	of	DFEBV	to	include	latent	proteins	(solid	red	dots).	(B)	
Modified	 DFEBV	 binds	 to	 antigen	 presenting	 cells	 (APCs)	 that	 express	 CD21	 and	 is	 taken	 up	 via	
receptor-mediated	 endocytosis.	 Alternatively,	modified	 DFEBV	 is	 phagocytosed	 by	 phagocytic	 APCs.	
Particles	 are	 degraded	 in	 endolysosomes/phagolysosomes	 to	 release	 peptides	 from	 multiple	
structural	 proteins	 (e.g.	 membrane	 proteins	 (solid	 green	 dots),	 capsid	 proteins	 (not	 shown)	 and	
tegument	proteins	(solid	blue	dots).	(C)	Epitopes	from	various	proteins	are	loaded	onto	MHC	class	II	
molecules.	(D)	Epitope-loaded	MHC	class	II	molecules	are	transported	to	the	surface	of	the	APC	and	
engage	the	TCRs	of	T	cells.	Structural	proteins	and	latent	proteins	can	prime	different	T-cell	clones.		
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3.	Results		
3.1.	Enlarging	the	antigenic	spectrum	of	wtEBV	with	latent	proteins		
3.1.1.	Constructing	EBV	mutants	containing	BNRF1-latent	protein	fusions	
To	 determine	 the	 possibility	 of	 introducing	 latent	 proteins	 into	 DFEBV,	 we	 opted	 to	 first	
modify	wtEBV.		Since	wtEBV	can	be	accurately	quantified	with	real-time	qPCR,	it	enables	the	
antigenicity	of	modified	particles	to	be	accurately	assessed;	i.e.	reliably	relate	antigenicity	to	
virus	 titre.	 In	 order	 to	 introduce	 latent	 proteins	 into	 viral	 particles,	 the	 major	 tegument	
protein	 BNRF1	 was	 utilised.	 Since,	 BNRF1	 is	 abundant	 within	 virions	 and	 is	 highly	
immunogenic	[8,	9,	22],	it	implied	that	latent	proteins	could	be	incorporated	into	virions	by	
fusing	 them	 to	 BNRF1.	 Thus,	 the	 BNRF1	 ORF	 was	 modified	 with	 galK	 recombination	 to	
accommodate	 latent-protein	 coding	 sequences.	 The	 5’	 region	 of	 the	 BNRF1	 ORF	 was	
specifically	modified	because	it	is	not	conserved	amongst	γ-herpesviruses	and	has	not	been	
ascribed	 a	 function	 (Fig.	 3.1A).	 BNRF1	 is	member	 of	 the	 family	 of	 viral	 proteins	 known	 as	
viral	 phosphoribosylformylglycineamide	 amidotransferases	 (vFGARATs)	 [123].	Members	 of	
this	 protein	 family	 have	 conserved	 FGAM	 and	 GAT1	 domains	 towards	 their	 C-terminus.	
Hence,	it	was	rationalised	that	modification	of	the	5’	region	of	BNRF1	is	unlikely	to	influence	
packaging	of	BNRF1-fusion	proteins	into	virions.	
Galk	recombination	was	performed	on	wtEBV	bacterial	artificial	chromosome	(BAC)	DNA	to	
generate	 a	BNRF1-EBNA3C	 gene	 fusion.	 Since,	 is	 EBNA3C	 is	 a	 highly	 immunogenic	 protein	
[115]	 that	 is	 expressed	 during	 latency	 type	 III	 [142],	 it	 is	 a	 promising	 vaccine	 candidate.	
Details	 regarding	galK	 recombination	are	described	 in	 section	5.2.10.	The	 first	 step	 in	galK	
recombination	was	the	insertion	of	the	galK	cassette	into	the	target	site,	in	this	case,	the	5’	
region	of	the	BNRF1	ORF1.	 In	a	second	step,	the	galK	cassette	was	replaced	with	a	150	bp	
fragment	encoding	 the	5H11	epitope	 from	EBNA3C.	Figure	3.1B	 illustrates	 the	BNRF1	ORF	
before	and	after	galK	recombination.		
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Once	a	BAC	mutant	was	generated	in	E.coli,	 it	was	introduced	into	mammalian	293	cells	to	
generate	 producer	 cells	 upon	 hygromycin	 selection.	 The	 EBV-EC3	 (150	 bp)	 BAC	 DNA	
contained	within	293	producer	cells		was	rescued		in		E.coli		and		analysed	through	restriction		
	
Figure	3.1:	Construction	of	EBV	BAC	DNA	encoding	a	BNRF1-EBNA3C	fusion	protein.	(A)	The	structure	
of	the	BNRF1	ORF.	Domains	conserved	amongst	vFGARATs	(FGAM	and	GAT1)	are	highlighted	in	dark	
grey,	while	the	functional	Daxx-interaction	domain	(DID)	interaction	domain	is	shown	in	dark	grey.	(B)	
Galk	recombination	was	carried	out	with	a	150	bp	fragment	encoding	the	5H11	epitope	of	EBNA3C.	
The	schematic	indicates	EcoRI	and	BamHI	restriction	sites	before	and	after	recombination,	as	are	the	
sizes	of	 the	 fragments	generated	by	 these	enzymes.	 (C)	Recombinant	BAC	DNA	from	E.coli	and	293	
producer	cells	were	analysed	via	restriction	digestion.	EcoRI	and	BamHI	was	selected	to	 interrogate	
the	integrity	of	EBV-E3C	(150	bp).	White	arrows	emphasise	DNA	fragments	that	are	different	between	
wtEBV	DNA	(B95-8)	and	DNA	modified	with	galK	recombination.	(D)	The	BNRF1-latent	protein	fusion	
does	 not	 influence	 lytic	 replication	 in	 293	 producer	 cells.	 Producer	 cells	were	 transfected	with	 the	
lytic	 cycle	 transactivator	BZLF1	and	were	analysed	 for	 the	expression	of	 the	 late	 lytic	 gene	product	
gp350.	 Induced	293	producer	cells	were	stained	with	and	analysed	with	α-gp350	and	α-mouse	 IgG-
Cy3	antibodies	immunofluorescence.		
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digestion	 (Fig.	3.1C).	Digestion	of	BAC	DNA	with	EcoRI	and	BamHI	confirmed	that	 the	DNA	
contained	 within	 producer	 cells	 was	 the	 same	 as	 the	 DNA	 constructed	 with	 galK	
recombination	 in	 E.coli.	 Furthermore,	 restriction	 digestion	 also	 showed	 that	 BAC	 DNA	
modified	through	galK	recombination	displayed	the	appropriate	digestion	pattern.	Digestion	
of	 EBV-E3C	 (150	 bp)	 BAC	 DNA	 with	 EcoRI	 and	 BamHI	 respectively	 showed	 that	
recombination	 gave	 rise	 to	 4.3	 kb	 and	 ∼10.9	 kb	 fragments	 as	 expected.	 Lastly,	 DNA	
sequencing	 was	 carried	 out	 to	 confirm	 that	 the	 BNRF1-latent	 protein	 gene	 fusion	 was	
correctly	constructed.		
Next,	 the	 newly	 generated	 293/EBV-EC3	 (150	 bp)	 producer	 cell	 line	 was	 analysed	 for	 its	
ability	to	support	lytic	replication	and	produce	modified	virions.	A	plasmid	encoding	the	lytic	
cycle	transactivator	BZLF1	was	transfected	into	producer	cells	and	they	were	analysed	with	
immunofluorescence	 for	 the	 expression	 of	 the	 late	 lytic	 protein	 gp350	 (Fig.	 3.1D).	 This	
showed	that	the	293/EBV-EC3	(150	bp)	cell	line	gave	a	similar	percentage	of	gp350-positive	
cells	as	the	293/wtEBV	producer	cell	line.	Furthermore,	qPCR	analysis	of	supernatants	from	
the	 293/EBV-EC3	 (150	 bp)	 producer	 cells	 frequently	 gave	 titers	 in	 the	 range	 of	 1	 x	 107	
genome	 equivalents	 (geq)/mL	 (data	 not	 shown),	 which	 is	 similar	 to	 293/wtEBV	 producer	
cells.	These	results	 indicate	that	BNRF1	can	be	modified	to	contain	latent	antigens	without	
influencing	lytic	replication	in	producer	cells.		
3.1.2.	The	antigenicity	of	EBV	mutants	containing	BNRF1-latent	protein	fusions	
The	next	step	was	to	test	the	antigenicity	of	the	EBV-E3C	(150	bp)	virus.	To	this	end,	T	cells	
specific	 for	 BNRF1	 and	 EBNA3C	 were	 used.	 Autologous	 lymphoblastoid	 cell	 lines	 (LCLs),	
which	served	as	antigen-presenting	cells	(APCs),	were	pulsed	with	increasing	amounts	(geq)	
of	wtEBV	and	EBV-E3C	 (150	bp).	Concurrently,	 LCLs	were	pulsed	with	peptide	 (BNRF1	VSD	
epitope	or	EBNA3C	5H11	epitope)	or	medium	only,	which	respectively	served	as	positive	and	
negative	controls.	The	pulsed	LCLs	were	then	cocultured	with	HLA-matched	CD4+	T	cells	that	
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were	specific	for	BNRF1	VSD	or	EBNA3C	5H11	epitopes	and	T-cell	activation	was	determined	
by	 quantifying	 IFN-γ	 in	 cell	 culture	 supernatants	 (Fig.	 3.2).	 This	 revealed	 that	 LCLs	 pulsed	
with	 EBV-E3C	 (150	 bp)	 and	 wtEBV	 were	 recognised	 to	 the	 same	 degree	 by	 BNRF1	 VSD-
specific	CD4+	T	cells.	This	indicates	that	BNRF1	contained	within	the	EBV-E3C	(150	bp)	virus	is	
as	 antigenic	 as	 that	 of	 wtEBV.	 This	 implies	 that	 modification	 of	 BNRF1	 to	 contain	 latent	
antigen	does	not	influence	the	antigenicity	of	BNRF1.	Furthermore,	the	T-cell	responses	that		
	
Figure	3.2:	EBV	virions	containing	BNRF1-EBNA3C	fusion	proteins	are	recognised	by	EBNA3C-specific	
CD4+	T	cells.	The	antigenicity	of	EBV-E3C	(150	bp)	and	wtEBV	were	concurrently	tested	against	BNRF1	
VSD-	and	EBNA3C	5H11-specific	T	 cells.	 LCLs	were	pulsed	with	1	x	104,	1	x	105	and	1	x	106	genome	
equivalents	(geq)	or	peptide	controls	(pg	to	μg	quantities)	and	then	cocultured	with	the	relevant	CD4+	
T	 cells.	 The	degree	of	 T-cell	 activation	was	determined	by	measuring	 IFN-γ	 release	with	 ELISA.	 The	
data	shown	in	each	graph	represents	triplicate	values	and	error	bars	indicate	standard	deviation.	Each	
graph	is	a	representative	experiment	of	at	least	three.		
were	generated	corresponded	to	the	amount	of	virus	applied.	The	antigenicity	of	the	EBV-
E3C	(150	bp)	virus	was	further	confirmed	through	a	T-cell	activation	assay	with	the	EBNA3C	
5H11-specific	 CD4+	 T-cell	 clone.	 LCLs	 pulsed	 with	 the	 EBV-E3C	 (150	 bp)	 virus	 was	 well	
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recognised	 by	 the	 EBNA3C	 5H11-specific	 CD4+	 T	 cells,	 whilst	 LCLs	 pulsed	with	wtEBV	was	
unrecognised.	 This	 confirms	 that	 the	 antigenic	 spectrum	 of	 wtEBV	 could	 be	 enlarged	
through	the	construction	of	BNRF1-latent	proteins	fusions.	
To	confirm	that	the	antigenicity	of	supernatants	containing	EBV-E3C	(150	bp)	was	exclusively	
due	 to	BNRF1-EBNA3C	 fusion	proteins	 contained	within	 viruses,	 a	 control	 experiment	was	
performed	 with	 the	 72A1	 neutralising	 antibody	 [143].	 Specifically,	 EBV-E3C	 (150	 bp)	 and	
wtEBV	supernatants	were	preincubated	with	neutralising	antibody	and	used	in	T-cell	antigen		
	
Figure	 3.3:	 Neutralising	 antibody	 that	 recognises	 gp350	 impairs	 the	 antigenicity	 of	 EBV	 containing	
BNRF1-EBNA3C	 fusion	 proteins.	 EBV-E3C	 (150	 bp)	 and	wtEBV	 supernatants	 containing	 1	 x	 106	 geq	
were	 pre-incubated	 with	 different	 concentrations	 of	 the	 72A1	 antibody	 (50,	 5	 and	 0	 μg/mL)	 and	
mixed	with	LCLs.	Pulsed	LCLs	were	cocultured	with	BNRF1	VSD-	and	EBNA3C	5H11-specific	CD4+	T	and	
the	 release	of	 IFN-γ	was	quantified	by	 ELISA.	 Each	data	point	 shown	 in	 the	presented	 graph	 is	 the	
average	of	triplicate	values	and	error	bars	represent	standard	deviation.	Furthermore,	each	graph	is	a	
representative	experiment	of	at	least	three.		
recognition	assays	as	before	(Fig.	3.3).	This	showed	that	the	72A1	neutralising	antibody	was	
able	 to	 diminish	 the	 antigenicity	 of	 EBV-E3C	 (150	bp)	 and	wtEBV,	with	 higher	 neutralising	
antibody	concentrations	having	a	greater	impact.	Furthermore,	this	was	the	case	for	BNRF1	
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and	 EBNA3C.	 This	 confirmed	 that	 EBV-E3C	 (150	 bp)	 stimulates	 EBNA3C	 5H11-	 and	 BNRF1	
VSD-specific	CD4+	T	cells	with	proteins	contained	within	virions.		
3.2.	Confirming	the	antigenicity	of	BNRF1-latent	protein	fusions	in	DFEBV	
3.2.1.	The	construction	of	DFEBV	encoding	a	BNRF1-latent	protein	fusion	
The	next	objective	was	to	confirm	whether	BNRF1-latent	protein	fusions	could	also	be	used	
to	 enlarge	 the	 antigenic	 spectrum	 of	 DFEBV.	 Since	 deletion	 of	 the	 glycoprotein	 gp110	
prevents	 EBV	 from	 fusing	 with	 host	 cells	 [37]	 and	 eliminates	 the	 toxic	 potential	 of	 its	
structural	proteins	[141],	only	DFEBV	lacking	gp110	was	utilised	in	the	present	study.		
The	 BNRF1	 ORF	 of	 wtEBV	 and	 DFEBV	 BAC	 DNA	 were	 concurrently	 modified	 to	 contain	
EBNA3C	 and	 EBNA1	 coding-sequences.	 EBNA1	 is	 the	 latent	 protein	 most	 frequently	
recognised	by	the	population	[144],	and	is	expressed	in	all	types	of	 latency	(except	type	0)	
and	 in	 all	 EBV-positive	 malignancies	 [145].	 This	 implies	 that	 EBNA1	 is	 also	 a	 promising	
candidate	for	prophylactic	vaccination	 in	addition	to	EBNA3C.	A	300	bp	fragment	encoding	
the	 EBNA3C	 5H11	 and	 EBNA1	 3E10	 epitopes	was	 successfully	 introduced	 into	wtEBV	 and	
DFEBV	BAC	DNA	(Fig.	3.4A	and	B).	Next,	recombinant	BAC	DNA	mutants	were	introduced	into	
293	cells	 in	order	to	generate	producer	cells.	The	BAC	DNA	contained	within	293	producer	
cells	were	rescued	in	E.coli	and	were	analysed	alongside	the	BAC	DNA	originally	generated	in	
E.coli	through	galK	recombination	(Fig.	3.4C	and	D).	Digestion	of	DFEBV-E3C-E1	(300	bp)	and	
DFEBV-E3C-E1	(300	bp)	BAC	DNA	with	EcoRI	gave	rise	to	a	4.5	kb,	while	digestion	with	BamHI	
gave	 rise	 to	a	11	kb	 fragment.	This	 showed	that	BAC	DNA	contained	within	producer	cells	
was	the	same	as	the	BAC	DNA	constructed	in	E.coli.	Lastly,	recombinant	BAC	DNA	mutants		
were	subjected	to	DNA	sequencing	to	confirm	that	the	BNRF1-EBNA3C-EBNA1	gene	fusions	
were	correctly	constructed.		
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Figure:	 3.4	 Construction	 of	 wtEBV	 and	 DFEBV	 BAC	 clones	 encoding	 BNRF1-EBNA3C-EBNA1	 fusion	
proteins.	The	BNRF1	ORF	 from	wtEBV	 (A)	and	DFEBV	 (B)	are	 shown	before	and	after	 recombination	
with	 the	 300	 bp	 EBNA3C-EBNA1	 fragment.	 The	 schematic	 indicates	 position	 of	 EcoRI	 and	 BamHI	
restriction	 sites	 before	 and	 after	 recombination,	 as	 are	 the	 size	 of	 fragments	 generated	 by	 these	
enzymes.	 	Digestion	of	EBV-E3C-E1	(300	bp)	 (C)	and	DFEBV-E3C-E1	(300	bp)	 (D)	BAC	DNA	from	E.coli	
and	 293	 producer	 cells	 with	 EcoRI	 and	 BamHI.	 White	 arrows	 emphasise	 DNA	 fragments	 that	 are	
different	between	unmodified	and	modified	BAC	DNA.		
3.2.2.	Quantification	of	DFEBV	with	flow	cytometry		
The	quantification	of	DFEBV	was	a	prerequisite	to	determine	its	antigenicity.	However,	since	
DFEBV	lacks	DNA,	one	cannot	use	real-time	qPCR	for	quantification	purposes.	Instead,	the	B-
cell-binding	 ability	 of	 DFEBV	 was	 exploited	 for	 quantification	 purposes	 (Fig.	 3.5A).	 First,	
wtEBV	was	titrated	and	incubated	with	Elijah	B	cells	and	quantified	with	flow	cytometry	(Fig.	
3.5B).	This	 showed	the	amount	of	virus	 that	bound	 to	B	cells	 correlated	 to	virus	 titre.	The	
median	 fluorescence	 intensity	 (MFI)	was	 determined	 for	 each	histogram	and	 then	plotted	
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against	virus	titre	(geq)	(Fig.	3.5C).	This	revealed	that	the	relationship	between	the	MFI	and	
virus	 titre	 was	 linear.	 Since	 MFI	 values	 could	 be	 easily	 determined	 for	 DFEBV,	 the	 linear	
relationship	shown	in	Figure	3.5	C	could	be	used	to	quantify	the	number	of	DFEBV	particles	
that	were	contained	within	cell	culture	supernatants.			
	
	
Figure	3.5:	DFEBV	can	be	reliably	quantified	with	flow	cytometry.	(A)	Schematic	representation	of	the	
experimental	 setup.	 B	 cells	 exposed	 to	 wtEBV	 or	 DFEBV	 were	 stained	 with	 mouse	 α-gp350	 (72A1	
clone)	and	α-mouse	IgG-Cy3	antibodies	and	analysed	with	flow	cytometry.	(B)	wtEBV	quantified	with	
real-time	qPCR	was	added	in	increasing	amounts	(2.5	x	106	-	1.0	x	107	geq)	to	B	cells	and	analysed	with	
flow	 cytometry.	 Histograms	 representing	 B	 cells	 bound	 by	 wtEBV	 are	 overlaid.	 (C)	 The	 median	
fluorescence	intensity	(MFI)	values	from	the	histograms	shown	in	(B)	were	plotted	against	virus	titre	
(qeq).	This	revealed	a	linear	relationship	between	MFI	and	virus	titre.		
3.2.3.	A	comparison	of	EBV-E3C-E1	(300	bp)	and	DFEBV-E3C-E1	(300	bp)		
After	normalisation	with	 flow	cytometry,	 the	B-cell	binding	ability	and	antigenicity	of	EBV-
E3C-E1	(300	bp)	and	DFEBV-E3C-E1	(300	bp)	were	compared.	Equal	quantities	of	EBV-E3C-E1	
(300	bp)	and	DFEBV-E3C-E1	(300	bp)	were	incubated	with	EBV-negative	Elijah	B	cells	and	then	
analysed	with	immunofluorescence	(Fig.	3.6A).	This	indicated	that	EBV-E3C-E1	(300	bp)	and	
DFEBV-E3C-E1	(300	bp)	bound	to	B	cells	to	a	similar	degree,	as	is	indicated	by	the	number	of	
particles	 bound	 to	 cells.	 Similarly,	 B	 cells	 were	 incubated	 with	 EBV-E3C-E1	 (300	 bp)	 and	
DFEBV-E3C-E1	(300	bp)	as	before	and	analysed	with	flow	cytometry	(Fig.	3.6B).	This	showed	
that	82.6%	of	B	cells	incubated	with	EBV-E3C-E1	(300	bp)	were	gp350-postive,	while	83.7%	
of	B	cells	 incubated	with	DFEBV-E3C-E1	(300	bp)	stained	gp350-postive.	This	confirmed	that	
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that	 both	 EBV-E3C-E1	 (300	 bp)	 and	 DFEBV-E3C-E1	 (300	 bp)	 bound	 to	 B	 cells	with	 a	 similar	
efficiency.	Thus,	confirming	that	DFEBV	can	be	reliably	quantified	with	flow	cytometry.		
	
Figure	 3.6:	 Normalised	 EBV-E3C-E1	 (300	 bp)	 and	 DFEBV-E3C-E1	 (300bp)	 bind	 to	 B	 cells	 to	 a	 similar	
degree.	 	EBV-negative	Elijah	B	cells	were	exposed	to	EBV-E3C-E1	(300	bp)	(1	x	106	geq)	and	DFEBV-
E3C-E1	(300bp)	(1	x	106	particles)	and	analysed	by	immunofluorescence	(A)	and	flow	cytometry	(B).	
Particles	bound	to	B	cells	were	stained	with	α-gp350	and	α-mouseIgG-Cy3	antibodies	prior	to	analysis.	
DAPI	 staining	was	 carried	 out	 in	 order	 visualise	 individual	 cells	with	 immunofluorescence.	 PBS	was	
used	as	a	negative	control	in	all	experiments.		
Next,	 the	antigenicity	of	normalised	EBV-E3C-E1	 (300	bp)	and	DFEBV-E3C-E1	 (300	bp)	were	
compared	in	T-cell	activation	assays.	T	cells	having	four	different	specificities	were	analysed	
for	 their	 ability	 to	 recognise	 LCLs	pulsed	with	EBV-E3C-E1	 (300	bp)	 and	 DFEBV-E3C-E1	 (300	
bp)	 (Fig.	 3.7).	 This	 showed	 that	 BNRF1	 VSD-,	 gp350	 1D6-,	 EBNA3C	 5H11-,	 EBNA1	 3E10-
specific	 CD4+	 T	 cells	 released	 similar	 amounts	 of IFN-γ	when	 cocultured	with	 EBV-E3C-E1	
(300	 bp)-	 or	 DFEBV-E3C-E1	 (300	 bp)-pulsed	 LCLs.	 This	 confirmd	 that	 the	 antigenicity	 of	
modified	DFEBV,	which	 lacked	gp110,	was	the	same	as	modified	EBV	that	contained	gp110.	
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Additionally,	 these	 results	 showed	 that	 DFEBV	 could	 successfully	 be	 modified	 to	 contain	
different	latent	antigens.			
	
Figure	3.7:	 DFEBV	 containing	 EBNA3C	 (E3C)	 and	 EBNA1	 (E1)	 is	 antigenic	 despite	 lacking	 gp110.	 LCLs	
were	concurrently	pulsed	with	1	x	106	particles	of	DFEBV-E3C-E1	(300bp)	and	1	x	10
6	geq	of	EBV-E3C-
E1	(300	bp)	and	cocultured	with	BNRF1	VDS-,	gp350	1D6-,	EBNA3C	5H11-	and	EBNA1	3E10-specicific	
CD4+	 T	 cells.	 Additionally,	 LCLs	 were	 pulsed	 with	 the	 relevant	 control	 peptides	 prior	 to	 being	
cocultured	with	T	cells.	 	The	recognition	of	LCLs	by	the	relevant	T	cells	was	quantified	with	an	IFN-γ	
ELISA.	Each	data	point	shown	in	the	presented	graph	is	the	average	of	triplicate	values	and	error	bars	
represent	 standard	 deviation.	 Furthermore,	 each	 graph	 is	 a	 representative	 experiment	 of	 at	 least	
three.		
3.3.	BNRF1	mutants	containing	large	latent	protein	fragments	
3.3.1.	The	construction	BNRF1	mutants	containing	large	EBNA3C	fragments	
Thus	 far,	 DFEBV	was	 successfully	 engineered	 to	 contain	well-defined	 epitopes	 from	EBNA1	
and	 EBNA3C.	 However,	 the	 ideal	 prophylactic	 candidate	 should	 contain	 enough	 latent	
protein	epitopes	to	cover	the	majority	of	HLA	haplotypes	encoded	by	the	human	population.	
One	way	to	maximise	 the	number	of	epitopes	within	 DFEBV,	 is	 through	the	 introduction	of	
large	latent	protein	fragments.		
To	explore	this	possibility,	large	EBNA3C	coding-sequences	were	introduced	into	the	BNRF1	
of	EBV.	 Specifically,	600	bp	and	900	bp	 fragments	 from	EBNA3C	were	 introduced	 into	 the	
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BNRF1	 ORF	 using	 galK	 recombination.	 Since,	 two	 EBV	 mutants	 have	 already	 been	
constructed	that	contain	150	bp	or	300	bp	within	the	BNRF1	ORF,	it	enabled	the	analysis	of	
EBV	mutants	that	encode	BNRF1-latent	protein	fusions	of	different	size.	The	construction	of	
EBV-E3C	(600	bp)	and	EBV-E3C	(900	bp)	BAC	DNA	mutants	are	shown	in	Figure	3.8	A	and	B.	
Producer	cells	were	generated	using	the	mutant	EBV	BAC	DNA	and	BAC	DNA	from	293/EBV-
E3C	 (600	 bp)	 and	 29/EBV-E3C	 (900	 bp)	 producer	 cells	 digested	 with	 EcoRI	 and	 BamHI	 to	
determine	their	integrity	(Fig.	3.8	C	and	D).	As	expected,	digestion	with	of	EBV-E3C	(600	bp)		
	
Figure	3.8:	Construction	of	EBV	BAC	DNA	encoding	large	BNRF1-EBNA3C	fusions.	Galk	recombination	
was	carried	out	with	EBNA3C-coding	sequences	spanning	600	bp	(A)	and	900	bp	(B).	The	schematic	
indicates	position	of	EcoRI	and	BamHI	restriction	sites	before	and	after	recombination,	as	well	as	the	
size	of	fragments	generated	by	these	enzymes.	Recombinant	BAC	DNA	from	E.coli	and	293	producer	
cells	 were	 analysed	 via	 restriction	 digestion.	 EcoRI	 and	 BamHI	 were	 selected	 to	 interrogate	 the	
integrity	of	EBV-E3C	(600	bp)	(C)	and	EBV-E3C	(900	bp)	(D).	White	arrows	emphasise	DNA	fragments	
that	are	different	between	wild-type	EBV	DNA	(B95-8)	and	DNA	modified	with	galK	recombination.	
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and	 EBV-E3C	 (900	 bp)	 BAC	 DNA	 with	 EcoRI	 respectively	 gave	 rise	 to	 4.7	 kb	 and	 5	 kb	
fragments,	whilst	digestion	with	BamHI	gave	rise	to	a	9.1	kb	band.	Lastly,	BAC	DNA	mutants	
were	analysed	by	sequencing	to	confirm	their	integrity.	
3.3.2.	The	expression	and	packaging	of	BNRF1-latent	protein	fusions	of	increasing	
size	
The	293/EBV-E3C	(150	bp),	293/EBV-E3-E1C	 (300	bp),	293/EBV-E3C	(600	bp)	and	293/EBV-
E3C	(900	bp)	producer	cells	were	analysed	for	their	ability	to	express	BNRF1-fusion	proteins	
and	 package	 them	 into	 virions.	 The	 expression	 of	 BNRF1	 within	 producer	 cell	 lines	 was	
tested	after	they	had	been	induced	to	undergo	lytic	replication	(Fig.	3.9A).	This	showed	that	
almost	 all	 BNRF1-latent	 protein	 fusions,	 except	 for	 the	 one	 encoded	 by	 the	 293/EBV-E3C	
(900	 bp)	 producer	 cell	 line,	 were	 successfully	 expressed.	 In	 those	 producer	 cell	 lines	 that	
were	positive	 for	 BNRF1-latent	 protein	 expression,	 the	molecular	weight	 of	 proteins	were	
higher	 when	 they	 encoded	 larger	 latent	 protein-coding	 sequences.	 Additionally,	 the	
expression	levels	of	different	BNRF1-latent	protein	fusions	were	found	to	vary.	It	is	unclear	
whether	 the	 slight	 variation	 in	 expression	 levels	 were	 due	 to	 differences	 in	 expression	
efficiency,	protein	stability	or	whether	it	was	due	to	different	degrees	of	lytic	replication	in	
the	induced	producer	cells.	However,	none	of	these	possibilities	were	followed-up.		
Next,	 the	 ability	 of	 the	 different	 BNRF1-latent	 protein	 fusions	 to	 be	 packaged	 into	 virions	
was	 tested.	The	ability	of	virions	 to	stimulate	BNRF1	VSD-specific	CD4+	T	cells	 (see	section	
3.1.2	 and	 3.2.3)	 implies	 that	 they	 contain	 BNRF1.	 Thus,	 the	 ability	 of	 virions	 to	 stimulate	
BNRF1-specific	CD4+	T	cells	was	used	as	a	read-out	for	successful	packaging	of	BNRF1-latent	
protein	 fusions.	 This	 revealed	 that	 all	 modified	 viruses,	 except	 for	 EBV-E3C	 (900	 bp),	
successfully	stimulated	BNRF1	VSD-specific	CD4+	T	cells	 (Fig.	3.9B),	 indicating	that	the	EBV-
E3C	(900	bp)	virus	was	the	only	one	that	did	not	contain	a	BNRF1-latent	protein	fusion.	This	
result	is	unsurprising,	especially	since	the	293/EBV-E3C	(900	bp)	producer	cell	line	was	found	
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to	 lack	 BNRF1	 protein	 upon	western	 blot	 analysis.	 The	 the	 EBV-E3C	 (150	 bp),	 EBV-E3C-E1	
(300	bp)	and	EBV-E3C	(600	bp)	viruses	were	all	shown	to	stimulate	the	BNRF1	VSD-specific	
CD4+	T	cells,	indicating	that	they	all	successfully	packaged	their	BNRF1-latent	protein	fusions.	
There	was	 a	 slight	 reduction	 in	 recognition	 by	 the	 T	 cells	 as	 the	 size	 of	 the	 BNRF1-latent	
protein	 fusions	 increased,	 indicating	 that	 an	 increase	 in	 fusion	 protein	 size	 might	 have	 a	
slight	negative	impact	on	packaging	into	virions.	Taken	together,	these	results	indicate	that	
large	 BNRF1-latent	 epitope	 fusions,	 assuming	 they	 are	 expressed	 by	 producer	 cells,	 are	
successfully		incorporated		into		virus			particles.		From		the		current		set		of			experiments,		it			
	
Figure	 3.9:	 Testing	 the	 expression	 and	 antigenicity	 of	 BNRF1-EBNA3C	 fusions	 of	 increasing	 size.	 (A)	
Induced	293	producer	cells	containing	various	recombinant	EBV	mutants	were	analysed	by	western	
blot	with	α-BNRF1	and	α-actin	antibodies.	(B)	The	antigenicity	of	BNRF1-EBNA3C	fusions	of	increasing	
size.	 Autologous	 LCLs	 were	 pulsed	 with	 the	 same	 amount	 (1	 x	 106	 genomes/mL)	 of	 modified	 EBV	
encoding	 BNRF1-latent	 protein	 fusions	 of	 increasing	 size.	 The	 pulsed	 LCLs	 were	 cocultured	 with	
BNRF1-specific	CD4+	T	cells	and	the	release	of	IFN-γ	quantified	with	ELISA.	Each	data	point	shown	in	
the	presented	graph	 is	 the	average	of	 triplicate	values	and	error	bars	represent	standard	deviation.	
Furthermore,	each	graph	is	a	representative	experiment	of	at	least	three.		
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appears	as	though	600	bp	is	the	largest	latent	protein	coding-sequence	that	can	successfully	
be	accommodated	by	BNRF1.	From	this	perspective	it	is	unclear	whether	EBNA3C	is	optimal	
for	fusion	to	BNRF1.	EBNA3C	has	a	very	large	ORF,	2982	bp	to	be	exact,	and	only	encodes	a	
total	of	eleven	CD4-restricted	epitopes	[115].	
3.4.	DFEBV	encoding	BNRF1-EBNA1	fusion	proteins	
3.4.1.	The	construction	of	DFEBV	mutants	encoding	BNRF1-EBNA1	fusion	proteins		
A	 strategy	 for	 maximising	 the	 number	 of	 latent	 protein	 epitopes	 within	 DFEBV	 is	 by	
exclusively	 utilising	 epitope-rich	 antigens.	 A	 previous	 study	 has	 mapped	 the	 epitopes	 of	
several	 latent	proteins,	and	has	shown	that	EBNA1	is	particular	abundant	 in	CD4-restricted	
epitopes	 [115].	Furthermore,	 the	majority	of	epitopes	within	EBNA1	are	concentrated	 in	a	
single	region	spanning	roughly	200	amino	acids	(Fig.	3.10A).		
The	epitope-rich	region	of	EBNA1	was	used	to	construct	three	DFEBV	BAC	DNA	mutants	(Fig.	
3.10	B	and	C).	One	mutant,	termed	DFEBV-EBNA1RI:II,	was	constructed	to	encode	the	majority	
of	 CD4+	 epitopes	 from	EBNA1.	 The	EBNA1-coding	 sequence	used	 to	 construct	 this	mutant	
was	 around	∼700	 bp	 in	 length.	 Since	 700	 bp	 is	 very	 close	 to	 the	 upper	 limit	 identified	 in	
section	3.3,	two	additional	mutants	were	constructed	to	contain	smaller	regions	of	EBNA1.	
These	mutants,	 DFEBV-EBNA1RI	and	 DFEBV-EBNA1RII,	 contained	 regions	 from	 the	EBNA1	ORF	
that	are	∼350	bp	in	length.	Recombinant	BAC	DNA	mutants	were	introduced	into	293	cells	to	
generate	producer	 cell	 lines.	 Restriction	 analysis	 of	was	performed	with	EcoRI	 (Fig.	 3.10C)	
and	BamHI	(not	shown)	to	confirm	the	integrity	of	BAC	DNA	contained	within	producer	cells.	
Digestion	 of	 DFEBV-EBNA1RI,	DFEBV-EBNA1RII	and	DFEBV-EBNA1RI:II	with	EcoRI	 and	BamHI	 gave	
rise	 to	 the	 expected	 restriction	 fragments.	 In	 particular,	 digestion	 of	 DFEBV-EBNA1RI	 and	
DFEBV-EBNA1RII	with	 EcoRI	 rise	 to	 4.5	 kb	 fragment,	while	 digestion	 of	 DFEBV-EBNA1RI:II	gave	
rise	 to	 a	4.8	 kb	 fragment.	 Finally,	 BAC	DNA	was	 analysed	with	 sequencing	 to	 validate	 the	
BNRF1-EBNA1	gene	fusions.	
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Figure	3.10:	Construction	of	DFEBV	BAC	DNA	encoding	BNRF1-EBNA1	fusions.	(A)	The	EBNA1	protein	
contains	numerous	CD4+	T-cell	 epitopes.	Many	of	 the	CD4+	T-cell	 epitopes	 contained	within	EBNA1	
are	 found	within	 a	 single	 stretch	 a	 little	 bit	more	 than	 200	 aa	 in	 length.	 	 In	 total,	 the	 epitope	 rich	
region	encompasses	approximately	20	CD4-restricted	epitopes,	with	each	epitope	being	represented	
by	a	black	bar.	The	EBNA1	gene	also	contains	a	stretch	of	gly-ala	repeats	that	prevent	presentation	on	
HLA	 class	 I	molecules.	 The	 coding	 sequences	 for	 region	 I,	 II	 and	 I:II,	which	were	 arbitrarily	 named,	
were	 introduced	 into	 the	 BNRF1	ORF	 to	 respectively	 give	 rise	 to	 DFEBV-EBNA1
RI,	
DFEBV-EBNA1
RII	and	
DFEBV-EBNA1
RI:II	 BAC	 mutants.	 (B)	 Schematic	 representations	 of	 the	 BNRF1	 ORF	 before	 and	 after	
recombination	with	EBNA1-coding	sequences.	The	BNRF1	gene	was	modified	to	contain	region	I	(left),	
region	 II	 (middle)	 and	 region	 I:II	 (right)	 of	 EBNA1.	 EcoRI	 restriction	 sites	 are	 indicated,	 as	 are	
restriction	 fragments	generated	by	EcoRI	digestion.	 (C)	Recombinant	DFEBV	BAC	DNA	constructed	 in	
E.coli	 is	 the	 same	 as	 BAC	 DNA	 contained	 within	 293	 producer	 cells.	 DFEBV-EBNA1
RI	 (left),	 DFEBV-
EBNA1RII	 (middle)	 and	 DFEBV-EBNA1
RI:II	 (right)	 BAC	 DNA	 from	 E.coli	 and	 293	 producer	 cells	 were	
analysed	 via	 restriction	 digestion	 with	 EcoRI.	 White	 arrows	 emphasise	 DNA	 fragments	 that	 are	
different	between	unmodified	DFEBV	BAC	DNA	and	DNA	modified	with	galK	recombination.		
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3.4.2.	The	expression	DFEBV	encoding	BNRF1-EBNA1	fusions		
The	 ability	 of	 293/DFEBV-EBNA1RI,	 293/DFEBV-EBNA1RII	 and	 293/DFEBV-EBNA1RI:II	 producer	
cells	 to	 express	 the	 BNRF1-EBNA1	 fusion	 proteins	was	 tested	 via	western	 blot	 (Fig.	 3.11).	
This	 showed	 that	 the	293/DFEBV-EBNA1RI:II	producer	 cell	 line	 failed	 to	expressed	 its	BNRF1-
EBNA1	 fusion	 protein,	 whilst	 the	 293/DFEBV-EBNA1RI	and	 293/DFEBV-EBNA1RII	producer	 cell	
lines	successfully	expressed	their	BNRF1-EBNA1	fusion	proteins.	This	is	the	second	instance	
in	which	the	insertion	of	a	latent	protein-coding	sequence	larger	than	600	bp	precluded	the	
expression	 of	 a	 BNRF1-latent	 protein	 fusion.	 Since	 the	 DFEBV-EBNA1RI:II	mutant	 failed	 to	
express	the	BNRF1-EBNA1	fusion	protein,	it	was	excluded	from	further	analysis.	Conversely,	
DFEBV-EBNA1RI	and	DFEBV-EBNA1RII	successfully	expressed	their	BNRF1-EBNA1	fusion	proteins	
and	were	used	in	further	experiments.		
	
Figure	3.11:	The	expression	of	BNRF1-EBNA1	 fusion	proteins	by	 the	293/DFEBV-EBNA1
RI,	 293/DFEBV-
EBNA1RII	 and	 293/DFEBV-EBNA
RI:RII	 producer	 cell	 lines.	 The	 lytic	 cycle	 transactivator	 BZLF1	 was	
transfected	 into	producer	cells	and	 they	were	analysed	after	3	days	with	western	blotting.	Staining	
was	pefromed	with	the	α-BNRF1	and	α-actin	antibodies.		
3.5.	Investigating	the	antigenicity	of	DFEBV	containing	EBNA1	ex	vivo	
Next,	 the	 antigenicity	 DFEBV	 containing	 BNRF1-EBNA1	 fusion	 proteins	was	 tested	 in	 an	 ex	
vivo	 setting.	 To	 this	 end,	 DFEBV-EBNA1RI	 and	 DFEBV-EBNA1RII	were	 combined	 in	 1:1	 ratio,	
hereafter	referred	to	as	DFEBV-EBNA1RI+RII,	and	used	to	stimulate	memory	CD4+	T	cells	 from	
an	 unhaplotyped	 EBV-positive	 donor.	 However,	 since	 DFEBV-EBNA1RI+II	 is	 an	 assemblage	 of	
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several	dozen	EBV	proteins	[8],	it	would	stimulate	of	a	broad	pool	of	EBV-specific	memory	T	
cells	from	EBV-positive	donors.	In	order	to	assess	the	relevance	of	EBNA1	contained	within	
DFEBV	ex	vivo,	 it	was	necessary	to	develop	a	means	of	distinguishing	EBNA1-specific	T	cells	
from	structural	protein-specific	T	cells.	For	this	purpose,	antigen-armed	antibodies	 (AgAbs)	
were	utilised	[146].	AgAbs	are	antibody-antigen	fusion	proteins	that	enable	the	stimulation	
of	CD4+	T	cells	of	 interest.	AgAbs	deliver	their	antigenic	attachments	to	antigen-presenting	
cells,	which	process	and	present	the	antigenic	peptides	on	HLA	class	II	molecules	to	CD4+	T	
cells.	 Section	 3.5.1	 describe	 the	 construction	 of	 AgAbs	 that	 contain	 EBNA1	 or	 gp350	
antigenic	attachments	and	their	validation	as	tools	for	the	ex	vivo	expansion	of	T	cells,	whilst	
section	3.5.2	describes	the	use	of	AgAbs	to	expand	EBNA1-	and	gp350-specific	CD4+	T	cells	
from	polyclonal	pools	of	T	cells	generated	with	DFEBV-EBNA1RI+RII.	
3.5.1.	Antigen-Armed	antibodies	as	a	means	of	expanding	CD4+	T	cells	ex	vivo	
3.5.1.1.	Generation	of	Antigen-armed	antibodies		
In	 the	present	study,	AgAbs	were	constructed	by	 fusing	antigenic	moieties	downstream	of	
the	 CH3	 domain	 of	 an	 α-CD20	 antibody	 (see	 section	 5.2.11	 for	 details).	 Since	 the	 α-CD20	
antibody	specifically	binds	to	CD20	on	B	cells,	it	enables	α-CD20-based	AgAbs	to	be	delivered	
to	LCLs.	AgAbs	that	bind	to	LCLs	are	internalised,	processed	and	their	antigenic	peptides	are	
presented	 to	 the	 relevant	 T	 cells	 [146].	 AgAbs	 containing	 EBNA1	 and	 gp350	 antigenic	
attachments	 are	 shown	 in	 Figure	 3.12A.	 These	 AgAbs	 were	 engineered	 to	 contain	 large	
antigenic	fragments	from	EBNA1	(232	aa)	and	gp350	(470	aa)	to	maximise	their	potential	of	
expanding	EBV-specific	T	cells	from	unhaplotyped	EBV-positive	individuals.		
In	the	present	study,	the	EBNA1-AgAb	and	gp350-AgAb	were	produced	by	transfecting	293	
cells	 with	 AgAb	 heavy	 chains	 along	 with	 an	 α-CD20	 light	 chain.	 Assembled	 AgAbs	 were	
secreted	 into	 the	 cell	 culture	 medium,	 quantified	 with	 ELISA	 and	 analysed	 with	 western	
blotting	under	non-reducing	conditions	(Fig.	3.12B).	This	showed	that	the	EBNA1-AgAb	and	
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gp350-AgAb	 were	 larger	 than	 the	 unmodified	 α-CD20	 antibody.	 Next,	 the	 ability	 of	 the	
AgAbs	 to	bind	 to	LCLs	was	 tested	 (Fig.	3.12C).	 LCLs	were	 incubated	with	medium	or	equal	
quantities	of	EBNA1-AgAB,	gp350-AgAb,	α-CD20	or	 isotype	control	and	analysed	with	 flow	
cytometry.	This	showed	that	both	AgAbs	bound	to	LCLs	to	the	same	degree	as	unmodified	α-
CD20	antibody,	whilst	 the	 isotope	control	antibody	did	not	 interact	strongly	with	the	LCLs.	
This	indicated	that	the	antigenic	attachments	of	AgAbs	do	not	interfere	with	their	ability	to	
bind	to	LCLs.			
	
Figure	 3.12:	 Production	 of	 EBNA1	 and	 gp350	 containing	 AgAbs.	 (A)	 The	 domain	 structure	 of	
assembled	 AgAb	 molecules	 compared	 to	 unmodified	 α-CD20.	 (B)	 Western	 blot	 analysis	 of	 AgAbs	
under	non-reducing	conditions.	A	 total	of	1	ng	of	each	AgAb	and	α-CD20	antibody	was	 loaded	and	
staining	 was	 performed	 with	 α-mouse	 IgG-HRP.	 (C)	 AgAbs	 bind	 efficiently	 to	 B	 cells.	 LCLs	 were	
incubated	with	125	pmole	of	α-CD20	(black	line),	EBNA1-AgAb	(red	line),	gp350-AgAb	(green	line)	or	
isotype	 control	 (dotted	 line),	 stained	 with	 α-mouse	 IgG2a-PE	 and	 analysed	 with	 flow	 cytometry.	
Unstained	LCLs	were	analysed	in	parallel	(solid	grey).	
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3.5.1.2.	Confirming	the	antigenicity	of	AgAbs	
AgAbs	 were	 interrogated	 in	 vitro	 and	 ex	 vivo	 to	 confirm	 their	 antigenicity.	 For	 in	 vitro	
experiments,	CD4+	T	cells	were	used	that	recognise	the	EBNA1	3G2	or	gp350	1D6	epitopes.	
Autologous	LCLs	were	pulsed	with	EBNA1-AgAb,	gp350-AgAb,	control	peptides	(3G2	and	1D6	
epitopes)	 or	 medium	 (negative	 control)	 and	 then	 cocultured	 with	 the	 CD4+	 T	 cells.	 T-cell	
activity	was	 determined	by	 quantifying	 the	 release	 of	 IFN-γ	with	 an	 ELISA	 (Fig.	 3.13).	 This	
showed	 LCLs	 pulsed	 with	 EBNA1-AgAb,	 gp350-AgAb	 or	 control	 peptides	 were	 capable	 of	
stimulating	the	EBNA1-	and	gp350-specific	CD4+	T	cells,	whilst	LCLs	pulsed	with	medium	only	
were	not	recognised	by	the	T	cells.		
	
Figure	 3.13:	 The	 EBNA1-AgAb	 and	 gp350-AgAb	 are	 antigenic.	 T	 cells	 specific	 for	 the	 EBNA1	 3G2	
epitope	(A)	and	the	gp350	1D6	epitope	(B)	were	cocultured	with	LCLs	pulsed	with	peptide	controls,	
AgAbs	or	medium.	The	release	of	 IFN-γ	was	measured	with	an	ELISA.	Each	data	point	shown	 in	 the	
presented	 graph	 is	 the	 average	 of	 triplicate	 values	 and	 error	 bars	 represent	 standard	 deviation.	
Furthermore,	each	graph	is	a	representative	experiment	of	at	least	three.		
Next,	the	ability	of	the	gp350-AgAb	and	EBNA1-AgAb	to	expand	EBV-specific	memory	T	cells	
from	 EBV-positive	 donors	 was	 tested.	 Freshly	 isolated	 PBMCs	 from	 three	 donors	 were	
consecutively	stimulated	with	AgAbs	to	expand	gp350-	and	EBNA1-specific	CD4+	T	cells	(Fig.	
3.14A).	After	a	minimum	of	six	round	of	stimulation,	expanded	cells	were	analysed	with	flow	
cytometry	 to	 confirm	 the	 presence	 of	 CD4+	 T	 cells	 (Fig.	 3.14B).	 This	 showed	 that	 samples	
from	all	donors	consisted	primarily	of	CD4+	T	cells.	Next,	 it	was	 important	 to	 test	whether	
the	 ex	 vivo	 expanded	 CD4+	 T	 cells	were	 specific	 towards	 the	 EBNA1-AgAb	 or	 gp350-AgAb	
(Fig.	 3.14C).	 T-cell	 activation	 assays	 showed	 that	 CD4+	 T	 cells	 specifically	 recognised	 LCLs	
pulsed	 with	 AgAbs	 containing	 EBNA1	 or	 gp350	 antigenic	 attachments,	 whilst	 LCLs	 pulsed	
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with	 α-CD20	 or	 medium	 only	 were	 not	 recognised.	 These	 results	 confirm	 that	 AgAbs	
containing	large	antigenic	attachments	can	be	used	to	expand	EBV-specific	memory	CD4+	T	
cells	ex	vivo.	
		
Figure	3.14:	AgAbs	specifically	expand	EBV-specific	CD4+	memory	T	cells	from	EBV-positive	donors	ex	
vivo.	 (A)	 Bulk	 PBMCs	 were	 stimulated	 with	 AgAbs	 for	 several	 rounds	 to	 enable	 the	 expansion	 of	
EBNA1-	and	gp350-specific	cell	lines.	During	the	first	two	rounds	of	stimulation,	cells	were	stimulated	
with	both	the	EBNA1-AgAb	and	gp350-AgAb.	However,	after	the	second	round	the	EBNA1-AgAb	and	
gp350-AgAb	were	used	separately	to	respectively	enable	the	expansion	of	EBNA1-	and	gp350-specific	
T	 cells.	 (B)	 Ex	 vivo	 cultures	 consisted	 primarily	 of	 CD4+	 T	 cells.	 After	 a	 minimum	 of	 six	 rounds	 of	
stimulation,	 cells	were	 stained	with	α-CD4-PE-Cy5	and	α-CD3-FITC	and	analysed	by	 flow	cytometry.	
The	percentage	of	CD3/CD4	double-positive	cells	are	indicated.	(C)	Ex	vivo	expanded	CD4+	T	cells	are	
specific	for	AgAbs	containing	EBNA1	and	gp350.	Autologous	LCLs	were	pulsed	with	EBNA1-	or	gp350-
AgAbs,	as	well	as	α-C20	and	medium.	Pulsed	LCLs	were	cocultured	with	T	cells	and	IFN-gamma	release	
was	measured	 via	 an	 ELISA.	 Representative	 results	 from	 a	 single	 donor	 are	 given.	 Each	 data	 point	
shown	 in	 the	presented	graph	 is	 the	average	of	duplicate	values	and	error	bars	 represent	standard	
deviation.	Furthermore,	each	graph	is	a	representative	experiment	of	at	least	two.	
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3.5.2.	Expansion	of	EBV-specific	memory	CD4+	T	cells	with	DFEBV-EBNA1	and	AgAbs	
Having	validated	AgAbs	as	tools	for	expanding	EBV-specific	memory	CD4+	T	cells	from	EBV-
positive	donors,	the	EBNA1-AgAb	and	gp350-AgAb	were	respectively	used	to	expand	EBNA1-	
and	 gp350-specific	 CD4+	 T	 cells	 from	 PBMCs	 stimulated	 with	 unmodified	 DFEBV	 or	 DFEBV-
EBNA1RI+RII	(Fig.	3.15).		
	
Figure	 3.15:	 Stimulation	 scheme	 using	 DFEBV	 or	 DFEBV-EBNA1
RI+RII	 and	 AgAbs	 containing	 EBNA1	 or	
gp350.	 Bulk	 PBMCs	 were	 exclusively	 stimulated	 with	 DFEBV	 or	 DFEBV-EBNA1
RI+RII	 for	 the	 first	 two	
stimulation	 rounds	 (∼30	days).	 Thereafter,	 the	EBNA1-AgAb	or	 gp350-AgAb	were	used	 to	enrich	ex	
vivo	cultures	for	the	presence	of	gp350-	or	EBNA1-specific	T	cells.		
Ex	 vivo	 cultures	 that	 resulted	 from	 at	 least	 six	 rounds	 of	 stimulation	 (see	 Fig.	 3.15)	were	
analysed	by	 flow	cytometry	and	 interrogated	with	T-cell	 activation	assays	 (Fig.	3.16).	 Flow	
cytomteric	analysis	confirmed	that	ex	vivo	cultures	consisted	primarily	of	CD4+	T	cells.	T-cell	
recognition	assays	showed	that	gp350-specific	CD4+	T	cells	were	expanded	from	PBMCs	that	
were	 initially	 stimulated	 with	 DFEBV	 or	 DFEBV-EBNA1RI+RII.	 However,	 EBNA1-specific	 T	 CD4+	
cells	 were	 only	 expanded	 from	 PBMCs	 that	 were	 stimulated	 with	 DFEBV-EBNA1RI+RII.	 This	
validated	 the	 antigenicity	 of	 the	 EBNA1	 moieties	 contained	 within	 DFEBV-EBNA1RI+RII.	 The	
expanded	CD4+	T	cells	were	also	screened	against	several	epitope	peptides,	and	found	that	
the	 EBNA1-specific	 T	 cells	 and	 gp350-specific	 T	 cells	 respectively	 responded	 to	 the	 EBNA1	
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3G2	and	 gp350	1D6	peptides.	However,	 the	 gp350-specific	 T	 cells	 stimulated	 initially	with	
DFEBV-stimulated	 PBMCs	were	 only	weakly	 reactive	 to	 the	 gp350	 1D6	 epitope.	 Suggesting	
that	the	majority	of	gp350-specific	T	cells	expanded	in	this	instance	are	specific	for	another	
gp350	epitope.		
Taken	 together,	 these	 results	 confirm	 that	 the	 EBNA1	 contained	within	modified	 DFEBV	 is	
antigenic	in	an	ex	vivo	setting,	enabling	the	stimulation	of	EBNA1-specific	CD4+	T	cells	from	
an	 unhaplotyped	 EBV-positive	 donor.	 Additionally,	 the	 antigenicity	 of	 gp350	 contained	
within	modified	and	unmodified	DFEBV	was	also	confirmed.		
	
Figure	 3.16:	 The	 expansion	 of	 antigen-specific	 CD4+	 T	 cells	 from	PBMCs	 stimulated	with	 DFEBV	 and	
DFEBV-EBNA1
RI+RII.	 PBMCs	 from	 a	 healthy	 EBV-positive	 donor	 were	 stimulated	 exclusively	 with	
unmodified	DFEBV	or	DFEBV-EBNA1
RI+RII	for	two	rounds.	Subsequently,	ex	vivo	cultures	were	stimulated	
with	the	gp350-AgAb	and/or	EBNA1-AgAb	for	a	minimum	of	 four	rounds	 in	order	to	enrich	cultures	
for	 gp350-	 or	 EBNA1-specific	 T	 cells.	 (Top	 panel)	 After	 six	 rounds	 of	 stimulation	 ex	 vivo	 cultures	
contained	 primarily	 CD4+	 T	 cells.	 Cells	 were	 stained	 with	 α-CD4-PE-Cy5	 and	 α-CD3-FITC	 prior	 to	
analysis.	 The	 percentage	 of	 CD3/CD4	 double-positive	 cells	 in	 ex	 vivo	 cultures	 are	 shown.	 (Bottom	
panel)	 The	 expanded	 CD4+	 T	 cells	 are	 specific	 for	 EBV	 antigens.	 Autologous	 LCLs	were	 pulsed	with	
EBNA1-AgAb,	gp350-AgAb,	EBNA1	3G2	peptide	or	gp350	1D6	peptide.	Pulsed	LCLs	were	cocultured	
overnight	with	 the	expanded	CD4	T-cell	 lines	 and	 IFN-γ	 release	was	quantified	with	 an	 ELISA.	 Each	
data	point	shown	in	the	presented	graph	is	the	average	of	triplicate	values	and	error	bars	represent	
standard	deviation.	Furthermore,	each	graph	is	a	representative	experiment	of	at	least	three.	
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3.6.	Determining	the	cytotoxic	ability	of	ex	vivo	expanded	memory	CD4+	T	cells		
Cytolytic	 CD4+	 T	 cells	 are	 important	 for	 controlling	 EBV	 infection	 and	 its	 malignant	
consequences	 [147-149].	 Hence,	 the	 ex	 vivo	 stimulated	 EBNA1-	 and	 gp350-specific	 T	 cells	
(see	section	3.5.2)	were	further	characterised	to	determine	whether	they	were	cytolytic	 in	
character.	 First,	 the	 memory	 CD4+	 T	 cells	 were	 tested	 for	 the	 expression	 of	 CD107a,	 a	
surrogate	marker	for	degranulation	[150].	The	EBNA1-	and	gp350-specific	CD4+	T	cells	were	
cocultured	with	LCLs	 that	were	pulsed	with	either	α-CD20	or	 the	relevant	AgAb,	and	were	
stained	 for	CD4	and	CD107a	and	analysed	via	 flow	cytometry	 (Fig.	4.17).	This	showed	that	
both	 EBNA1-	 and	 gp350-specific	 CD4+	 T-cells	 were	 capable	 of	 expressing	 CD107a	 when	
cocultured	 with	 the	 LCLs	 that	 were	 pulsed	 with	 the	 either	 EBNA1-AgAb	 or	 gp350-AgAb.	
Importantly,	LCLs	that	were	pulsed	with	α-CD20	were	significantly	less	proficient	at	inducing	
CD107a	expression	in	the	CD4+	memory	T-cell	lines.	In	the	case	of	the	EBNA1-specific	CD4+	T-
cell	 line,	 CD107a	 expression	 was	 shown	 to	 range	 between	 8	 and	 10%.	While	 the	 gp350-
specific	CD4+	T-cell	 line	was	 shown	 to	express	CD107a	considerably	more,	with	expression	
ranging	between	35	and	50%.		
Once	the	memory	T	cells	were	shown	to	be	positive	for	CD107	expression,	it	was	necessary	
to	 determine	 whether	 they	 were	 capable	 of	 releasing	 molecules	 directly	 involved	 in	
cytolysis.	Hence,	memory	CD4+	T	 cells	were	analysed	 for	 their	 ability	 to	 release	 the	 serine	
protease	 granzyme	 B	 [151].	 EBNA1-	 and	 gp350-specific	 CD4+	 T	 cells	were	 cocultured	with	
LCLs	pulsed	with	the	relevant	AgAbs	and	epitope	peptides	and	the	secretion	of	granzyme	B	
was	detected	with	an	ELISA	(Fig.	3.18).	This	showed	that	EBNA1-	and	gp350-specific	T	cells	
released	considerable	amounts	of	granzyme	B	in	the	presence	of	LCLs	pulsed	with	AgAb	and	
epitope	 peptides	 derived	 from	 EBNA1	 or	 gp350.	 Conversely,	 when	 the	 CD4+	 T	 cells	 were	
incubated	 with	 LCLs	 that	 were	 pulsed	 with	 medium	 or	 α-CD20,	 they	 did	 not	 release	
substantial	amounts	of	granzyme	B.		
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Figure	3.17:	Memory	CD4+	 T	 cells	 specific	 for	 EBNA1	and	 gp350	express	CD107a.	 LCLs	were	pulsed	
with	EBNA1-AgAb	or	gp350-AgAb	and	respectively	cocultured	with	EBNA1-	or	gp350-specific	CD4+	T-
cells.	LCLs	were	pulsed	with	α-CD20	as	a	negative	control	prior	to	cocultured	with	the	T	cells.	After	a	
total	of	eight	hours	of	coculture,	cells	were	stained	with	α-CD4-PE-Cy5	and	CD107a-FITC	and	analyzed	
with	 flow	 cytometry.	 The	 percentage	 of	 cells	 that	 were	 CD4+CD107a+	 double-positive	 is	 shown.	
Representative	results	from	at	least	three	experiments	are	shown.		
	
	
	
Figure	 3.18:	 Ex	 vivo	 expanded	memory	 CD4+	 T	 cells	 release	 granzyme	 B	 in	 response	 to	 EBNA1	 or	
gp350.	 LCLs	 were	 pulsed	 with	 EBNA1-AgAb	 or	 gp350-AgAbs	 and	 were	 cocultured	 overnight	 with	
memory	 CD4+	 T	 cells.	 Similarly,	 LCLs	 were	 also	 pulsed	 with	 EBNA	 3G2	 or	 gp350	 1D6	 peptide	 and	
cocultured	with	the	T	cells.	Cell	culture	supernatants	were	tested	for	granzyme	B	with	an	ELISA.	Each	
data	point	shown	in	the	presented	graph	is	the	average	of	triplicate	values	and	error	bars	represent	
standard	deviation.	Furthermore,	each	graph	is	a	representative	experiment	of	at	least	three.		
	
	
	
	
62	
The	expression	of	CD107a	and	the	release	of	granzyme	B	suggested	that	both	EBNA1-	and	
gp350-specific	CD4+	memory	T	cells	were	cytolytic.	However,	for	this	to	be	confirmed	it	was	
important	to	determine	whether	they	could	directly	kill	target	cells.	To	examine	the	cytolytic	
ability	of	the	expanded	CD4+	memory	T	cells,	a	calcein	release	assay	was	performed	[152].	
Living	 cells	 convert	non-fluorescent	 calcein	AM	 to	 fluorescent	 calcein.	 The	 killing	of	 target	
cells	 by	 cytolytic	 T	 cells	 releases	 calcein	 into	 the	 cell	 culture	 supernatant,	 which	 can	 be	
measured	with	a	fluorimeter.	LCLs	were	pulsed	with	EBNA1	3G2,	gp350	1D6,	EBNA3C	5H11	
(unrelated	 peptide)	 peptides	 or	 DFEBV-EBNA1RI+RII	 and	were	 used	 in	 calcein	 release	 assays	
with	 EBNA1-	 and	 gp350-specific	 CD4+	 T	 cells	 (Fig.	 3.19).	 This	 showed	 that	 the	 gp350-	 and	
EBNA1-specific	 CD4+	 T	 cells	 were	 capable	 of	 specifically	 killing	 LCLs	 pulsed	 with	 DFEBV-
EBNA1RI+RII	and	the	appropriate	peptide	epitopes.	Importantly,	LCLs	pulsed	with	the	EBNA3C	
5H11	 peptide	 was	 incapable	 of	 inducing	 significant	 levels	 of	 killing.	 The	 expression	 of	
CD107a,	the	release	of	granzyme	B	and	the	specific	killing	of	target	cells	confirm	that	both	
the	EBNA1-	and	gp350-specific	CD4+	T-cell	lines	were	cytotoxic.	
	
Figure	 3.19:	 CD4+	memory	 T	 cells	 specific	 for	 EBNA1	and	 gp350	directly	 kill	 target	 cells.	 LCLs	were	
pulsed	with	 DFEBV-EBNA1
RI+RII	 (grey	 line),	 EBNA1	3G2	 (red	 line)	 or	 gp350	1D6	 (green	 line)	 peptides,	
and	were	incubated	with	calcein	AM.	As	a	negative	control,	LCLs	were	pulsed	with	the	EBNA3C	5H11	
peptide	(black	line).	The	pulsed	LCLs	were	incubated	with	calcein	AM	and	then	cocultured	with	CD4+	T	
cells	specific	for	EBNA1	or	gp350.	The	release	of	calcein	from	targeted	cells	was	measured	at	535	nm	
after	excitation	with	485	nm	 light.	Each	data	point	 shown	 in	 the	presented	graph	 is	 the	average	of	
triplicate	 values	 and	 error	 bars	 represent	 standard	 deviation.	 Furthermore,	 each	 graph	 is	 a	
representative	experiment	of	at	least	two.	
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Next,	 the	 ability	 of	 EBNA1-	 and	 gp350-specific	 CD4+	 T	 cells	 to	 target	 recently	 infected	 B	 cells	 was	
tested.	The	infection	of	primary	B	cells	results	in	their	transformation,	outgrowth	and	the	expression	
of	 CD23.	 Thus,	 CD23	 serves	 as	 a	 marker	 for	 EBV-mediated	 B-cell	 proliferation	 [153].	 To	 this	 end,	
autologous	 primary	 B	 cells	 were	 infected	 with	 B95-8	 EBV	 (moi	 =	 10),	 cocultured	 with	 EBNA1-	 or	
gp350-specific	CD4+	T	cells	for	12	days	and	analysed	with	CD19-	and	CD23-specific	antibodies	by	flow	
cytometry	 (Fig.	 3.20).	 As	 a	 positive	 control	 for	 B-cell	 outgrowth,	 infected	 B	 cells	 were	 cultured	 in	
medium	only.	 Conversely,	 freshly	 isolated	 PBMCs	were	 analysed	 to	 identify	 untransformed	 B	 cells.	
Flow	 cytomteric	 analysis	 of	 ex	 vivo	 cultures	 revealed	 the	 presence	 of	 three	 B-cell	 populations,	 viz.	
CD19+CD23-,	CD19+CD23low	and	CD19+CD23high	populations.	 Infected	B	cells	cultured	 in	medium	only	
were	 found	 to	 contain	 primarily	 (89.7	 %)	 CD19+CD23high	B	cells,	 whilst	 B	 cells	 from	 freshly	 isolated	
PBMCS	contain	almost	no	CD19+CD23high	B	cells.	Nearly	all	 the	B	cells	within	 freshly	 isolated	PBMCs	
were	CD19+CD23-.	 The	 coculture	of	 EBNA1-	or	 gp350-specific	CD4+	T	 cells	with	 infected	B	 cells	was	
shown	 to	 reduce	 the	percentage	of	CD19+CD23high	B	 cells.	 In	 the	presence	of	gp350-specific	CD4+	T	
cells	the	CD19+CD23high	population	only	accounted	for	∼16	%	of	total	B	cells,	whilst	in	the	presence	of	
EBNA1-specific	 CD4+	 T	 cells	 the	 CD19+CD23high	 accounted	 for	∼50	 %	 of	 total	 B	 cells.	 These	 results	
suggest	 that	 both	 EBNA1-	 and	 gp350-specific	 CD4+	 T	 cells	 can	 target	 CD19+CD23high	infected	B	 cells,	
but	it	is	the	gp350-specific	T	cells	that	are	most	capable	of	controlling	infected	B	cells	during	the	early	
stage	of	infection.		
	
Figure	3.20:	EBNA1-	and	gp350-specific	CD4+	T	cells	target	EBV-infected	B	cells.	Infected	B	cells	were	
cocultured	with	CD4+	T	cells	 for	12	days,	stained	with	α-CD19-APC	and	α-CD23-PE-Cy7	and	analysed	
with	 flow	 cytometry.	 Additionally,	 infected	 B	 cells	 cultured	 in	 medium	 only	 served	 as	 a	 positive	
control	for	B-cell	transformation,	whilst	the	B	cells	from	freshly	 isolated	B	cells	served	as	a	negative	
control	 for	 B-cell	 transformation.	 Total	 B	 cells	 were	 analysed	 for	 the	 relative	 percentages	 of	
CD19+CD23-,	CD19+CD23low	and	CD19+CD23high	populations.		
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3.7.	Regression	of	EBV-infected	B	cells	in	the	presence	of	DFEBV-EBNA1RI+RII	-specific	T	
cells		
Since	 gp350-	 and	 EBNA1-specific	 CD4+	 T	 cells	 were	 shown	 target	 EBV-infected	 cells,	
polyclonal	 T	 cells	 specific	 for	 the	 whole	 spectrum	 of	 antigens	 contained	 within	 DFEBV-
EBNA1RI+RII	was	tested	for	their	ability	to	control	EBV-infected	B	cells.	Additionally,	the	ability	
of	DFEBV-EBNA1RI+RII-specific	T	cells	to	target	infected	B	cells	was	compared	to	gp350-specific	
T	cells.	In	contrast	to	gp350,	DFEBV-EBNA1RI+RII	would	enable	the	expansion	of	a	broad	range	
of	 EBV-specific	 T-cell	 clones,	 especially	 those	 that	 recognise	 structural	 proteins,	 from	 the	
PBMCs	of	EBV-positive	individuals.			
To	 generate	 DFEBV-EBNA1RI+RII-	 or	 gp350-specific	 T	 cells,	 PBMCs	 from	 four	 EBV-positive	
donors	were	stimulated	in	the	presence	of	IL-2	for	two	rounds	using	DFEBV-EBNA1RI+RII	or	the	
gp350-AgAb.	Thereafter,	the	T	cells	were	cocultured	with	primary	B	cells	that	were	infected	
with	the	B95.8	strain.	In	parallel,	EBV-infected	B	cells	were	cocultured	in	medium	only	or	in	
the	 presence	 of	 unstimulated	 CD19-depleted	 (CD19-)	 PBMCs,	 respectively	 serving	 as	
negative	and	positive	controls	for	T-cell	mediated	targeting	of	infected	B	cells.	Five	days	post	
infection,	ex	vivo	 cultures	were	analysed	with	 flow	cytometry	and	 immunofluorescence	 to	
observe	EBV-infected	B	cells	during	the	initial	phase	infection	(Fig.	3.21	A	and	B).	Infected	B	
cells	were	detected	by	flow	cytometry	by	identifying	CD19+GFP+	double-positive	cells.	Since	
the	 B95-8	 strain	 that	 was	 used	 for	 B-cell	 infection	 encodes	 GFP,	 infected	 B	 cells	 were	
positive	for	GFP	expression.		Flow	cytomteric	analysis	revealed	that	infected	B	cells	strongly	
expressed	GFP	when	they	were	cultured	in	medium	only,	which	indicates	that	EBV-infection	
occurred	 in	 these	cells	and	 that	viral	gene	expression	had	ensued	 (Fig.	3.21A).	Conversely,	
infected	 B	 cells	 that	 were	 cocultured	 with	 CD19-	 PBMCs	 were	 found	 to	 express	 GFP	 less	
intensely.	 CD19-	 PBMCs	 form	 EBV-positive	 donors	 would	 have	 contained	 the	 normal	
repertoire	and	frequency	of	EBV-specific	memory	T	cells	[45],	enabling	infected	B	cells	to	be		
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Figure	 3.21:	 PBMCs	 stimulated	 with	 DFEBV-EBNA1
RI+RII	 control	 EBV-infected	 B	 cells.	 Primary	 B	 cells	
infected	 with	 wtEBV	 (B95-8)	 were	 cocultured	 with	 PBMCs	 stimulated	 with	 either	 gp350-AgAb	 or	
DFEBV-EBNA1
RI+RII.	 Infected	 B	 cells	 were	 also	 cultures	 with	 CD19-	 PBMCs	 or	 in	 medium	 only,	
respectively	serving	as	positive	and	negative	controls	for	T-cell-mediated	targeting	of	infected	B	cells.		
(A)	Analysis	 of	ex	 vivo	 cultures	 for	 the	presence	of	 CD19+GFP-	and	CD19+GFP+	B	 cells	 five	 days	 post	
infection.	Since	the	B95-8	genome	has	been	modified	to	encode	GFP,	it	enabled	the	identification	of	
cells	in	which	viral	gene	transcription	occurred	based	on	GFP	expression.	Staining	with	anti-CD19-APC	
enables	the	identification	of	B	cells.	The	result	from	a	single	donor	is	shown,	with	the	percentage	of	
cells	that	are	CD19+GFP-	and	CD19+GFP+	being	highlighted.	(B)	Regression	of	EBV-infected	B	cells	in	ex	
vivo	 cultures	 of	 4	 donors.	 Results	 are	 expressed	 as	 fold	 change	 over	 the	medium	 only	 control.	 (C)	
Immunofluorescence	 confirm	 that	 DFEBV-EBNA1
RI+RII	 stimulated	 PBMCs	 can	 efficiently	 control	 EBV-
infected	 B	 cells.	 Co-staining	 was	 performed	 with α-CD21	 (green),	 α-EBNA2	 (red)	 and	 DAPI	 (blue).	
Scale	bars	represent	50 μm.		
targeted	to	some	degree.	Infected	B	cells	that	were	cocultured	with	gp350-AgAb-	and	DFEBV-
EBNA1RI+RII-stimulated	 PBMCs,	 showed	 a	 marked	 decrease	 in	 GFP-expressing	 cells.	 The	
results	from	four	donors	are	summarised	in	Figure	3.21B.	This	confirms	that	memory	T	cells	
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specific	 for	 DFEBV-	 EBNA1RI+RII	 and	 gp350	 can	 target	 EBV	 infected	 B	 cells	 during	 the	 early	
phase	 of	 infection.	 However,	 it	 is	 evident	 that	 DFEBV-	 EBNA1RI+RII-specific	 T	 cells	 are	
considerably	more	 adept	 than	 the	 gp350-specific	 T	 cells.	 To	 confirm	 this	 result,	 ex	 vivo	
cultures	were	analysed	by	immunofluorescence	(Figure	3.21C).	Ex	vivo	cultures	were	stained	
for	CD20	and	EBNA2,	respectively	serving	as	a	B-cell	marker	and	an	indicator	of	early	gene	
expression	in	infected	cells.	This	showed	that	there	were	very	few	EBNA2-expressing	B	cells	
in	the	presence	of	PBMCs	stimulated	with	DFEBV-EBNA1RI+RII,	indicating	once	more	that	these	
cells	are	most	proficient	at	targeting	EBV-infected	B	cells	during	the	initial	phase	of	infection.	
Collectively,	 these	results	show	that	DFEBV-EBNA1RI+RII	can	stimulate	and	expand	T	cells	 that	
can	 efficiently	 target	 recently	 infected	 B	 cells,	 even	 when	 compared	 to	 a	 well-known	
structural	antigen	like	gp350.		
3.8.	PBMCs	stimulated	with	DFEBV-EBNARI+RII	can	control	the	outgrowth	of	B	cells	
infected	with	B95-8	and	M81	
Since	 polyclonal	 DFEBV-EBNA1RI+RII-specific	 T	 cells	 efficiently	 targeted	 EBV-infected	 B	 cells,	
their	ability	 to	prevent	B-cell	outgrowth	was	also	 tested.	Additionally,	 the	ability	of	 DFEBV-
EBNA1RI+RII-specific	 T	 cells	 to	 control	 B	 cells	 infected	with	 the	 B95-8	 and	M81	 strains	 was	
tested.	The	B95-8	strain	 is	 representative	of	strains	 found	 in	Western	countries,	whilst	 the	
M81	strain	was	isolated	from	a	Chinese	nasopharyngeal	carcinoma	patient	[87].	PBMCs	from	
8	 donors	 were	 stimulated	 for	 two	 rounds	 as	 before	 (see	 section	 3.7)	 with	 either	 DFEBV-
EBNA1RI+RII	or	gp350-AgAb,	and	were	incubated	with	B	cells	infected	with	B95-8	(moi	=	5)	or	
M81	 (moi	 =	 30).	 Since	 different	 EBV	 strains	 transform	 B	 cells	 at	 different	 rates,	 it	 was	
important	to	use	the	appropriate	dose	for	each	strain	[153].	Ex	vivo	cultures	were	analysed	
after	15	days	for	the	presence	of	CD19+CD23+	double-positive	cells	 (Fig.	3.22).	This	showed	
that	PBMCs	stimulated	with	DFEBV-EBNA1RI+RII	and	gp350-AgAbs	were	capable	of	controlling	
infected	B	cells	over	the	15	day	period,	with	the	former	being	superior	at	preventing	B-cell	
outgrowth	 (Fig.	 3.22A).	 Interestingly,	 the	 CD19-	 PBMCs	 from	 some	 donors	 outperformed	
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gp350-specific	 T	 cells.	 This	 indicates	 that	 some	 donors	 contained	 EBV-specific	 T	 cells	 in	
addition	 to	 gp350	 that	 have	 the	 ability	 to	 target	 EBV-infected	 B	 cells.	 Nonetheless,	 the	
DFEBV-EBNA1RI+RII-stimulated	PBMCs	were	shown	to	be	the	most	proficient	at	controlling	the	
EBV-infected	B	cells.	Indeed,	cultures	having	DFEBV-EBNA1RI+RII-stimulated	PBMCs	were	found		
		
	
Figure	3.22:	T	cells	specific	for	DFEBV-EBNA1
RI+RII	prevent	the	outgrowth	of	B95-8-	and	M81-infected	B	
cells.	 PBMCs	 from	 8	 donors	 were	 expanded	 with	 either	 DFEBV-EBNA1
RI+RII	 or	 gp350-AgAb	 and	
cocultured	with	primary	B	cells	 infected	with	B95-8	or	M81	strains.	CD19-	PBMCs	and	medium	only,	
also	 cultured	with	 infected	 B	 cells,	 respectively	 served	 as	 positive	 and	 negative	 controls	 for	 T-cell-
mediated	 targeting	of	 EBV-infected	 cells.	 (A)	After	 15	days,	 cells	were	 strained	with	CD19-APC	and	
CD23-PE-Cy7	antibodies	and	analysed	by	flow	cytometry.	Representative	results	are	shown,	indicating	
CD19+CD23-,	CD19+CD23low	and	CD19+CD23high	populations.	(B)	A	result	summary	from	8	donors.	The	
percentage	of	CD19+CD23+	cells	in	ex	vivo	cultures	were	determined	and	are	expressed	as	fold	change	
relative	 to	 CD19+CD23+	 cells	 within	 cultures	 containing	 gp350-AgAb-stimulated	 PBMCs.	 Statistical	
analysis	was	performed	using	a	two-tailed	student	T-test.		
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to	contain	very	few	total	B	cells	after	the	15-day	culture	period.	 Importantly,	 this	was	also	
found	 to	 be	 the	 case	 for	 B95-8-	 and	 M81-	 infected	 B	 cells.	 Considering	 the	 summarised	
result			from			eight			donors	(Fig.	3.22B),	it	is	clear	that	the	DFEBV-	EBNA1RI+RII-specific	T	cells	
were	 extremely	 proficient	 at	 preventing	 B-cell	 outgrowth.	 This	 is	 the	 first	 instance	where	
vaccine-specific	T	cells	have	been	shown	to	efficiently	target	and	control	B	cells	infected	with	
distantly	related	EBV-strains,	albeit	during	short-	term	culture	ex	vivo.	
3.9.	Investigating	the	antigenicity	of	DFEBV-EBNA1RI+RII	in	humanised	NSG-A2	mice	
Humanised	 mouse	 models	 are	 powerful	 tools	 to	 investigate	 human	 viruses	 [154].	 Mice	
reconstituted	with	human	immune	system	components	are	susceptible	to	EBV	infection	and	
can	 exert	 EBV-specific	 immune	 control	 [155].	 	 In	 the	 present	 study,	 humanised	 NSG-A2	
(huNSG-A2)	 mice	 were	 used	 to	 assess	 the	 ability	 of	 DFEBV-EBNA1RI+RII	 to	 protect	 against	
wtEBV	(B95-8	strain)	 infection.	To	this	end,	huNSG-A2	mice	were	 injected	 intraperitoneally	
with	PBS,	unmodified	DFEBV	and	DFEBV-EBNA1RI+RII,	using	50	μg	of	poly	(I:C)	as	adjuvant	(Fig.	
3.23A).	Subsequently,	mice	were	boosted	as	before,	challenged	with	1	x	105	green	Raji	units	
(GRUs)	of	EBV	and	euthanised	8	weeks	later.	The	spleens	of	challenged	mice	were	analysed	
by	histology	(Fig.	3.23B).	This	revealed	that	mice	contained	B	cells	(CD19-positive)	and	T	cells	
(CD3	 positive)	 of	 human	 origin.	 Furthermore,	 the	 abundance	 of	 human	 B	 and	 T	 cells	 in	
spleens	were	not	influenced	by	the	different	treatments.	In	situ	hybridisation	revealed	that	
mice	 from	 the	 PBS	 and	 unmodified	 DFEBV	 groups	 contained	 EBV-positive	 cells;	 i.e.	
splenocytes	were	 shown	 to	 express	 Epstein-Barr	 virus	 (EBV)-encoded	 small	 RNAs	 (EBERs).	
Conversely,	none	of	the	mice	from	the	DFEBV-EBNA1RI+RII	group	were	found	to	contain	EBERs	
in	their	spleens.	In	total,	60%	of	mice	from	the	PBS	group	were	found	to	contain	EBER+	cells,	
while	37.5%	of	mice	in	the	from	the	unmodified	DFEBV	group	were	shown	to	contain	EBER+	
cells	 (Fig.	 3.23C).	Whilst	mice	 vaccinated	with	 unmodified	 DFEBV	 had	 a	 lower	 incidence	 of	
EBV		infection,		statistical		analysis	(one-tailed	Chi-square	test)		revealed	this		result		was		not		
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Figure	 3.23:	 Vaccination	 of	 humanised	 mice	 with	 DFEBV	 containing	 EBNA1	 confers	 protective	
immunity.	(A)	Histological	analysis	of	mice	spleens	8	weeks	after	challenge	with	EBV.	Spleen	sections	
were	 stained	 with	 eosin	 and	 haematoxylin	 (H&E)	 and	 immunostained	 with	 antibodies	 specific	 for	
CD20	and	CD3.	The	 incidence	of	EBV	 infection	amongst	PBS,	DFEBV	and	DFEBV-EBNA1
RI+RII	vaccinated	
groups	was	 determined	 from	 EBER	 staining	 (B)	 and	 RT-qPCR	 analysis	 (C).	 P	 values	 lower	 than	 0.05	
obtained	after	one-tailed	Chi-square	analysis	are	shown.		
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significant	 (P	 >	 0.05).	 However,	 statistical	 analysis	 showed	 that	 DFEBV-EBNA1RI+RII	afforded	
significantly	more	protection	than	the	PBS	(P	=	0.009)		and		unmodified		DFEBV	(P	=	0.035).	To	
detect	EBV	in	peripheral	blood	of	mice,	real-time	qPCR	was	used	(Fig.	3.23D).	EBV	genomes	
were	detected	 in	100%	of	mice	from	the	PBS	group	and	75%	of	mice	from	the	unmodified	
DFEBV	 group.	 Real-time	 qPCR	 analysis	 of	 blood	 from	 DFEBV-EBNA1RI+RII	 vaccinated	 mice	
revealed	 that	 only	 one	 mouse,	 equivalent	 to	 14%,	 was	 EBV-positive.	 Statistical	 analysis	
revealed	that	DFEBV-EBNA1RI+RII	was	significantly	better	than	PBS	(P	=	0.0027)	and	DFEBV	(P	=	
0.0286).	 These	 results	 suggest	 that	 the	 presence	 of	 EBNA1	 within	 DFEBV	 significantly	
improved	vaccine-induced	immunity.	
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4.	Discussion	
DFEBV	 is	 non-toxic,	 non-infectious,	 structurally	 complex	 and	 highly	 immunogenic	 [9,	 141].	
This	 infers	 that	 DFEBV	 retains	 the	 antigenicity	 of	 wtEBV	 virions,	 without	 the	 potential	 to	
recapitulate	 the	adverse	consequences	of	EBV	 infection.	 	However,	vaccination	with	DFEBV	
would	 not	 be	 able	 to	 sensitise	 the	 immune	 system	 against	 proteins	 that	 are	 expressed	
during	 viral	 latency.	 Latency	 is	 an	 essential	 aspect	 of	 the	 EBV	 life	 cycle,	 and	 the	
establishment	 of	 latency	 enables	 life-long	 carriage	 of	 EBV	 within	 memory	 B	 cells	 [156].	
Furthermore,	it	is	latency	transcription	programs	that	take	place	in	EBV-associated	diseases	
and	malignancies.	To	facilitate	sensitisation	against	 latent	proteins,	 the	antigenic	spectrum	
of	DFEBV	was	enlarged	to	include	latent	antigens.	The	fusion	of	latent	antigen	moieties	to	the	
major	 tegument	 protein	 BNRF1	 successfully	 enabled	 the	 incorporation	 of	 latent	 antigens	
into	DFEBV.	The	incorporated	latent	antigens	were	successfully	processed	by	APCs,	which	in	
turn	 presented	 the	 antigenic	 epitopes	 to	 the	 relevant	 T	 cells.	 The	 antigenic	 potential	 of	
modified	 DFEBV	 was	 confirmed	 in	 vitro,	 ex	 vivo	 and	 in	 vivo.	 DFEBV	 equipped	 with	 latent	
epitopes	 is	 the	 first	 prophylactic	 vaccine	 candidate	 with	 the	 potential	 to	 sensitise	 the	
immune	system	against	many	of	the	proteins	expressed	throughout	the	EBV	life	cycle.		
4.1.	BNRF1	as	a	carrier	of	latent	antigens		
BNRF1	was	selected	in	the	present	study	as	a	carrier	of	latent	antigens	due	to	its	abundance	
within	 particles	 and	 its	 well-documented	 antigenicity	 [8,	 9,	 22].	 BNRF1-fusion	 proteins	
containing	 latent	 antigen	 moieties	 of	 moderate	 size,	 up	 to	 200	 aa	 in	 size,	 were	 well	
expressed	 and	 successfully	 incorporated	 into	 DFEBV	 particles.	 Fusing	 latent	 antigens	 to	
BNRF1	was	not	found	to	influence	the	production	of	DFEBV	particles,	nor	the	antigenicity	of	
envelope	(e.g.	gp350)	and	tegument	(e.g.	BNRF1)	proteins.	Importantly,	the	incorporation	of	
latent	antigens	into	DFEBV	successfully	enlarged	their	antigenic	spectrum.	This	indicates	that	
BNRF1-latent	antigen	fusion	proteins	are	antigenic	and	do	not	impact	on	the	antigenicity	of	
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structural	proteins,	validating	their	use	to	enlarge	the	antigenic	spectrum	of	DFEBV.	However,	
the	 insertion	of	 latent	 antigens	 into	 the	BNRF1	 larger	 than	 200	 aa	was	 found	 to	 preclude	
BNRF1	 expression.	Whilst	 the	 exact	 reason	 for	 this	 observation	was	 not	 followed	 up,	 it	 is	
possible	that	the	insertion	of	large	foreign	fragments	into	BNRF1	prevented	proper	folding,	
leading	 to	 its	 degradation	 within	 producer	 cells.	 It	 is	 known	 that	 misfolded	 proteins	 are	
degraded	by	the	mammalian	cells,	preventing	their	build-up	within	cells	and	mitigating	their	
toxicity	[157].		
Since	 ex	 vivo	 and	 in	 vivo	 experiments	 were	 performed	with	 unhaplotyped	 donors,	 it	 was	
necessary	 to	 incorporate	 as	 many	 latent	 epitopes	 as	 possible	 into	 DFEBV.	 However,	 since	
BNRF1	could	only	accommodate	antigenic	 fragments	of	a	relatively	small	size,	epitope-rich	
fragments	 from	 EBNA1	 were	 selected	 to	 fuse	 to	 BNRF1.	 Using	 EBNA1,	 DFEBV	 could	
successfully	 be	 modified	 to	 contain	 as	 much	 as	 10	 epitopes	 through	 the	 introduction	 of	
EBNA1	fragments	of	approximately	110	amino	acids.	In	comparison,	a	protein	like	EBNA3C	is	
very	 large,	 and	 whilst	 being	 highly	 immunogenic,	 it	 only	 has	 11	 epitopes	 distributed	
throughout	its	992	amino	acids	[115,	158].	This	suggests	that	EBNA3C	is	not	the	as	suitable	
for	 fusion	 to	 BNRF1	 as	 EBNA1.	 Furthermore,	 EBNA3C	 is	 only	 expressed	 during	 type	 III	
latency,	whilst	EBNA1	is	expressed	in	all	forms	of	latency	(except	for	type	0)	and	in	all	EBV-
positive	malignancies	 [145].	 Taken	 together,	 this	 implies	 that	 EBNA1	 is	 more	 suitable	 for	
fusion	to	BNRF1	from	a	technical,	immunological	and	virological	perspective.	However,	since	
latent	antigens	from	the	EBNA3	and	LMP	families	are	expressed	in	latently	infected	cells	and	
are	immunogenic	[45],	DFEBV	would	surely	benefit	from	their	inclusion.	However,	it	 is	 likely	
that	additional	tegument	proteins	would	have	to	be	explored	to	accommodate	these	latent	
antigens.	
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4.2.	The	antigenicity	of	DFEBV	equipped	with	proteins.	
The	antigenicity	of	DFEBV	containing	latent	proteins	was	extensively	examined	in	the	present	
work.	In	vitro	interrogation	of	modified	particles	was	performed	with	LCLs	and	HLA-matched	
T-cell	clones	that	were	established	previously	[111,	146].	These	experiments	confirmed	that	
that	 modified	 DFEBV	 could	 successfully	 stimulate	 gp350-,	 BNRF1-,	 EBNA3C-	 and	 EBNA1-
specific	CD4+	T	cells.	Ex	vivo	stimulation	of	bulk	PBMCs	from	an	unhaplotyped	EBV-positive	
individual	with	DFEBV	containing	EBNA1	enabled	the	expansion	of	gp350-	and	EBNA1-specific	
CD4+	 T	 cells.	 Conversely,	 the	 stimulation	 of	 the	 same	 PBMCs	with	 unmodified	 DFEBV	 only	
enabled	 the	 expansion	 of	 gp350-specific	 CD4+	 T	 cells.	 This	 confirmed	 that	 the	 EBNA1	
contained	 within	 modified	 DFEBV	 was	 antigenic	 in	 an	 ex	 vivo	 setting.	 In	 addition	 to	
confirming	the	antigenicity	of	modified	DFEBV,	it	also	showed	that	memory	CD4+	T	cells	from	
an	EBV-positive	individual	recognises	modified	DFEBV.		
The	T	cells	from	EBV-positive	individuals	have	been	found	to	recognise	an	impressive	variety	
of	EBV	proteins	[45]	and	there	is	considerable	evidence	that	implicates	EBV-specific	T	cells	in	
the	 control	 of	 EBV-associated	 malignancies.	 Immunocompromised	 individuals	 have	 an	
increased	 risk	 of	 developing	 life-threatening	 EBV-associated	 lymphoproliferative	 disease	
[158]	 and	 the	 adoptive	 transfer	 of	 cytolytic	 EBV-specific	 T	 cells	 have	 been	 shown	 to	 can	
combat	EBV-associated	malignancies	[159,	160].	Along	these	lines,	the	EBV-specific	memory	
CD4+	 T	 cells	 expanded	 in	 the	 present	 study	 were	 shown	 to	 express	 CD107a,	 release	
granzyme	B	and	specifically	lysed	target	cells	exposed	to	modified	DFEBV.	This	in	accordance	
with	previous	studies	that	have	identified	EBNA1-	[145,	161,	162]	and	gp350-	[108]	specific	
cytolytic	CD4+	T	cells.	The	cytolytic	ability	of	DFEBV-specific	T	cells	suggests	that	vaccination	
with	modified	 DFEBV	 has	 the	 potential	 to	 prime	 T	 cells	 that	 play	 a	 role	 in	 controlling	 EBV	
infection.	 Testing	 the	 EBNA1-	 and	 gp350-specific	 CD4+	 T	 cells	 in	 an	 ex	 vivo	model	 of	 EBV	
infection	confirmed	that	they	were	capable	of	targeting	proliferating	(CD19+CD23high)	B	cells	
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during	short-term	culture.	However,	it	was	the	gp350-specifc	T	cells	that	were	shown	to	be	
more	 adept	 at	 targeting	 the	 proliferating	 B	 cells.	 The	 observed	 difference	 between	 the	
gp350-	and	EBNA1-specific	T	cells	can	be	accounted	for	when	the	antigenic	load	of	structural	
and	 latent	 proteins	 during	 EBV	 infection	 is	 considered.	 Structural	 proteins	 are	 directly	
delivered	to	B	cells	during	infection	and	are	presented	to	CD4+	T	cells	via	the	canonical	MHC	
class	II	pathway	[50].	Conversely,	latent	proteins	are	only	expressed	once	viral	DNA	reaches	
the	nucleus	and	requires	autophagy	before	being	presented	on	MHC	class	II	molecules	[116].	
Hence,	structural	proteins	are	efficiently	presented	to	CD4+	T	cells	soon	after	infection	(<24	
hours),	while	 latent	 proteins	 are	 only	 efficiently	 recognised	 by	 CD4+	 T	 cells	∼1	week	 after	
infection	[50].		
The	efficient	presentation	of	structural	proteins	during	 the	 initial	phase	of	EBV	 infection	 is	
also	 likely	 to	 explain	why	 T	 cells	 specific	 for	modified	 DFEBV	were	 so	 efficient	 at	 targeting	
infected	B	cells	during	 the	early	phase	of	 infection.	Modified	DFEBV	contains	several	dozen	
structural	proteins	 [8],	 and	 it	would	have	enabled	 the	expansion	of	 a	polyclonal	pool	of	 T	
cells	that	recognise	glycoproteins,	tegument	proteins	and	capsid	proteins.	Analysis	of	ex	vivo	
cultures	 shortly	 after	 infection	 (5	 days)	 and	 at	 a	 later	 time	 point	 (15	 days)	 showed	 that	
DFEBV-EBNA1RI+RII-specific	T	cells	were	considerably	more	efficient	than	gp350-specific	T	cells	
at	 controlling	 EBV-infected	 cells.	 DFEBV-EBNA1RI+RII-specific	 T	 cells	 not	 only	 reduced	 the	
presence	of	infected	cells	5	days	post	infection,	but	also	prevented	B	cell	outgrowth	over	a	
15	 day	 culture	 period.	 The	 superior	 ability	 of	 DFEBV-EBNA1RI+RII-specific	 T	 cells	 to	 control	
infected	B	cells	compared	to	gp350-specific	T	cells	likely	stems	from	their	polyclonal	nature.	
Numerous	T-cell	clones	that	simultaneously	recognise	epitopes	from	different	antigens	are	
likely	to	have	a	protective	benefit	over	T	cells	that	only	recognise	one	or	two	epitopes	from	a	
single	 antigen.	 This	 suggests	 that	 DFEBV	 contain	multiple	 T-cell	 epitopes	 that	 contribute	 to	
immune	 responses	during	 the	early	 phase	of	 infection.	However,	 since	 structural	 antigens	
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are	also	expressed	during	virus	reactivation	[163],	it	suggests	that	the	same	polyclonal	T	cells	
could	potentially	target	infected	B	cells	undergoing	reactivation.		
To	assess	the	immunogenicity	of	DFEBV	containing	EBNA1	in	vivo,	a	humanised	mouse	model	
was	 employed.	 Mice	 reconstituted	 with	 human	 immune	 system	 components	 were	
vaccinated	 and	 boosted	 with	 PBS,	 unmodified	 DFEBV	 or	 DFEBV-EBNA1RI+RII	 prior	 to	 being	
challenged	with	 the	 B95-8	 EBV	 strain.	 This	 showed	 that	 DFEBV	 containing	 EBNA1	 afforded	
protection	to	86%	of	mice,	whilst	unmodified	DFEBV	only	afforded	protection	to	38%	of	mice.	
This	suggests	that	EBNA1-specific	T	cells	play	an	important	role	in	controlling	EBV	infection,	
likely	by	directly	targeting	infected	cells	displaying	EBNA1	peptides	[145,	161,	162].	Since	the	
in	vivo	challenge	experiment	extended	for	8	weeks,	it	would	have	enabled	the	antigenic	load	
of	latent	proteins	to	be	higher	than	in	the	ex	vivo	experiments.	This	is	especially	true	for	the	
B95-8	 strain	 used	 for	 challenge,	 since	 it	 does	 not	 readily	 reactivate	 once	 it	 establishes	
latency	[153].		
Taken	together,	these	results	confirm	that	the	antigenic	spectrum	of	DFEBV	was	successfully	
enhanced	using	BNRF1-lanent	antigen	fusion	proteins.	It	is	also	evident	that	T	cells	are	more	
efficient	 at	 targeting	 EBV-infected	 B	 cells	 during	 the	 early	 phase	 of	 infection	 when	 they	
recognise	 a	 broad	 spectrum	 of	 EBV	 antigens.	 This	 suggests	 that	 vaccine	 candidates	 that	
contain	only	a	few	EBV	structural	antigens	are	likely	to	induce	suboptimal	EBV-specific	T	cell	
responses.	 Furthermore,	 the	 inclusion	of	 a	 latent	antigen,	 in	 this	 case	EBNA1,	 significantly	
improved	vaccine-induced	immunity.	This	suggests	that	prophylactic	EBV	candidates	benefit	
from	the	inclusion	of	both	latent	and	lytic	proteins.		
4.3.	Modified	DFEBV	compared	to	other	prophylactic	EBV	vaccines		
Prophylactic	EBV	vaccines	 that	 consist	of	 the	 latent	protein	EBNA3A	 [164]	or	 the	 late	 lytic	
protein	gp350	[71,	165-167]	have	previously	been	tested	in	humans.	Of	these,	gp350	is	the	
only	one	that	was	tested	in	a	phase	II	clinical	trial,	which	confirmed	that	the	gp350	subunit	
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vaccine	was	 unable	 to	 prevent	 EBV	 infection.	 Despite	 the	 underperformance	 this	 vaccine,	
gp350	 has	 subsequently	 continued	 to	 receive	 attention	 as	 a	 vaccine	 candidate.	 This	 is	
understandable	 considering	 the	 important	 role	 gp350	 plays	 in	 attaching	 virions	 to	 B	 cells	
during	the	infection	process	[168],	and	when	one	considers	that	gp350	is	a	frequent	target	
of	neutralising	antibodies	 [107,	169].	However,	 instead	of	being	used	as	a	subunit	vaccine,	
emerging	 prophylactic	 vaccines	 have	 introduced	 gp350	 into	 nanoparticles	 [170]	 or	
Newcastle	 disease	 virus	 (NDV)	 VLPs	 [171].	 It	 is	 well	 established	 that	 subunit	 vaccines	 are	
relatively	 weak	 immunogens,	 and	 that	 their	 incorporation	 into	 nanoparticles	 or	 VLPs	
improve	their	immunogenicity	[172-174].	Indeed,	gp350	contained	within	nanoparticles	and	
NDV-VLPs	was	 shown	 to	 dramatically	 improve	 neutralising	 antibody	 responses,	 with	 both	
vaccines	clearly	outperforming	soluble	gp350	[170,	171].	Interestingly,	one	of	these	studies	
analysed	 NDV-VLPs	 containing	 gp350	 and	 UV-inactivated	 EBV	 in	 parallel,	 and	 found	 UV-
inactivated	EBV	to	be	even	more	potent	at	inducing	neutralising	antibodies	[171].	Since	UV-
inactivated	EBV	contains	several	EBV	glycoproteins,	it	would	have	enabled	the	generation	of	
antibody	 responses	 that	 target	 several	glycoproteins	 in	addition	 to	gp350.	This	bodes	well	
for	 DFEBV	 as	 a	 prophylactic	 vaccine,	 as	 suggests	 that	 DFEBV	 might	 be	 able	 to	 generate	
neutralising	 antibody	 responses	 in	 addition	 to	 protective	 T-cell	 immunity.	 However,	 since	
humanised	mice	have	 low	antibody	responses,	which	stems	 from	their	 inability	 to	execute	
affinity	maturation	and	class	switch	recombination	[154],	modified	DFEBV	was	not	tested	in	
the	present	work	for	its	ability	to	generate	neutralising	antibodies	responses.	The	inability	of	
humanised	 mice	 to	 generate	 normal	 antibody	 reponses	 might	 also	 partly	 explain	 why	
vaccination	with	unmodified	DFEBV	did	not	afford	significant	protection	upon	challenge	with	
infectious	 viruses.	 DFEBV	 certainly	 contains	 several	 glycoproteins	 that	 are	 targeted	 by	
antibody	 responses	 [107,	 175].	 In	 particular,	 DFEBV	 contains	 gp350	 and	 gH/gL,	 which	
respectively	enable	the	attachment	EBV	to	B	cells	and	epithelial	cells	 [33,	34].	This	 implies	
that	DFEBV	has	an	advantage	over	vaccines	 that	consist	exclusively	of	gp350,	 since	 it	 could	
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potentially	 elicit	 antibody	 responses	 that	 target	 glycoproteins	 responsible	 for	 B-cell	 and	
epithelial	cell	 infection.	A	mouse	challenge	model	has	been	developed	to	test	the	ability	of	
EBV	 vaccine	 candidates	 to	 elicit	 protective	 antibody	 responses	 [170].	 However,	 in	 this	
model,	 vaccine	 success	or	 failure	 is	 solely	based	on	weight	 loss	and	does	not	allow	sterile	
immunity	to	be	assessed.	Nonetheless,	testing	DFEBV	in	such	a	model	will	certainly	be	a	good	
starting	point	to	assess	the	quality	of	DFEBV	elicited	neutralising	antibodies	in	vivo.		
Whilst	neutralising	antibodies	are	likely	to	provide	a	protective	benefit	against	EBV	infection	
[176,	177],	it	is	uncertain	whether	neutralising	antibodies	alone	are	sufficient	to	prevent	EBV	
infection.	EBV	has	a	complex	lifecycle	that	comprises	several	 latency	programs	and	healthy	
individuals	 keep	 EBV-infected	 cells	 under	 control	 through	 an	 assortment	 of	 EBV-specific	 T	
cells,	 many	 of	 which	 recognise	 latently	 proteins	 [110].	 It	 was	 for	 this	 reason	 DFEBV	 was	
modified	 in	 the	present	study	 to	contain	 latent	antigens.	 In	principle,	a	vaccine	 that	solely	
contains	 lytic	 antigens	 (e.g.	 gp350	or	 gH/gL)	would	not	provide	protection	against	 latently	
infected	cells.	Hence,	vaccines	that	are	comprised	of	structural	proteins	would	have	to	elicit	
neutralisation	antibodies	and	T-cell	responses	that	are	100%	effective	at	targeting	incoming	
virus	or	recently	 infected	B	cells.	 If	 latency	is	established	in	 just	a	handful	of	cells,	 it	would	
enable	 the	 viral	 genome	 to	 amplify	 through	 simple	 cell	 division.	 The	 inability	 to	 protect	
against	latently	infected	cells	is	especially	important	to	consider,	since	it	is	the	establishment	
of	 latency	 that	 enables	 EBV	 to	 be	 carried	 lifelong	 [47]	 and	 it	 is	 latency	 transcription	
programs	that	are	carried-out	in	EBV-associated	malignancies	[178].	
Using	 VZV	 as	 example,	 the	 only	 herpesvirus	 for	 which	 there	 is	 a	 vaccine	 available,	
vaccination	 generates	 immune	 responses	 that	 mirror	 those	 observed	 during	 wild-type	
infections,	with	vaccinated	individuals	having	humoral	and	cell-mediated	immune	responses	
that	 recognise	 a	 broad	 range	 of	 lytic	 and	 latent	 proteins	 [179-182].	 This	 implies	 that	 the	
ideal	EBV	vaccine	should	prime	humoral	and	cell-mediated	immunity	against	a	broad	set	of	
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latent	and	 lytic	antigens	[45].	However,	prophylactic	EBV	vaccines	have	traditionally	aimed	
at	either	targeting	 lytic	or	 latent	antigens,	suggesting	that	they	are	 inherently	 incapable	of	
targeting	 EBV	 during	 all	 the	 stages	 of	 its	 life	 cycle.	 However,	 DFEBV	 equipped	 with	 latent	
antigens	 would	 enable	 the	 induction	 of	 immune	 responses	 that	 target	 antigens	 that	
predominate	throughout	the	EBV	life	cycle.		
4.4.	EBV	strain	heterogeneity	
EBV	strains	that	are	found	around	the	world	have	been	classified	as	either	type	1	or	2	based	
on	 the	 sequence	 of	 their	 EBNA2	 gene	 [183].	 Recently,	 the	 advent	 of	 next	 generation	
sequencing	has	produced	complete	genomes	from	23	EBV	stains,	enabling	detailed	analysis	
of	 genome-wide	 polymorphism	 [184].	 This	 has	 revealed	 that	 some	 proteins	 are	 more	
polymorphic	 than	 others,	 with	 latent	 proteins	 having	 the	 tendency	 of	 being	 more	
polymorphic	than	lytic	proteins.		
Thus	 far,	 EBV	 vaccine	 candidates	 have	 not	 addressed	 the	 intimidating	 task	 of	 affording	
protection	against	the	plethora	of	EBV	strains	found	around	the	world.	A	recently	study	has	
analysed	 polymorphisms	 within	 T-cell	 epitopes	 [158],	 as	 well	 as	 their	 flanking	 regions,	
between	three	distantly	related	EBV	strains	(viz.	B95-8,	M81	and	AG876).	This	revealed	that	
there	 is	 considerable	 variation	between	 the	 three	 strains	 in	 terms	of	 their	 CD4+	 and	CD8+	
epitopes.	The	B95-8	and	M81	strains	were	 found	to	respectively	differ	by	almost	30%	and	
50%	in	their	CD8	and	CD4	epitopes.	Several	of	these	polymorphisms	were	shown	to	present	
a	 hurdle	 to	 T	 cells	 by	 influencing	 the	 recognition	 of	 pulsed	 target	 cells.	 However,	 despite	
these	 polymorphisms,	 M81-	 and	 B95-8-infected	 B	 cells	 were	 efficiently	 controlled	 during	
short-term	ex	vivo	culture	by	T	cells	specific	for	modified	DFEBV.		
Epitope	 variations	 between	 different	 EBV	 strains	 could	 be	 addressed	 by	 generating	 a	
prophylactic	 vaccine	 that	 only	 focuses	 only	 highly	 conserved	 proteins.	However,	 the	most	
conserved	proteins	 are	not	 always	 the	most	 immunologically	 relevant	 [184].	 This	 suggests	
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that	 vaccines	might	be	 fair	 better	 if	 they	 contain	multiple	 EBV	proteins	 [158].	 Since	 DFEBV	
already	contains	multiple	structural	antigens,	it	would	not	only	be	beneficial	for	generating	
polyclonal	T-cell	pools	 that	simultaneously	 target	 recently	 infected	B	cells,	but	 it	would	be	
beneficial	from	the	standpoint	of	EBV	strain	heterogeneity.		However,	since	latent	antigens	
tend	to	be	more	polymorphic	than	structural	proteins,	 it	 is	 likely	that	DFEBV	would	need	to	
contain	several	latent	antigens	to	be	optimal	for	prophylactic	vaccination	around	the	globe.		
4.5.	The	therapeutic	potential	of	modified	DFEBV	
Whilst	modified	DFEBV	was	 investigated	 in	the	present	study	as	a	prophylactic	vaccine,	 it	 is	
also	possible	 for	modified	DFEBV	to	have	therapeutic	applications.	The	adoptive	transfer	of	
EBV-specific	T	cells	has	 successfully	been	used	 to	 treat	EBV-associated	 lymphoproliferative	
diseases	 [159].	 Since	EBV-associated	 lymphoproliferative	diseases	arise	due	 to	 impaired	T-
cell	 responses,	 the	 adoptive	 transfer	 of	 EBV-specific	 T	 cells	 combats	 proliferating	 EBV-
infected	cells.	Such	EBV-specific	T-cell	 lines	were	originally	generated	by	simply	stimulating	
PBMCs	 with	 autologous	 LCLs	 [113].	 However,	 using	 this	 method,	 the	 expanded	 T	 cells	
recognised	primarily	EBV	structural	antigens.	More	recent	methods	have	been	developed	to	
expand	latent	protein-specific	T	cells	using	peptide	mixes	[185-187].		
Since	 DFEBV	 can	 be	 engineered	 to	 contain	 latent	 antigens	 of	 relevance	 to	 EBV-associated	
lymphoproliferative	diseases,	i.e.	antigens	like	EBNA1	and	EBNA3C	that	are	expressed	during	
type	 III	 latency,	 it	 could	 be	 used	 to	 expand	 a	 broad	 range	 of	 EBV-specific	 T	 cells	 that	
recognise	structural	and	latent	antigens.	The	engineering	of	DFEBV	to	contain	large	antigenic	
segments	from	various	latent	antigens	would	be	especially	useful,	since	it	might	negate	the	
haplotyping	of	patients,	enabling	modified	DFEBV	to	serve	as	an	off-the-shelf	product.		
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4.6.	Future	studies		
In	 the	present	 study,	 DFEBV	containing	EBNA1	was	 shown	 to	 significantly	 improve	vaccine-
induced	 immunity.	 EBNA1	 is	 a	 good	 option	 for	 prophylactic	 vaccination	 due	 to	 its	
immunogenicity	 [144]	 and	 presence	 in	 latently	 infected	 cells	 and	 EBV-associated	
malignancies	[145].	However,	this	does	not	imply	EBNA1	is	the	only	latent	protein	that	can	
be	beneficial	for	prophylactic	vaccination.	Indeed,	healthy	individuals	frequently	develop	T-
cell	 responses	against	EBNA-2,	 -3A,	 -3B,	 -3C	and	 to	some	degree	LMP-1	and-2	 [45].	Whilst	
many	of	these	are	interesting	candidates,	EBNA2	is	a	particularly	attractive	option.	EBNA2	is	
relatively	small	(∼	450	aa)	and	is	one	of	the	first	proteins	expressed	in	infected	cells.	Hence	it	
would	 enable	 the	 recognition	 of	 B	 cells	 at	 a	 very	 early	 time	 point	 after	 infection	 [50].	 In	
addition	 to	 latent	 proteins,	 several	 immediate	 early	 and	 early	 lytic	 proteins	 are	 also	
expressed	 early	 after	 infection	 (e.g.	 BZLF1	 and	 BHRF1),	 marking	 them	 as	 potential	
candidates	[50,	188].	
Since	BNRF1	was	found	in	the	present	work	to	only	accommodate	antigens	with	a	maximum	
of	size	of	200	amino	acids,	 it	 is	 likely	that	 it	would	not	enable	the	 incorporation	of	several	
antigens.	An	alternate	candidate	for	accommodating	latent	antigens	within	DFEBV	is	the	large	
tegument	protein	BPLF1.	Since	it	is	BPLF1	is	350	kDa	in	size	and	BNRF1	is	140	kDa	in	size,	it	
might	be	more	suitable	for	the	introduction	of	latent	antigens	into	DFEBV.		
The	incorporation	of	the	most	conserved	and	immunologically	relevant	antigens	into	DFEBV,	
expressed	 in	 infected	B	 cells	 and	 EBV-malignancies,	 is	 likely	 to	 induce	 highly	 potent	 T-cell	
responses	 upon	 vaccination,	 whilst	 enabling	 the	 generation	 of	 neutralising	 antibodies	 in	
their	 natural	 context.	 Such	 a	 multipronged	 approach	 is	 likely	 to	 increase	 the	 protective	
ability	of	DFEBV,	and	maximise	its	potential	to	be	used	around	the	globe.		
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5.	Materials	and	Methods	
5.1.	Materials	
5.1.1.	Cells	
5.1.1.1.	Bacteria	 	
	
Strain			 Primary	Use	 Genotype	
E.coli	
DH5α	
Molecular	
cloning	
F-	Φ80lacZΔM15	Δ(lacZYA-argF)	U169	 recA1	endA1	hsdR17	 (rk-,	mk+)	
phoA	supE44	λ-thi-1	gyrA96	relA1			
E.coli	
DH10B		 Plasmid	rescue	
mcrA	Δ	(mrr-hsdRMS-mcrBC)	Φ	80dlacZ	Δ	M15	Δ	lacX74	recA1	endA1	
araD139	Δ	(ara,	leu)7697	galU	pglΔ8	rpsL	nupG	[189]	
E.coli	
SW102		
Recombineering	
with	galK	
counter	
selection	
mcrA	Δ	(mrr-hsdRMS-mcrBC)	Φ	80dlacZ	Δ	M15	Δ	lacX74	recA1	endA1	
araD139	 Δ	 (ara,	 leu)7697	 galU	 pglΔ8	 rpsL	 nupG	 λ(cI857ind1)	 Δ{(cro-
bioA)<>tetRA}	(TetR)	gal490	ΔgalK			[190]	
5.1.1.2.	Eukaryotic	cells	
Name	 Description	
HEK293	
Human	embryonic	kindey	cell	line	transformed	with	sheared	Adenovirus	5	
DNA	[191]	
CD4+	and	
CD8+	
clones/lines	
T-cell	 clones/lines	were	 generated	 through	 ex	 vivo	 stimulation	 of	 PBMCs	
from	healthy	donors	with	peptide.	They	were	kindly	provided	by	Prof.	Josef	
Mautner	(Helmholz-Zentrum,	München,	Germany).	
LCL	JM,	GB	
and	HM	
B	cells	from	healthy	donors	were	transformed	through	infection	with	EBV.	
They	 were	 kindly	 provided	 by	 Prof.	 Josef	 Mautner	 (Helmholz-Zentrum,	
München,	Germany).	
Elijah	
negative	
An	EBV-negative	B	cell	 lymphoma	cell	 line.	It	was	kindly	provided	by	Prof.	
Alan	Rickinson	(University	of	Birmingham).	
Raji	Cells	 An	EBV-positive	Burkitt’s	lymphoma	cell	line	[192].	
Producer	
cells	
Several	EBV	and	DFEBV	producer	cell	lines	were	used	in	this	study.	Producer	
cell	 lines	were	generated	by	 transfecting	HEK293	cells	with	BAC	DNA	and	
selecting	with	hygromycin	(100	μg/mL).		
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5.1.2.	Mice		
Strain		 Supplier	
NSG-A2	mice	(NOD.Cg-PrkdcscidIl2rgtm1WjlTg	(HLA-
A2.1)	[155]	
The	Jackson	
Laboratory	
5.1.3.	Cell	culture	media	
Name		 Supplier		
RPMI	1640	 GIBCO	by	Life	Technologies		
FreeStyleTM	293	 GIBCO	by	Life	Technologies	
AIM	V®	Medium	 GIBCO	by	Life	Technologies	
Opti-MEM®	 GIBCO	by	Life	Technologies	
Composed	media	
Name		 Composition	
LCL	
Medium	
RPMI	supplemented	with	10%	fetal	calf	serum,	1	mM	sodium	pyruvate,	2	mM	L-
glutamine,	1%	nonessential	amino	acids	and	50	µg/ml	gentamicin	
T-cell	
medium	
AIM	V®	Medium	supplemented	with	10%	pooled	human	serum	(heat-inactivated),	
10	mM	HEPES,	2	mM	L-glutamine,	50	μg/mL	gentamicin	and	0.4	mg/	mL	
ciprofloxacin	
5.1.4.	Plasmids	
Internal	lab.	Label	 Description	
p509	 encodes	BZLF1	
2670_(pRA)	 pRK5-B95-8.BALF4(=gp110=gB)	
B1261	 pRK5-aHuCD20.HC-NotI	
B1342	 gp350	ligand	binding	domain	(1	to	1410	bp)	HuCD20	AgAb	
B1394	 BNRF1	(EBNA1	1168bp-1548bp)	
B1395	 BNRF1	(EBNA1	1498bp-1866bp)	
B1396	 BNRF1	(EBNA1	1168bp-1866bp)	
B1450	 EBNA1	huCD20	AgAb	(EBNA1	fragment	=	1158	to	1856	bp)	
B581	 pRK5-aCD20-Light	chain	
B673	 pCDNA3.1(+)-CD2	
B560		 anti-CD20	Heavy	chain	in	pRK5	
pGal	 Galk	casette	
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5.1.5.	EBV-BACs		
Internal	lab.	Label	 Description	
2089	 Prototypic	EBV	strain	
M81		 EBV	strain	from	Hong	Kong	
B1009	 EBV-E3C	(150	bp)	
B1118	 EBV	+	galK	
B1151	 EBV-E3C-E1(300	bp)	
B1191	 EBV-E3C(600	bp)	
B1192	 EBV-E3C(600	bp)	
B1287	 DFEBV-E3C-E1(300	bp)	
B1229	 DFEBV	+	galK	
B1400	 DFEBV-EBNA1RI	
B1401	 DFEBV-EBNA1RII	
B1402	 DFEBV-EBNA1RI:RII	
	
5.1.6.	Oligonucleotides	
Aim	 Name	 Sequence	
α-CD20	
HC	
fwd	 TCGATTGAATTCATGGCTGTCC	
rev	 TTTCATAAGCTTTATTAGATCTAATTGCGGCCGCTTTACCCGGAGTCCGGGAG	
EBNA1-
AgAb	
fwd	 CGTAGCGGCCGCACAGTCATCATCATCCGGGTCTCC	
rev	 TTTCATAGATCTTAATGGTGATGGTGATGATGCGCGGCAGCCCCTTCC	
gp350-
AgAb	
fwd	 CGTAGCGGCCGCAATGGAGGCAGCCTTGCTTG	
rev	 TTTCATAGATCTTAATGGTGATGGTGATGATGGGTGGATACAGTGGGGCCTG	
EBV-galK		
fwd	 GAGCAGGGTGAACACTTGGGCACGGAGAGTGCCCTGGAGGCCTCAGGCAACCTGTTGACAATTAATCATCGGCA	
rev	 ATGTGGAAGGCCTTGCCATCCAGTCTGGTCCGTAGGCATACACATAGTTGTCAGCACTGTCCTGCTCCTT	
VLPs/LPs-
galK		
fwd	 GAGCAGGGTGAACACTTGGGCACGGAGAGTGCCCTGGAGGCCTCAGGCAACCTGTTGACAATTAATCATCGGCA	
rev	 ATGTGGAAGGCCTTGCCATCCAGTCTGGTCCGTAGGCATACACATAGTTGTCAGCACTGTCCTGCTCCTT	
EBV-E3C	
(150	bp)	
fwd	 GAGCAGGGTGAACACTTGGGCACGGAGAGTGCCCTGGAGGCCTCAGGCAATGCACCACCTAATGAAAATCCATATCAC	
rev	 ATGTGGAAGGCCTTGCCATCCAGTCTGGTCCGTAGGCATACACATAGTTGCCTGACGCAGGTTTACGGC	
EBV-E3C-
E1	(300	
bp)	
fwd	 AGCAGGGTGAACACTTGGGCACGGAGAGTGCCCTGGAGGCCTCAGGCAACAATGCACCACCTAATGAAAATCC	
rev	 CATGTGGAAGGCCTTGCCATCCAGTCTGGTCCGTAGGCATACACATAGTTTCCAGGGGCCATTCCAAAG	
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EBV-E3C	
(600	bp)	
fwd	 GTGCCCTGGAGGCCTCAGGCAACATAATGGCGCCTCCCGTC	
rev	 CATCCAGTCTGGTCCGTAGGCATACACATAGTTCTGGGTGTGCCCATGCAC	
EBV-E3C	
(900	bp)	
fwd	 GTGCCCTGGAGGCCTCAGGCAACATAATGGCGCCTCCCGTC	
rev	 CATCCAGTCTGGTCCGTAGGCATACACATAGTTACTGGCAAAGGGCATGCTTG	
DFEBV-
E3C-E1	
(300	bp)	
fwd	 AGCAGGGTGAACACTTGGGCACGGAGAGTGCCCTGGAGGCCTCAGGCAACAATGCACCACCTAATGAAAATCC	
rev	 CATGTGGAAGGCCTTGCCATCCAGTCTGGTCCGTAGGCATACACATAGTTTCCAGGGGCCATTCCAAAG	
DFEBV-
EBNA1RI	
fwd	 TAATCCCTCAGGCCAGTCATCATCATCCGGGTCTCCAC	
rev	 TTAGATCCTGAGGCACTACCTCCATATACGAACACACCGGC	
DFEBV-
EBNA1RII	
fwd	 GGCACTACCGACGAAGGAACTTGGGTCG	
rev	 GGCCGCGGCAGCCCCTTCCAC	
DFEBV-
EBNA1RI:RII	
fwd	 GGCACTACCGACGAAGGAACTTGGGTCG	
rev	 GGCCGCGGCAGCCCCTTCCAC	
	
5.1.7.	Antibodies	
Name	 Supplier	(catalog	no.)	
α-gp350	 supernatant	from	hybridoma	clone	72A1	
α-mouse	IgG		 Promega	(W402b)	
α-mouseIgG	Cy3	 Dianova	(115-165-146)	
α-BNRF1		 Antiserum	collected	from	rabbit	([22])	
α-CD3-FITC	 Miltenyi	Biotech(130-080-401)	
α-CD4-PE-Cy5	 eBioscience	(15-0042-82)	
α-CD19-APC	 eBioscience	(17-0199-41)	
α-CD23-PE-Cy7	 eBioscience	(25-0238-42)	
α-EBNA2	 kind	gift	from	E.Kremmer		
α-C20	 Dako	(M0755)	
CD107a-FITC	 eBioscience	(11-1079-42)	
	
5.1.8.	Enzymes	
Name	 Supplier	
Bgl	II	 ThermoFisher	Scientific		
Xba	I	 ThermoFisher	Scientific		
Eco	RI	 ThermoFisher	Scientific		
Bam	HI	 ThermoFisher	Scientific		
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Dra	I	 ThermoFisher	Scientific		
Hind	III	 ThermoFisher	Scientific		
Not	I	 ThermoFisher	Scientific		
Dpn	I	 ThermoFisher	Scientific		
Phusion	high-fidelity	polymerase		 ThermoFisher	Scientific		
Proteinase	K	 Roche	
DNase	I		 ThermoFisher	Scientific		
T4	DNA	ligase	 ThermoFisher	Scientific		
RNase	A	 ThermoFisher	Scientific		
Calf	intestinal	alkaline	phosphatase	 Roche	
	
5.1.9.	Chemicals,	reagents,	Kits	and	peptides	
Name		 Suplpier	
Absolute	Ethanol		 Sigma	
1-butanol		 AppliChem	
10	bp	DNA	ladder		 Invitrogen	
1kb	DNA	ladder	 Invitrogen	
SDS	solution	(20%)	 	MP	Biomedics	
Acetic	Acid		 Sigma-Aldrich	
Agarose		 Sigma-Aldrich	
Bromphenol	blue		 Serva	
CaCl2	 	Invitrogen	
Chloroform		 Carl	Roth	
Complete	Mini	Protease	Inhibitor		 Roche	
Biotin	 Sigma-Aldrich	
Galactose		 Sigma-Aldrich	
2-deoxy-galactose	 Sigma-Aldrich	
DMSO		 Sigma-Aldrich	
dNTP	mix		 Roche	
Ethanol		 Sigma-Aldrich	
Ethidiumbromide	 	Carl	Roth	
Fetal	Bovine	Serum		 Biochrom	
Ficoll	Plus		 Amersham	Biosciences	
Glycerol		 VWR	International	
Glycine		 GERBU	
GlycoBlue		 Invitrogen	
Hygromycin	B		 Invitrogen	
Isopropanol	 	Sigma-Aldrich	
Agar	 	Sigma-Aldrich	
Yeast	extract		 	Sigma-Aldrich	
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Tryptone	 	Sigma-Aldrich	
Metafectene		 Biontex	
MNCl2		 Sigma-Aldrich	
NP-40		 Biochemika	
4%	Paraformaldehyde	(PFA)	 	AppliChem	
PBS	tablets	for	cell	culture		 Gibco	
Phenol		 Carl	Roth	
Potassium	acetate	(KAc)	 Carl	Roth	
NucleoBond®	BAC	100	 Macherey-Nagel	
Plasmid	Midi	Kit	 QIAGEN	
Human	Granzyme	B	ELISA	develpment	kit	(HRP)	 MABTECH	
Human	IFN-gamma	ELISA	develpment	kit	(HRP)	 MABTECH	
Dynabeads	CD19	Pan	B		 ThermoFischer	
DETACHaBEAD	CD19	 ThermoFischer	
EBNA3C	5H11	peptide	
Kindly	donated	by	Prof.	J.	Mautner	
EBNA1	3E10	peptide	
EBNA1	3G2	peptide	
gp350	1D6	peptide	
BNRF1	VSD	peptide	
5.1.10.	Buffers	and	solutions	
Name	 Composition	
PBS	
137mM	NaCl,	2.7	mM	KCl,	10	mM	Na2HPO4	and	1.8	mM	KH2PO4	
(pH	7.4)	
PBS-T	 PBS	containing	0.05%	Tween-20	
5x	RIPA	buffer	
100	mM	Tris-HCl	(pH	7.5),	750	mM	NaCl,	25	mM	EDTA,	2,5	%	NP-
40	and	5%	Sodium	deoxycholate	
4x	Protein	loading	buffer	
200	mM	Tris.Cl	(pH	6.8),	8	%	SDS,	1%	bromophenol	blue,	40%	
glycerol	and	10%	2-mercaptoethanol	
10x	DNA	loading	buffer	
200	μL	0.5	M	EDTA,	10	%	SDS,	0.5%	bromophenol	blue,	and	40%	
glycerol	
10x	SDS-PAGE	running	
buffer	
30	g	Tris	base,	144	g	glycine,	and	10	g	SDS	in	1	L	of	dH20	
PFA	 4%	paraformaldehyde	in	PBS		(pH	7.4)	
ACK	buffer	 0.15	M	NH4CL,	1	mM	KHCO3	and	0,1	mM	EDTA	(autoclaved)	
Potassium	Acetate	
buffer	
3	M	Potassium	acetate,	add	glacial	acetic	acetate	to	pH	5.5	
Blocking	buffer	 5%	Skim	milk	powder	in	PBST	
TE	buffer	 10	mM	Tris-HCL	and	1	mM	EDTA	(pH	8.0)	
Blotting	buffer	 25	mM	Tris	base,	150	mM	Glycine	and	20%	Methanol	
50	x	TAE	 2.0	M	Tris	base	0,05	M	EDTA	and	1.0	M	glacial	acetic	acid	
Polyacrylamide	
separating	gel	(10	%)	
335	mM	Tris	(pH	8.9),	25	%	(v/v)	acrylamide	stock,	3.3	mM	EDT	
Polyacrylamide	 335	mM	Tris	(pH	8.9),	42	%	(v/v)	acrylamide	stock,	3.3	mM	EDT	
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separating	gel	(7,5	%)	
Polyacrylamide	stacking	
gel	(4.5	%)	
125	mM	Tris	(pH	6.8),	15	%	(v/v)	acrylamide	stock,	4.4	mM	EDT	
Lysis	buffer	for	circle	
prep	
SDS	1%,	EDTA	2	mM,	NaCl	50	mM	and	40	mM	NaOH	
M9	medium	
6	g	Na2HPO4,	3	g	KH2PO4,		1	g	NH4Cl	and		0.5	g	NaCl		and	fill	to	1	L	
with	water	
M63	minimal	medium	 10	g	(NH4)2SO4,	68	g	KH2PO4	and	2.5	mg	FeSO4·7H2O,	adjust	to	
pH	7	with	KOH	and	fill	to	1	L	with	water	
	
5.1.11.	Consumables,	software	and	equipment	
Name	 Supplier	
Software:	
	
CellQuest	Prosoftware	 BD	Biosciences	
FlowJo	Software	 FlowJo,	LLC	
Prism	 GraphPad	
MacVector	Software	15.1.1	 MacVector	Inc.	
	 	
Consumables:	
	
Amersham	membrane	Hybond	ECL	 GE	Healthcare	
Cell	culure	plates	 Techno	Plastic	Products	
Cell	strainer	70	μm	 Falcon	
Cryo	vials	 Greiner	Bio-one	
Disposable	Scalpel	 Feather	
Falcon	Tubes	(15/50	mL)	 Techno	Plastic	Products	
Safe-Lock	tubes	(0.5/1.5/2.0	mL)	 Eppendorf	AG	
Vivaspin	20	centrifugal	conectrators	(10	000	MWCO)	 Satorus	
Ultrafree-CL	centrifugal	device	(0.22	μm	)	 Merck	Millipore		
Electroporation	civettes	(1	mm)	 Carl	Roth	
1	x	8	Stripwell	96	well	plates									 Corning	
	Cell	strainer	(70	μm)	 Corning	
	
	Equipment:	
	
BD	FACSCalibur	flow	cytometer	 BD	Biosciences	
HydroFlex™	microplate	washer	 Tecan	
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OLS200	Shaking	waterbath		 Grant	Scientific	
Incubator	Hood	TH	30	 Edmund	Bühler	GmbH	
Incubator		for	bacteria	(B	5060)	 Heraeus	
Hera	Cell	150	incubator	 Thermo	Scientific	
Light	inverted	microscope,	DMIL-Led	 Leica	
Fluorescent	microscope	DM5000B											 Leica	
Heraues	Pico17	 Thermo	Scientific	
GSA	rotor	(RC-5C)	 Thermo	Scientific	
SS34	rotor	(RC-5C)	 Thermo	Scientific	
RC-5C	centrifuge	 Thermo	Scientific	
Multidoc-It	Digital	Imaging	System	 UVP	
MultiscanEx	microplate	reader	 Thermo	Elctron	Corporation	
Nanodrop	2000	 Thermo	Scientific	
pH-meter	766		 Knick	
Power	PAC	300		 BioRad	
Sonicator	UW2070	 Bandelin	Electronics	
Vortex-Genie	2	 Sceintific	Industies	
Step	One	Plus™	qPCR	machine	system									 	Applied	Biosystems	
TProfessional	Thermocycle	 Biometra	
Large	Gel	Horizontal	Electrophoresis	System	(OWL	A5)	 ThermoFisher	Scientific	
Gene	Pulser	II	Electroporation	system	 BioRad	
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5.2.	Methods	
5.2.1.	Culture	of	bacteria	
In	all	cases,	unless	specified	otherwise,	low-salt	Luria-Bertani	(LB)	medium	was	used	for	
liquid	or	agar	culture.	Liquid	cultures	were	maintained	at	170	rpm.		
5.2.2.	Transformation	of	Bacteria		
5.2.2.1.	Heat	shock	of	E.coli	DH5α	
Chemically	 competent	E.coli	DH5α	was	 transformed	via	a	heat	 shock	protocol.	Competent	
cells	 were	 thawed	 on	 ice	 and	mixed	with	 10	 μL	 of	 ligation	mixture	 or	 1	 μL	 of	 covalently	
closed	circular	DNA.	The	cell-DNA	mixture	was	incubated	on	ice	for	20	minutes,	after	which	
cells	were	incubated	at	42°C	for	90	seconds.	Next,	the	cells	were	returned	to	ice	for	another	
90	seconds.		The	transformed	cells	were	mixed	with	700	μL	of	LB	medium	and	incubated	at	
37°C	with	shaking	(180	rpm)	for	30	–	60	minutes.	The	cells	were	centrifuged	at	13000	x	g	for	
1	 min	 and	 the	 culture	 supernatant	 was	 removed.	 The	 pelleted	 bacterial	 cells	 were	
resuspended	in	100	μL	of	fresh	LB	medium	and	plated	on	LB	agar	containing	the	appropriate	
antibiotic.	The	plates	were	incubated	for	16-20	hours	and	stored	at	4°C	for	no	more	than	2	
week.		
5.2.2.2.	Electroporation	of	E.coli	with	BAC	DNA	
To	 introduce	BAC	DNA	 into	E.coli,	cells	were	transformed	through	electroporation.	A	small	
aliquot	of	BAC	DNA	(5-10	µL)	was	added	to	the	side	of	a	pre-chilled	electroporation	cuvette	
(0.1	cm	gap).	Next,	electrocompetent	cells	were	removed	from	-80°C,	thawed	on	ice,	added	
to	 the	 chilled	 electroporation	 cuvette	 and	 incubated	 on	 ice	 for	 5	 minutes.	 Cells	 were	
electroporated	 with	 100	 Ω,	 25	 µFd	 and	 1200	 V	 with	 the	 Gene	 Pulser	 II	 Electroporation	
system.	Electroporated	cells	were	immediately	resuspended,	mixed	with	3	mL	of	LB	medium	
and	recovered	at	37°C	(180	rpm)	for	2	hours.	The	cells	were	centrifuged	at	3000	x	g	for	10	
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minutes,	 resuspended	 in	100	µL	of	 fresh	LB	medium	and	plated	on	LB	agar	containing	 the	
appropriate	antibiotic.	Cells	were	incubated	overnight	at	37°C	and	the	plate	stored	at	4°C	for	
no	longer	than	2	weeks.		
5.2.3.	Sequencing	of	plasmid	DNA	
Plasmid	DNA	 sequencing	was	performed	by	Eurofins	MWG	Operon	 (Ebersberg,	Gemrany).	
Samples	to	be	sent	for	sequencing	were	prepared	by	mixing	13,5	μL	of	template	DNA	(100	
ng/μL)	 and	 1,5	 μL	 of	 the	 appropriate	 oligonucleotide	 (10	 mM).	 Sequencing	 results	 were	
analysed	with	MacVector	software	15.1.1.	
5.2.4.	Sequencing	of	BAC	DNA		
BAC	 DNA	 sequencing	 was	 performed	 by	 SequiServe	 GmbH	 (Vaterstetten,	 Germany).	 BAC	
DNA	samples	to	be	sequenced	were	resuspended	in	dH2O	at	100	ng/mL.	Oligonucleotides	to	
be	 used	 for	 sequencing	 were	 resuspended	 at	 10	 mM	 in	 dH2O.	 BAC	 DNA	 (15	 μL)	 and	
oligonucleotides	 (15	 μL)	 were	 sent	 separately.	 Sequencing	 results	 were	 analysed	 by	
MacVector	software	15.1.1.	
5.2.5.	Agarose	gel	electrophoresis	
Agarose	DNA	electrophoresis	(AGE)	was	used	for	analytical	and	preparative	purposes.	In	all	
cases,	 agarose	 gels	 were	made	with	 1	 x	 TAE	 and	 0.8%	 agarose.	 Prior	 to	 separation,	 DNA	
samples	were	mixed	with	10	x	DNA	loading	buffer.		
To	 separate	 plasmid	 DNA	 and	 PCR	 products,	 the	 Owl	 B2	mini	 gel	 system	 (ThermoFischer	
Scientific)	 was	 used	 at	 120	 V	 and	 400	mA	 for	 45	minutes.	Mini	 gels	 were	made	with	 0.1	
μg/mL	 of	 ethidium	bromide.	 To	 separate	 digested	 BAC	DNA,	 the	Owl	 A5	 large	 gel	 system	
(ThermoFischer	 Scientific)	 was	 used	 at	 65	 V	 and	 400	 mA	 for	 16	 hours	 or	 more.	 After	
separation,	 large	gels	were	stained	for	30	minutes	with	dH2O	containing	1	μg/mL	ethidium	
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bromide.	Subsequently,	large	gels	were	washed	twice	with	400	mL	dH2O	for	30	minutes.	For	
size	determination	of	DNA,	the	1	kb	Plus	DNA	ladder	and/or	the	1	kb	Extension	ladder	was	
used.	Transilluminated	UV	light	was	used	for	visualisation	of	DNA	and	images	were	recorded	
using	the	Multidoc-It	Digital	Imaging	System.	
5.2.6.	SDS-PAGE	and	Immunoblotting	
Proteins	from	293	cells	and	cell	culture	supernatants	were	separated	by	SDS-PAGE	according	
to	 Laemmli	 (1970).	 Proteins	 contained	 within	 gels	 were	 transferred	 to	 nitrocellulose	
membranes	 (Hybond	 C,	 Amersham)	 using	 electroblotting.	 Membranes	 were	 blocked	
overnight	 at	 4°C	 with	 blocking	 buffer.	 Primary	 and	 secondary	 antibodies	 were	 diluted	 in	
blocking	buffer	and	were	added	sequentially.	In	both	cases,	antibodies	were	incubated	for	1	
hour	at	room	temperature.	Washes	were	performed	3	times	with	PBST	to	remove	unbound	
antibodies.	 Bound	 antibodies	 were	 detected	 with	 Western	 Lightning	 Plus-ECL	 substrate	
(PerkinElmer)	and	Hyperfilm	ECL	(Amersham).		
5.2.7.	Isolation	of	plasmid	DNA	from	E.coli		
5.2.7.1.	Alkaline	lysis	minipreparation	of	plasmid	and	BAC	DNA		
Alkaline	 lysis	 minipreparation	 of	 plasmid	 and	 BAC	 DNA	 was	 carried	 out	 to	 obtain	 small	
quantities	 of	 DNA.	 Bacteria	 were	 cultured	 overnight	 at	 37°C	 in	 5	 mL	 of	 LB	 medium	
(supplemented	with	 the	appropriate	 antibiotic)	 and	were	harvested	with	 centrifugation	at	
13	 000	 x	 g	 for	 2	 minutes.	 The	 medium	 was	 removed	 and	 the	 bacterial	 pellet	 was	
resuspended	in	250	μL	of	TE	buffer	containing	50	μg/mL	of	RNase.	The	bacterial	suspension	
was	transferred	to	a	clean	1.5	mL	eppendorf	tube	and	one	volume	of	freshly	prepared	lysis	
buffer	(1%	SDS	and	0.2	M	NaOH	in	water)	was	added	to	the	resuspended	cells.	Immediately	
after	 adding	 the	 lysis	 solution,	 the	 tube	 was	 gently	 inverted	 two	 times	 and	 incubated	 at	
room	temperature	for	2	minutes.	A	250	μL	aliquot	of	3	M	Potassium	Acetate	was	added	to	
lysed	 cells	 and	 the	 tube	 inverted	 two	 times.	 The	 mixture	 was	 incubated	 on	 ice	 for	 10	
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minutes	and	centrifuged	at	13	000	x	g	for	5	minutes.	The	supernatant	was	transferred	to	a	
clean	tube	and	centrifuged	as	before.	The	supernatant	was	transferred	to	a	clean	tube	and	
mixed	 with	 635	 μL	 of	 isopropanol.	 The	 DNA	 was	 precipitated	 on	 ice	 for	 5	 minutes	 and	
pelleted	at	13	000	x	g	for	15	minutes.	The	supernatant	was	removed	and	the	pellet	washed	
in	 1	 mL	 of	 70%	 ethanol.	 The	 pellet	 was	 air-dried	 for	 5	 minutes	 and	 the	 pellet	 was	
resuspended	in	50	μL	TE	buffer	and	stored	long	term	at	-20°C.	
5.2.7.2.	Isolation	of	plasmid	DNA	using	the	PureLink	HiPure	Plasmid	Maxiprep	kit	
To	 isolate	 large	quantities	of	pure	plasmid	DNA,	 the	PureLink	HiPure	Plasmid	Maxiprep	kit	
(ThermoFischer	Scientific)	was	used.	Plasmid	DNA	isolation	was	always	carried	out	according	
to	the	manufacturers	instruction.	
5.2.7.3.	Isolation	of	BAC	DNA	using	the	NucleoBond	BAC	100	kit	
To	isolate	large	quantities	of	pure	BAC	DNA,	the	NucleoBond	BAC	100	kit	(Macherey-Nagel)	
was	 used.	 BAC	 DNA	 isolation	 was	 always	 carried	 out	 according	 to	 the	 manufacturers	
instruction.	
5.2.8.	Restriction	digestion	
All	restriction	enzymes	were	obtained	from	ThermoFishcer	Scientific	and	all	digestions	were	
carried	out	according	to	manufacturer’s	 instructions.	Restriction	enzymes	never	comprised	
more	than	1/10	of	the	total	reaction	mixture,	minimising	the	occurrence	of	star	activity	due	
to	excessive	levels	of	glycerol.		
5.2.9.	Determination	of	virus	titre	by	quantitative	PCR	(qPCR)	
Virus	 supernatants	 were	 analysed	 by	 qPCR	 to	 determine	 their	 titre	 [9].	 Prior	 to	 qPCR	
analysis,	 the	 supernatants	 were	 first	 subjected	 to	 DNaseI	 and	 Proteinase	 K	 treatment.	
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DNaseI	 removed	 free-floating	 viral	DNA,	while	Proteinase	K	 released	 virus-associated	DNA	
from	capsids.	
For	DNaseI	digestion,	45	μL	of	virus	supernatant	was	mixed	with	5	μL	of	10	X	reaction	buffer	
(with	MgCl2)	and	1	unit	of	RNase-free	DNaseI.	The	mixture	was	incubated	at	37°C	for	1	hour	
and	at	70°C	for	10	minutes.	For	Proteinase	K	treatment,	5	μL	of	DNaseI-treated	supernatant	
was	mixed	with	5	μL	of	Proteinase	K	(100	μg/mL).	The	mixture	was	incubated	at	50°C	for	1	
hour	and	 then	at	75°C	 for	20	minutes.	After	Proteinase	K	 treatment,	90	μL	of	dH2O	water	
was	added	to	each	sample.		
To	quantify	the	amount	of	virus	genomes,	qPCR	was	carried	out	with	primers	that	target	the	
EBV	DNA	polymerase	gene	(BALF5)	was	used.	The	following	reaction	mixture	was	set	up	per	
sample:		 	
12,5	μL	 		 TaqMan	Fast	PCR	Master	mix	(2x)	
2.5	μL		 	 Forward	primer	
2.5	μL		 	 Reverse	primer	
1.0	μL		 	 Probe		
1.5	μL		 	 H2O		
5	μL		 	 DNaseI	and	Proteinase	K	treated	sample		
25	μL	Total	
With	all	the	samples	set	up	the	following	thermocyling	conditions	were	used:		
Step	1-	50°C	2	minutes	
Step	2-	95°C	10	minutes	
										Step	3-	95°C	15	seconds	
										Step	4-	60°C	1	minute	 	
	Threshold	 cycle	 (Ct)	 values	 were	 used	 to	 calculate	 the	 genomes	 per	 millilitre	 of	 virus	
supernatant.	 This	 was	 achieved	 through	 the	 use	 of	 a	 standard	 curve	 in	 which	 the	 linear	
relationship	between	Ct	values	and	genome/mL	have	been	established.		
40	cycles	
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5.2.10.	Recombineering	
Latent	protein-coding	sequences	were	introduced	into	the	BNRF1	gene	of	BAC	DNA	through	
galK	 recombination.	GalK	 recombination	 is	 an	elegant	 technique	 that	enables	positive	and	
negative	selection	to	be	carried	out	using	a	single	selection	marker;	i.e.	the	galK	gene	[190].	
This	recombination	strategy	relies	on	the	use	of	the	SW102	E.coli	strain,	which	lacks	the	galK	
gene.	This	 is	 in	contrast	to	wild-type	E.coli,	which	contains	an	 intact	galactose	operon.	The	
galactose	operon	is	comprised	of	the	galE,	galT,	galK	and	galM	genes,	with	galK	encoding	a	
galactokinase	that	carries	out	the	first	step	in	the	pathway.	Figure	5.1	illustrates	the	use	of	
galk	recombination	construct	BNRF1-latent	protein	gene	fusions.		
	
Figure	5.1:	GalK	recombination	enabled	the	introduction	of	latent	protein-coding	sequences	into	the	
BNRF1	ORF.	 SW102	cells	 that	 contained	wtEBV	or	 DFEBV	BAC	DNA	were	unable	 to	grow	 in	minimal	
medium	containing	galactose.	However,	once	the	BNRF1	ORF	was	targeted	with	the	galK	expression	
cassette,	 containing	 the	 H1	 and	 H2	 homology	 arms,	 cells	 were	 able	 to	 grow	 in	 minimal	 medium	
containing	galactose	as	the	sole	carbon	source.	This	targeting	event	constituted	positive	selection	and	
converted	 Gal-	 cells	 to	 Gal+.	 The	 cells	 containing	 the	 galK	 expression	 cassette	 were	 then	 used	 to	
initiate	 a	 second	 targeting	 event.	 Latent	 protein-coding	 sequences,	 flanked	 by	 the	 H1	 and	 H2	
homology	arms,	replaced	the	galK	cassette	in	BAC	DNA.	This	caused	the	Gal+	cells	to	be	converted	to	
Gal-.	 Cells	 that	 lacked	 the	 galK	 cassette	 were	 selected	 for	 on	medium	 containing	 glycerol	 and	 the	
galactose	 analogue	 known	 as	 2-deoxy-galactose	 (DOG).	 Phosphorylation	 of	 DOG	 by	 galaktokinase	
generated	a	toxic	product	that	could	not	be	further	metabolised	by	the	cells,	resulting	in	their	death.	
Hence,	only	cells	lacking	the	galK	cassette	survived.		
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5.2.10.1.	Introducing	the	galK	cassette	into	BAC	DNA	
To	initiate	galK	recombination,	the	BAC	DNA	of	interest	was	first	introduced	into	SW102	cells	
via	electroporation	(see	section	5.2.2.2).	Next,	the	integrity	of	BAC	DNA	within	SW102	cells	
was	 assessed	 through	 restriction	 analysis	 of	 miniprep	 DNA.	 The	 SW102	 cells	 were	 then	
prepared	 for	 the	 first	 targeting	 event.	 SW102	 cells	 containing	 the	 appropriate	 BAC	 were	
inoculated	 into	 5	 mL	 LB	 broth	 (containing	 12.5	 μg/mL	 chloramphenicol)	 and	 incubated	
overnight	at	32°C	with	shaking.	The	following	day,	2	mL	of	the	overnight	culture	was	diluted	
into	100	mL	LB	broth	(containing	12.5	μg/mL	chloramphenicol)	and	incubated	at	32°C	(180	
rpm)	 until	 an	 OD600	 of	 0.5	 was	 reached.	 The	 cells	 were	 then	 transferred	 to	 a	 shaking-
waterbath	 at	 42°C	 and	 incubated	 for	 exactly	 15	min.	 This	 induced	 the	 expression	 of	 Exo,	
Beta	and	Gam;	i.e.	the	proteins	carry	out	recombination	[190].	Exo	generates	3’	overhangs	
from	 dsDNA,	 Beta	 binds	 the	 3’	 overhangs	 and	 mediates	 homologous	 recombination	 and	
Gam	protects	 linear	DNA	from	degradation	by	 inhibiting	the	RecBCD	exonuclease	of	E.coli.	
After	induction	at	42°C,	the	cells	were	rapidly	cooled	in	an	ice-water	bath.	The	cooled	cells	
were	centrifuged	at	3000	x	g	for	10	minutes	at	3°C.	The	culture	medium	was	removed	and	
the	cells	resuspended	in	50	mL	ice-cold	ddH2O.	The	cells	were	centrifuged	and	resuspended	
as	before.	The	cells	were	centrifuged	one	last	time,	the	supernatant	removed	and	the	pellet	
resuspended	in	150	μL	ddH2O.	The	cells	were	now	ready	to	be	used	for	electroporation.	The	
cells	were	electroporated	with	60	ng	of	 the	galK	cassette.	The	galK	cassette	was	amplified	
from	the	pGALK	vector	via	PCR	(see	section	5.1.6	for	the	primers	used).	The	electroporated	
cells	were	 recovered	 in	 3	mL	 LB	broth	 for	 4	 hours	 at	 32°C.	After	 the	 recovery	period,	 the	
bacteria	were	centrifuged,	the	medium	removed	and	the	cells	washed	in	10	mL	1x	M9	salts.	
Washing	 in	 1x	 M9	 salts	 serves	 to	 remove	 residual	 medium	 from	 cells	 before	 plating	 on	
minimal	medium.	Washed	cells	were	pelleted	and	resuspended	in	1	mL	of	1x	M9	salts.	Cells	
were	 diluted	 1:100	 in	 100	 μL	 of	 1	 x	 M9	 salts	 and	 plated	 onto	 M63	 minimal	 medium	
(containing	20%	galactose	and	12.5	μg/mL	chloramphenicol).	Cells	were	 incubated	at	32°C	
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for	 4	 days.	 Single	 colonies	 were	 streaked	 out	 on	 LB	 agar	 (containing	 12.5	 μg/mL	
chloramphenicol	 and	 10	 μg/mL	 tetracycline)	 and	 their	 BAC	 DNA	 analysed	 by	 restriction	
digestion	to	determine	if	the	insertion	of	galK	was	successful.	Colonies	that	were	positively	
identified	by	restriction	digestion	were	analysed	by	DNA	sequencing.		
5.2.10.2.	Introducing	latent	protein	coding	sequences	into	BAC	DNA		
A	 Gal+	 SW102	 clone	 containing	 the	 appropriate	 BAC	 DNA	 was	 used	 to	 carry	 out	 counter	
selection.	 Cells	 were	 made	 competent,	 heat	 induced,	 electroporated	 and	 recovered	 as	
outlined	 in	 section	 5.2.10.1.	 However,	 in	 this	 case	 latent	 protein-coding	 fragments	 were	
generated	through	PCR	or	digested	from	a	shuttle	vector	(see	section	5.1.6	for	the	primers	
used).	 Recovered	 cells	 were	 pelleted	 at	 3000	 x	 g	 for	 10	minutes	 at	 3°C,	 the	 supernatant	
removed	 and	 the	 cells	 washed	 in	 10	mL	 1	 x	M9	 salts.	Washed	 cells	 were	 centrifuged	 as	
before	and	were	resuspended	in	1	mL	in	1	mL	of	1	x	M9	salts.	Cells	were	diluted	1:100	in	100	
μL	 of	 1x	M9	 salts	 and	 plated	 onto	M63	minimal	medium	 (containing	 20%	 DOG	 and	 12.5	
μg/mL	 chloramphenicol).	 Cells	 were	 incubated	 at	 32°C	 for	 4	 days.	 Single	 colonies	 were	
streaked	out	on	LB	agar	(containing	12.5	μg/mL	chloramphenicol	and	10	μg/mL	tetracycline)	
and	 their	 BAC	 DNA	 analysed	 by	 restriction	 digestion	 to	 determine	 if	 the	 latent	 protein-
coding	 sequences	 were	 successfully	 inserted.	 	 Colonies	 that	 were	 positively	 identified	 by	
restriction	digestion	were	analysed	by	DNA	sequencing.	
5.2.11.	Cloning	of	Antigen-Armed	Antibodies	
Antigen-armed	 antibodies	 (AgAbs)	 are	 antibodies	 that	 are	 fused	 to	 antigen.	 Previously,	 B	
cells	have	been	targeted	with	AgAbs	generated	from	α-CD19,	α-CD20,	α-CD21	and	α-CD22	
antibodies	 [146].	 Targeting	 of	 B	 cells	 with	 AgAbs	 enable	 their	 internalisation	 and	 the	
concomitant	presentation	of	antigenic	peptides	to	CD4+	T	cells.		
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In	 this	 study,	 AgAbs	 were	 used	 to	 deliver	 antigens	 to	 antigen-presenting	 cells	 (APCs)	 to	
enable	 the	 expansion	 of	 memory	 CD4+	T	 cells	 from	 EBV-positive	 individuals.	 AgAb	 heavy	
chains	were	constructed	by	fusing	antigen-coding	sequences	from	EBNA1	and	gp350	to	an	α-
CD20	 heavy	 chain	 (HC)	 gene	 (Figure	 5.2).	 The	 α-CD20	 HC	 used	 in	 this	 study	 consisted	 of	
domains	of	human	and	mouse	origin	and	was	previously	cloned	[146].	The		constant		regions		
	
Figure	 5.2:	 AgAb	heavy	 chains	were	 cloned	 into	 the	mammalian	 expression	 vector	 pRK5.	 (A)	An	α-
CD20	HC	expression	vector	was	cloned	to	contain	NotI	and	BglII	 restriction	sites.	Expression	vectors	
encoding	the	EBNA1-AgAb	HC	(B)	and	gp350-AgAb	HC	(C)	are	shown.		
originated	from	mouse	IgG2a,	while	the	variable	regions	originated	from	human	α-CD20.The	
first	 step	 in	 generating	AgAb	expression	vectors	was	 the	 construction	of	 an	α-CD20	heavy	
chain-expression	vector	with	NotI	and	BglII	restriction	sites	downstream	of	the	CH3	domain.	
This	enabled	the	cloning	of	antigen-coding	sequences	downstream	of	the	α-CD20	HC.	To	this	
end,	 EBNA1	 or	 gp350	 coding-sequences	 were	 PCR	 amplified	 (see	 section	 5.1.6	 for	 the	
primers),	 digested	 with	NotI	 and	BglII	 and	 introduced	 to	 the	 α-CD20	 HC	 encoding	 vector	
using.		
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5.2.12.	Eukaryotic	cell	culture	
5.2.12.1.	Generation	of	wtEBV	and	DFEBV	producer	cells	lines	
Producer	 cell	 lines	were	generated	by	 transfecting	293	 cells	with	BAC	DNA.	BAC	DNA	was	
prepared	as	described	in	section	5.2.7.3.	293	cells	were	plated	in	6	well	plates	at	3	x	105	cells	
per	well	and	allowed	to	attach	overnight	at	37°C.	For	each	well,	a	transfection	mixture	was	
prepared	by	mixing	 800	μL	 of	 RPMI	 1640	 (containing	 5	μL	BAC	DNA)	 and	200	μL	 of	 RPMI	
1640	(containing	7	μL	Metafectne).	The	mixture	was	incubated	at	room	temperature	for	20	
minutes	and	added	dropwise	 to	 the	 cells.	 The	 cells	were	 incubated	overnight	at	37°C	and	
inspected	 for	 GFP	 expression	 using	 a	 fluorescent	 microscope.	 Generally,	 a	 transfection	
efficiency	 of	 20%	 was	 satisfactory.	 Once	 the	 appropriate	 level	 of	 GFP	 expression	 was	
confirmed,	the	cells	were	collected	by	gentle	pipetting	and	added	to	a	15	cm	plate	in	30	mL	
RPMI	 medium	 (supplemented	 with	 10	 %	 FBS,	 300	 μL	 of	 1	 x	 sodium	 pyruvate,	 30	 μL	 of		
aTG/BCA	mix	and	100	μg/mL	of	hygromycin).	The	cells	were	incubated	at	37°C	for	2-3	weeks	
until	 single	 colonies	 grew	 out.	 The	 medium	 was	 aspirated	 and	 the	 single	 colonies	 were	
covered	with	 a	 small	 volume	 of	 0.05%	 trypsin	 (30	 μL)	 and	 collected	with	 a	micropipette.	
Each	colony	was	added	to	a	six	well	plate	in	containing	2	mL	RPMI	1640	medium	(10	%	FBS	
and	100	μg/mL	hygromycin)	per	well.	Cells	were	expanded	to	10	cm	plates	and	clones	were	
tested	 for	 their	 ability	 to	 express	 the	 late	 lytic	 gene	 product	 gp350	 upon	 induction	 with	
BZLF1	(p509)	(see	section	5.2.12.2).	Clones	that	had	between	5	and	20%	gp350	positive	cells	
were	further	analysed.	Cells	that	were	contained	EBV	BAC	were	further	screened	by	qPCR.	
However,	this	was	not	possible	for	DFEBV	producer	cell	lines	since	their	particles	lacked	DNA.	
Hence,	their	supernatants	were	analysed	in	a	B	cell	binding	assay	(see	section	5.2.12.6).	As	a	
control	wtEBV	with	a	 titre	of	1	x	107	was	analysed	alongside	DFEBV	supernatants.	The	BAC	
DNA	 from	 clones	 giving	 high	 titres	 were	 analysed	 by	 restriction	 digestion	 after	 plasmid	
rescue	(see	section	5.2.12.4).		
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5.2.12.2.	Production	of	EBV	and	DFEBV	
Cell	lines	stably	transfected	with	BAC	DNA	were	used	to	produce	virus	or	DFEBV.	Viable	cells	
were	plated	at	3.5	x	105	 in	a	6	well	plate	and	 incubated	overnight	at	37°C.	The	cells	were	
then	transfected	with	a	total	of	1	μg	of	DNA.	EBV	producer	cell	lines	were	transfected	with	
0.5	μg	of	the	BZLF1-encoding	vector	(p509)	to	induce	lytic	replication	and	0.5	μg	of	a	gp110-
encoding	vector	(pRA).	Increased	amounts	of	gp110	within	the	viral	envelope	increase	virus	
infection	100	times	[193].	DFEBV	producer	cell	lines	were	always	infected	with	0.5	μg	of	p509	
and	0.5	μg	of	empty	pCDNA.	Transfection	mixes	were	 set-up	mixing	100	μL	of	RPMI	1640	
containing	DNA	and	100	μL	of	RPMI	1640	containing	metafectene.	Transfection	mixes	were	
incubated	at	 room	 temperature	 for	20	minutes	and	added	 to	 cells	 in	a	drop-wise	 fashion.	
Cells	 were	 incubated	 for	 8	 to	 12	 hours	 and	 the	 metafectene-containing	 medium	 was	
replaced	with	 fresh	 RPMI	 1640	 supplemented	with	 10%	 FBS.	 The	 cells	 were	 incubated	 at	
37°C	for	three	days	and	supernatants	were	collected.	The	supernatants	were	centrifuged	at		
400	x	g	for	10	minutes	and	filtered	through	a	0.44	μm	filter.	EBV	and	DFEBV	used	for	the	ex	
vivo	expansion	of	T	cells	or	in	vivo	experiments	were	produced	in	serum-free	FreeStyle	293	
medium	instead	of	RPMI	1640	containing	10%	FBS.	Additionally,	EBV	and	DFEBV	used	for	 in	
vivo	experiments	were	concentrated	at	18	000	x	g	for	3	hours	and	resuspended	in	PBS.		
5.2.12.3.	Transient	expression	of	AgAbs	in	HEK	293	cells	
293	 cells	 (3	 x	 106	 cells)	were	 seeded	 in	 10	 cm	 plates	 and	 incubated	 overnight	 at	 37°C	 to	
allow	them	to	attach.	Next,	the	AgAb	expression	vectors	described	 in	section	5.2.11,	along	
with	an	expressing	 vector	encoding	an	α-CD20	 light	 chain,	were	 transfected	 into	293	 cells	
using	polyethylenimine	 (PEI).	 To	prepare	 the	 transfection	mixture	 for	each	plate,	 20	μg	of	
heavy	chain	and	20	μg	of	light	chain	encoding	plasmid	were	added	to	750	μL	of	Opti-MEM.	
Then,	50	μg	of	PEI	was	added	to	the	DNA	mixture	and	incubated	at	room	temperature	for	30	
minutes.	 The	 transfection	mix	was	 carefully	 added	 to	 a	plate	 containing	 the	293	 cells	 and	
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incubated	 overnight.	 The	 medium	 was	 aspirated	 the	 following	 day	 and	 replaced	 with	
FreeStyle	 293	 expression	 medium	 and	 incubated	 for	 3	 more	 days.	 The	 AgAb	 containing	
supernatant	 was	 centrifuged	 at	 500	 x	 g	 for	 15	 minutes	 to	 remove	 cell	 debris.	 The	
supernatant	 was	 then	 filtered	 through	 a	 0.22	 μm	 Acetate	 filter	 and	 concentrated	 with	
ultrafiltration	through	the	use	of	Vivaspin	20	centrifugal	concentrators	(10	000	MWCO).	The	
concentrated	AgAbs	were	supplemented	with	2	x	HEPES	buffer	and	quantified	with	an	IgG-
specific	ELISA.	The	quantified	AgAbs	were	aliquoted	and	stored	at	-20°C.		
5.2.12.4.	Plasmid	rescue	protocol	
Producer	cells	 from	a	15	cm	plate	were	 transferred	to	50	mL	 falcon	tube	and	collected	by	
centrifugation	 at	 400	 x	 g.	 The	 pelleted	 cells	 were	 washed	 twice	 with	 10	 mL	 PBS,	 the	
supernatant	gently	poured	off	and	the	cells	resuspended	in	the	remaining	liquid.	Circle	prep	
lysis	buffer	 (10	mL)	was	added	 to	 the	cells	and	 the	mixture	 incubated	 for	5	minutes,	after	
which	 500	 μL	 of	 Tris-HCL	 (pH	 7.1)	was	 added	 in	 a	 dropwise	 fashion.	 During	 the	 dropwise	
addition	of	Tris-HCL,	gentle	mixing	was	performed	in	a	circular	motion.	Subsequently,	2	mL	
of	 3	 M	 NaCl	 was	 added	 to	 the	 lysed	 cells	 and	 the	 mixture	 was	 inverted	 three	 times.	
Proteinase	 K	 (0.7	 mg)	 was	 added	 and	 digestion	 was	 carried	 out	 overnight	 at	 37°C.	 	 The	
following	day,	one	volume	of	Phenol/NaCl	was	added	and	the	solution	was	mixed	in	an	end-
over-end	fashion	for	10	minutes.	Centrifugation	was	performed	at	3400	x	g	for	15	minutes	
and	 the	 upper	 aqueous	 phase	was	 immediately	 transferred	 to	 a	 clean	 50	mL	 falcon	 tube.	
One	volume	of	n-Butanol	was	 then	added	and	end-over-end	mixing	 carried	out	as	before.	
Centrifugation	was	carried	out	at	2000	x	g	for	10	minutes	and	the	upper	phase	was	carefully	
removed	and	discarded.	The	bottom	phase	was	collected	and	transferred	to	a	50	mL	falcon	
tube	containing	2.5	volumes	containing	 ice-cold	ethanol	(100%).	The	DNA	was	precipitated	
at	 -20°C	 for	 1	 hour	 and	 pelleted	 by	 centrifugation	 at	 4000	 x	 g	 for	 1	 hour	 at	 room	
temperature.	The	supernatant	was	removed,	the	pellet	washed	 in	1	mL	ethanol	 (70%)	and	
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resuspended	in	50	μL	dH2O.	The	DNA	was	allowed	to	dissolve	overnight	at	4°C	and	was	used	
to	 electroporate	DH10B	 cells.	 The	DNA	 contained	within	 single	 colonies	was,	 isolated	 and	
analysed	by	restriction	digestion	to	confirm	the	BAC	integrity.	
5.2.12.5.	Determination	of	green	fluorescent	units	(GRU)	
The	green	fluorescent	units	(GFU)	of	viral	supernatants	were	used	to	determine	infectivity.	
Virus	supernatant	with	a	concentration	of	1	x	107	genomes/mL,	as	determined	by	qPCR,	was	
serially	diluted	in	96	well	plate	with	RPMI	1640	(supplemented	with	10%	FBS	and	Penstrep	
(1%).	Viable	Raji	cells	(1	x	104	cells)	were	added	to	each	well	and	the	plate	incubated	at	37°C	
for	2	days.	Subsequently,	1M	n-butyrate	and	30	μL	(20	ng/mL)	12-O-tetradecanoylphorbol-
13-acetate	 (TPA)	was	 added	 to	 each	well	 and	 the	 plate	 incubated	 overnight	 at	 37°C.	 The	
following	day	the	cells	were	examined	under	a	 fluorescent	microscope	(Leica	DM	IRB)	and	
the	percentage	GFP-positive	cells	were	determined.		
5.2.12.6.	B	cell	binding	assay	
Binding	assays	were	performed	with	Elijah	negative	B	cells	to	obtain	an	estimation	of	virus	
or	DFEBV	titre.	Viable	Elijah	negative	cells	(1	x	105	cells)	were	incubated	with	1	mL	of	virus	or	
DFEBV	supernatant	at	4°C	on	a	neutator	for	2	hours.	Cells	were	collected	at	300	x	g	(4°C)	and	
washed	3	times	with	ice-cold	PBS.	Washed	cells	were	dropped	on	slides	and	air-dried.	Cells	
were	fixed	with	acetone	for	exactly	20	minutes	and	stained	in	a	humidity	chamber	with	α-
gp350	(clone	72A1)	antibody	at	37°C	for	30	minutes.	Cells	were	washed	three	times	in	PBS	
and	 stained	with	 α-mouse	 Cy3	 in	 a	 humidity	 chamber	 at	 37°C	 for	 30	minutes.	 Cells	were	
washed	as	before,	mounted	with	glycerol	and	analysed	with	a	fluorescent	microscope	(Leica	
DM	500B).	
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5.2.12.7.	Maintenance	of	T-cell	clones/	lines.		
5.2.12.7.1.	Preparation	of	Human	serum		
For	T-cell	maintenance,	fresh	serum	was	used	to	formulate	T-cell	medium.	In	general,	fresh	
serum	was	 prepared	 every	 10	 days.	 Blood	 from	 two	healthy	 donors	 (∼	 75	mL	 each)	were	
drawn	and	added	to	50	mL	falcon	tubes.	The	blood	was	then	left	at	room	temperature	for	2	
hours	to	allow	clotting	take	place.	During	this	incubation	period	the	blood	was	mixed	three	
times	through	inversion.	The	blood	was	centrifuged	at	600	x	g	for	15	minutes	without	brake	
and	 the	upper	phase	 transferred	 to	a	 sterile	50	mL	 falcon	 tube.	The	collected	serum	from	
two	 donors	 was	 then	 pooled	 and	 centrifuged	 at	 600	 x	 g	 one	 last	 time	 to	 remove	 any	
contaminating	red	blood	cells.	The	clear	serum	then	heat	inactivated	at	56°C	for	30	minutes.	
The	 resulting	 serum	 was	 allowed	 to	 cool	 to	 room	 temperature	 and	 used	 immediately	 to	
supplement	T-cell	medium.	For	short	term	storage,	serum	was	kept	at	4°C	for	no	more	than	
two	weeks.		
5.2.12.7.2.	Isolation	of	Peripheral	Mononuclear	Cells	(PBMCs)		
PBMCs	were	 isolated	 from	 buffy	 coats	 that	were	 obtained	 from	 the	 ‘Institut	 für	 Klinische	
Transfusionsmedizin	und	Zelltherapie’	(IKTZ)	Heidelberg.	Blood	(∼	50	mL)	from	a	single	donor	
was	 added	 to	 a	 sterile	 250	 mL	 conical	 centrifuge	 tube	 containing	 50	 mL	 pre-chilled	 PBS	
(supplemented	with	500	μL	0.5	M	EDTA	(pH	8.0)).	Ficoll-Paque™	(50	mL)	was	then	carefully	
layered	 underneath	 the	 diluted	 blood	 and	 centrifuged	 without	 brake	 at	 500	 x	 g	 for	 30	
minutes.	 The	 layer	 containing	 the	PBMCs	was	 carefully	 transferred	 to	 sterile	50	mL	 falcon	
tubed,	 diluted	 1:2	 with	 ice-cold	 RPMI	 1640	 medium	 and	 centrifuged	 at	 500	 x	 g	 for	 15	
minutes.	The	supernatant	was	removed	and	the	pellet	resuspended	in	50	mL	ice-cold	RPMI	
1640.	 The	 PBMCs	 were	 then	 centrifuged	 twice	 at	 80	 x	 g	 for	 15	 minutes	 to	 remove	
contaminating	platelets.	 The	 resulting	PBMCs	were	 resuspended	 in	 50	mL	PRMI	1640	and	
counted	in	a	Neubauer	counting	chamber.	The	PBMCs	were	then	added	to	T-cell	medium	at	
a	concentration	of	1	x	106	cells/mL	and	irradiated	with	40	Gray.	
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5.2.12.7.13.	Pulsing	of	LCLs	with	antigen		
In	 order	 to	 stimulate	 T	 cells,	 LCLs	 were	 pulsed	 with	 the	 appropriate	 peptides.	 LCLs	 at	 a	
concentration	 of	 1	 x	 106	 cells/mL	 were	 mixed	 with	 at	 total	 of	 1	 μg	 peptide	 and	 then	
incubated	at	37°C	for	3	hours.	The	pulsed	LCLs	were	centrifuged	at	500	x	g	for	10	minutes	
and	 the	 peptide	 containing	 supernatant	 removed.	 Pelleted	 LCLs	 were	 washed	 twice	 with	
room	 temperature	 RPMI	 1640	 to	 remove	 unbound	 peptide.	 LCLs	 were	 resuspended	 at	 a	
concentration	of	1	x	106	cells/mL	in	T-cell	medium	and	irradiated	with	80	Gray.		
5.2.12.7.14.	Mix	T	cells	with	pulsed	LCLs	and	feeder	cells	
The	final	step	in	the	stimulation	protocol	entails	mixing	the	T	cells	with	PBMCs	(see	section	
5.2.12.7.12)	 and	 pulsed	 LCLs	 (see	 section	 5.2.12.7.13).	 Viable	 T	 cells	 were	 quantified	 in	 a	
Neubauer	 counting	 chamber	 and	 resuspended	 in	 T-cell	 medium	 (supplemented	 with	 IL-2	
10U/mL	 and	 250	 ng/mL	 of	 PHA)	 at	 1	 x	 106	 cells/mL.	 	 To	 each	millilitre	 of	 T	 cells	 another	
millilitre	 of	 T-cell	 medium	 (supplemented	 with	 10U/mL	 of	 IL-2	 and	 250	 ng/mL	 of	 PHA)	
containing	2	 x	105	 LCLs	and	1	 x	106	PMBCs	were	added.	The	T-cell-LCL-PBMC	mixture	was	
then	incubated	at	37°C.	After	two	days,	the	PHA	containing	medium	was	removed	and	
replaced	with	T-cell	medium	containing	10U/mL	of	IL-2.	
5.2.12.8.	The	ex	vivo	of	CD4+	T	cells	
AgAbs	were	utilised	 in	 the	present	study	to	expand	CD4+	T	cells	 from	EBV-positive	donors.	
The	use	of	EBNA1-AgAb	and	gp350-AgAb	respectively	enabled	the	expansion	of	EBNA1-	and	
gp350-specific	 CD4+	 T	 cells	 from	 bulk	 PBMCs	 or	 modified	 DFEBV-stimulated	 PBMCs.	 Once	
expanded,	these	cells	were	maintained	in	a	similar	fashion	as	described	in	section	3.2.12.7.		
To	expand	the	relevant	T	cells,	they	were	stimulated	biweekly,	using	PBMCs	or	LCLs	as	APCs	.		
A	total	of	50	ng	of	each	AbAb	was	used	to	pulse	enough	APCs	for	1	million	T	cells.	Prior	to	
cocultured	with	T	cells,	PBMCs	and	LCLs	were	respectively	irradiated	with	40	and	80	Gray.		
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5.2.12.9.	T-cell	activation	assays	
T-cell	 activation	was	determined	by	quantifying	 the	amount	of	 IFN-γ	 released	 from	T	 cells	
that	were	cocultured	with	pulsed	LCLs.	T	cells	were	cocultured	with	pulsed	LCLs	at	a	ratio	of	
1:1	 for	 16-20	hours	 and	 cell	 culture	 supernatants	were	 then	 analysed	 for	 the	presence	of	
IFN-γ	with	an	ELISA	(see	section	5.2.15.4.1).		
5.2.12.10.	Isolation	of	B	cells	from	PBMCs	
In	 the	 present	 study	 B	 cells	 were	 prepared	 from	 freshly	 isolated	 PBMCs	 (see	 section	
3.2.12.7)	 using	 the	 Dynabeads	 CD19	 Pan	 (Invitrogen)	 and	 DETACHaBEADs	 CD19	 kit	
(Invitrogen).		
Isolated	PBMCs	 from	a	single	donor	were	 resuspended	 in	5	mL	RPMI	1640	 (supplemented	
with	2%	FBS),	 to	which	a	 total	of	1.4	x	108	Dynabeads	CD19	Pan	were	added.	The	mixture	
was	 neutated	 at	 room	 temperature	 for	 45	minutes	 and	 B	 cell-Dynabead	 complexes	were	
collected	with	a	magnet.	The	supernatant	was	removed	and	the	pellet	was	washed	in	three	
times	10	mL	of	RPMI	1640	(supplemented	with	2%	FBS).	The	pellet	was	resuspended	in	1mL	
of	RPMI	1640	(supplemented	with	2%	FBS)	and	a	small	volume	(100	μL)	of	DETACHaBEADs	
was	 added.	 The	 mixture	 was	 neutated	 at	 room	 temperature	 for	 45	 minutes	 and	 the	
Dynabeads	CD19	Pan	was	collected	with	a	magnet.	The	supernatant,	 containing	purified	B	
cells	was	collected	and	 transferred	 to	 sterile	15	mL	 falcon	 tube.	The	Dynabeads	CD19	Pan	
fraction	was	washed	twice	with	5	mL	RPMI	1640	(supplemented	with	10%	FBS)	 to	remove	
residual	B	cells.	The	B	cell	containing	fractions	were	pooled	and	washed	one	 last	time	 in	5	
mL	RPMI	1640	(supplemented	with	10%	FBS).		
5.2.13.	Depletion	of	CD8+	T	cells	from	T-cell	cultures	
On	a	few	occasion,	CD8+	T	cells	managed	to	grow	and	expand	after	the	stimulation	of	PBMCs	
with	AgAbs	 or	 DFEBV	 (see	 section	 5.2.12.8).	Whilst	 the	 proportion	 of	 CD8+	 T	 cells	 in	 these	
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cultures	were	always	less	than	CD4+	T	cells,	ex	vivo	cultures	were	depleted	of	CD8+	T	cells	to	
enable	the	exclusive	analysis	of	CD4+	T	cells.		
CD8+	T	cells	were	depleted	from	T-cell	cultures	using	anti-PE	MicroBeads	(cat	no:	130-097-
054).	A	total	of	1	x	107	cells	were	 incubated	with	10	μL	anti-human	CD8a	PE	antibody	(cat	
no:	12-0087-41)	at	4°C	for	1	hour	and	pelleted	at	300	x	g	for	5	minutes.	The	supernatant	was	
removed	and	the	cell	pellet	was	resuspended	in	1	mL	cold	MACS	buffer	(PBS	supplemented	
with	0.5%	BSA	and	2nM	EDTA).	The	cells	were	washed	as	before	and	resuspended	in	100	μL	
of	cold	MACS	buffer	and	20	μL	of	anti-PE	MicroBeads	was	added.	The	mixture	was	incubated	
at	 4°C	 for	 1	 hour,	 washed	 as	 described	 above	 and	 resuspended	 in	 500	 μL	 of	 cold	MACS	
buffer.	An	LS	MACS	column	(cat	no:130-041-306)	was	placed	 in	magnetic	MACS	separator,	
washed	 with	 3	 mL	 MACS	 buffer	 and	 loaded	 with	 the	 cell	 suspension.	 The	 flow	 through	
containing	CD4+	T	cells	was	collected.	The	column	was	washed	with	2	x	5	mL	to	collect	any	
unbound	cells	CD4+	T	cells.		
5.2.14.	LCL	generation	
LCLs	were	generated	by	from	B	cells	that	were	freshly	isolated	from	the	PBMCs	(see	section	
5.2.12.10).	 B	 cells	 were	 infected	 with	 B95-8ΔBZLF1/BRLF1	 at	 an	 MOI	 of	 10	 at	 room	
temperature	for	2	hours.	Thereafter,	cells	were	washed	with	RPMI	1640,	mixed	with	RPMI	
1640	(supplemented	with	10%	FBS)	and	incubated	for	1	to	2	weeks	at	37°C	until	LCLs	grew	
out.	LCLs	were	maintained	as	suspension	cultures	in	LCL	medium	(RPMI	1640	with	10%	fetal	
calf	serum,	1	mM	sodium	pyruvate,	2	mM	L-glutamine,	1%	nonessential	amino	acids	and	50	
µg/ml	gentamicin)	
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5.2.15.	Flow	cytomteric	analyses	
5.2.15.1.	Quantification	of	DFEBV	
Flow	cytometry	was	used	as	the	principal	method	for	quantifying	DFEBV.	Elijah	negative	cells	
were	 harvested	 at	 400	 x	 g	 for	 10	minutes	 and	washed	once	with	 PBS	 (3%	BSA).	 The	 cells	
were	resuspended	in	ice-cold	PBS	(3%	BSA)	and	5	x	105	cells	were	aliquoted	into	sterile	1.5	
mL	 eppendorf	 tubes	 for	 every	 DFEBV	 supernatant	 to	 be	 analysed.	 DFEBV	 containing	
supernatant	(1	mL),	pre-chilled	on	ice,	was	mixed	with	Elijah	negative	cells	and	neutated	at	
4°C	for	2	hours.	Cells	were	centrifuged	at	400	x	g	for	5	minutes,	the	supernatant	containing	
unbound	DFEBV	removed	and	the	cells	resuspended	in	1	mL	ice-cold	PBS	(3%	BSA).	The	cells	
were	centrifuged	as	before	and	resuspended	 in	100	μL	of	 ice-cold	PBS	 (3%	BSA).	A	gp350-
specific	mouse	antibody	(clone	72A1)	was	added	to	the	cells	at	6	μg/mL	and	 incubated	on	
ice	 for	 1	 hour.	 Subsequently,	 the	 cells	 were	 washed	 as	 before	 and	 an	 α-mouse	 IgG-Cy3	
antibody	(115-165-146)	was	then	added	(1:100	dilution).		The	mixture	was	incubated	on	ice	
for	1	hour,	the	cells	washed	and	resuspended	in	400	μL	of	 ice-cold	PBS	(3%	BSA).	The	cells	
were	then	passed	through	a	cells	strainer	and	measured	with	a	BD	FACSCalibur™.		
5.2.15.2.	Quantification	of	CD4+	T	cells		
FACS	was	 used	 to	 identify	 CD4+	 T	 cells	 in	ex	 vivo-expanded	 cultures.	 Expanded	 cells	were	
collected	by	centrifugation	at	400	x	g	for	10	minutes,	washed	with	5	mL	of	PBS	(containing	
1%	BSA)	 resuspended	 in	 100	μL	 of	 PBS	 (containing	 1%	BSA)	 at	 a	 concentration	 of	 5	 x	 105	
cells/100	μL.	For	each	sample	to	be	analysed,	single	stains	(α-huCD4	PE-Cy5	or	α-huCD3-PE)	
and	double	stains	(α-huCD4	PE-Cy5	and	α-huCD3-PE)	were	performed,	with	unstained	cells	
serving	 as	 a	 negative	 control.	 Antibodies	 were	 used	 at	 the	 dilution	 suggested	 by	 the	
manufacturer.	Cells	were	incubated	for	1	hour	on	ice,	washed	thrice	with	1	mL	ice-cold	PBS	
(containing	1%	BSA)	and	resuspended	in	ice-cold	PBS	(containing	1%	BSA).	Cells	were	passed	
through	a	cells	strainer	and	analysed	with	a	FACSCalibur	device.		
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5.2.15.3.	Quantification	of	CD107a	expression	by	CD4+	T	cells	
LCLs	were	pulsed	overnight	with	AgAbs	(200	ng),	α-CD20	or	medium	(negative	control).	The	
next	day,	LCLs	were	washed	with	PBS	and	mixed	with	T	cells	at	an	E:T	ratio	of	3:1.	A	total	of	
8	 μL	 of	 α-CD107a-FITC	 (eBioH4A3)	 was	 immediately	 added	 to	 the	 T-cell-LCL	 mixture	 and	
incubated	 for	 8	 hours.	 Cells	were	 collected	 at	 400	 x	 g,	washed	 and	 3	 μL	 of	 α-CD4-PE-Cy5	
(RPA-T4)	and	3	μL	α-CD107a-FITC	(eBioH4A3)	was	added	to	cells	and	further	 incubated	for	
30	minutes.	Cells	were	washed	three	times	with	PBS,	resuspended	in	500	μL	of	PBS	(1%	BSA)	
and	analysed	by	flow	cytometry	with	a	FACSCalibur	device.	
5.2.15.4.	Infection	of	primary	B	cells	in	the	presence	of	EBNA1-	and	gp350-specific	T	
cells	
Primary	 B	 cells	were	 infected	 overnight	 using	 B95-8	 (MOI	 =	 10),	 washed	with	 RPMI	 1640	
without	additions	and	cocultured	with	EBNA1-	or	gp350-specific	T	cells	at	a	E:T	ratio	of	1:2	in	
T-cell	medium	supplemented	with	IL-2	(10U/mL).	B	cells	cultured	in	medium	alone	served	as	
a	positive	control	of	B	cell	outgrowth.	Cells	were	incubated	for	12	days	and	analysed	by	flow	
cytometry	for	the	presence	of	CD19+CD23+	double-positive	cells	by	staining	with	α-CD19-APC	
(HIB19	clone)	and	α-CD23-PE-Cy7	(EBVCS2	clone).		
5.2.15.5.	Infection	of	primary	B	cells	in	the	presence	of	DFEBV-EBNARI+RII-stimulated	
PBMCs	
Freshly	 isolated	PBMCs	were	 stimulated	 for	 two	 rounds	with	either	 gp350-AgAb	or	 DFEBV-
EBNA1RI+RII.	 Thereafter,	 primary	 B	 cells	were	 infected	with	 either	 B95-8	 (MOI	 =	 3)	 or	M81	
(MOI	=	30)	overnight.	Different	amounts	of	each	strain	were	used	for	infection	due	to	their	
different	transforming	abilities.	Infected	B	cells	were	cocultured	with	gp350-AgAb	or	DFEBV-
EBNA1RI+RII-stimulated	 PBMCs	 or	 CD19-PBMCs	 at	 an	 E:T	 ratio	 of	 1:1	 in	 T-cell	 medium	
supplemented	 with	 IL-2	 (10U/mL)	 for	 a	 total	 of	 15	 days.	 At	 day	 5,	 ex	 vivo	 cultures	 were	
analysed	by	immunofluorescence.	Cells	were	stained	with	α-CD20	(L26	clone),	α-EBNA2	(PE2	
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clone)	 and	DAPI	prior	 to	 immunofluorescence.	Cells	were	also	analysed	after	15	days,	but	
with	 flow	 cytometry	 instead	 of	 immunofluorescence.	 Cells	were	 stained	with	α-CD19-APC	
(HIB19	clone)	and	α-CD23-PE-Cy7	(EBVCS2	clone)	prior	to	flow	cytomteric	analysis.		
5.2.15.4.	Enzyme-linked	immunosorbent	assays	
5.2.15.4.1.	Interferon-γ	ELISA	
The	 human	 IFN-γ	 ELISA	 kit	 (HRP)	 from	Mabtech	was	 used	 for	 all	 interferon-γ	 based	 T-cell	
assays.	Stripwell	96	well	plates	(Sigma)	were	coated	overnight	with	100	μL	of	mAB	1-D1k	(2	
μg/ml)	 in	 PBS	 per	 well	 at	 room	 temperature.	 The	 following	 day,	 the	 96	 well	 plates	 were	
washed	 three	 times	 with	 300	 μL	 of	 PBS	 (0,05%	 Tween-20)	 per	 well	 using	 a	 HydroFlex	
microplate	 washer	 (Tecan).	 Throughout	 the	 duration	 of	 this	 protocol,	 all	 washes	 were	
carried	 out	 in	 the	 same	manner.	 The	washed	 plates	were	 blocked	 for	 two	 hours	 at	 room	
temperature	with	300	μL	of	PBS	(1%	BSA)	per	well.	Plates	were	washed	and	100	μL	of	cell	
culture	 supernatants	 (see	 section	 5.2.12.9)	 and	 IFN-γ	 standard	 (2-0.03	 ng)	was	 added	 per	
well.	Plates	were	incubated	at	room	temperature	for	2	hours,	washed	and	100	μL	of	mAb	7-
B6-1-biotin	(1	μg/ml)	in	PBS	(1%	BSA)	was	added	to	each	well.	Incubation	was	carried	out	at	
room	 temperature	 for	 2	hours.	 The	plates	were	washed,	 100	μL	 Streptavidin-HRP	 (1:1000	
dilution)	in	PBS	(1%	BSA)	was	added	to	each	well	and	plates	incubated	at	room	temperature,	
in	 the	 dark,	 for	 30	 minutes.	 The	 plates	 were	 washed	 and	 100	 μL	 of	 TMB	 substrate	 (BD	
Biosciences)	 was	 added	 to	 each	 well	 and	 incubated	 for	 a	 maximum	 of	 5	 minutes.	 The	
reaction	was	stopped	by	adding	50	μL	of	2M	H2SO4	to	each	well.	The	absorbance	of	each	well	
was	measured	at	450	nm	and	540	nm	in	a	MultiscanEx	microplate	reader	 (Thermo	Fischer	
Scientific).	Absorbance	values	measured	at	540	nm	were	subtracted	from	those	obtained	for	
450	nm.		
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5.2.15.4.2.	Granzyme	B	ELISA	
Granzyme	B	release	from	T	cells	was	measured	using	the	Granzyme	B	ELISA	kit	(HRP)	from	
Mabtech.	Stripwell	96	well	plates	(Sigma)	were	coated	overnight	with	100	μL	mAb	GB10	(2	
μg/ml)	 in	 PBS	 at	 room	 temperature.	 Plates	were	washed	 three	 times	with	 300	 μL	 of	 PBS	
(0.05%	 Tween	 20)	 using	 a	 HydroFlex	 microplate	 washer	 (Tecan).	 All	 washes	 within	 this	
protocol	 were	 carried	 out	 in	 this	 manner.	 Thereafter,	 plates	 were	 blocked	 at	 room	
temperature	with	300	μL	of	PBS	(1%	BSA)	for	two	hours.		Plates	were	washed	as	before	and	
100	μL	of	cell	culture	supernatant	or	Granzyme	standard	(10-0.3	ng)	 in	PBS	(containing	1%	
BSA)	 was	 added.	 Plates	 were	 incubated	 at	 room	 temperature	 for	 2	 hours,	 washed	 and	
incubated	at	room	temperature	with	100	μL	of	mAb	GB11-biotin	(1	μg/ml)	in	PBS	(1%	BSA)	
for	 an	 additional	 2	 hours.	 Washing	 was	 performed	 and	 plates	 were	 incubated	 at	 room	
temperature,	in	the	dark,	for	30	minutes	with	100	μL	of	Steptavadin-HRP	(1:1000	dilution)	in	
PBS	(1	%	BSA).	The	plates	were	washed	one	last	time	and	developed	as	detailed	in	section	
5.2.13.4.1.		
5.2.15.4.3.	IgG2a	ELISA		
An	 IgG2a	 ELISA	was	 used	 to	 quantify	 α-CD20	 and	 AgAbs.	 Stripwell	 96	well	 plates	 (Sigma)	
were	 coated	 overnight	 at	 room	 temperature	 with	 100	 μL	 (5	 μg/mL)	 of	 α-mouse	 IgG	
(Dianova)	 in	 PBS.	 Plates	 were	 washed	 three	 times	 with	 300	 μL	 of	 PBS	 (0.05%	 Tween	 20)	
using	a	HydroFlex	microplate	washer	(Tecan).	All	washes	in	this	protocol	were	conducted	in	
this	manner.	Blocking	was	performed	by	incubating	plates	with	300	μL	PBS		(1%	BSA)	for	two	
hours	at	room	temperature.	Plates	were	washed	and	incubated	with	100	μL	of	sample	and	
standard	 (4-0.0625	 ng/mL)	 for	 1	 hour	 at	 room	 temperature.	Washing	was	 performed	 and	
plates	were	 incubated	with	100	μL	of	α-mouse	 IgG-HRP	 (0.5	μg/mL)	 (Promega)	 in	PBS	 (1%	
BSA)	for	30	minutes.	Plates	were	washed	one	last	time	and	developed	as	detailed	in	section	
5.2.13.4.1.		
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5.2.16.	Experiments	with	humanised	NSG-A2	mice	
5.2.16.1.	Humanisation	of	NSG-A2	mice	
Mice	with	 reconstituted	 human	 immune	 system	 components	 serve	 as	 a	 powerful	 tool	 to	
study	 human-tropic	 pathogens	 such	 as	 EBV	 [154].	 In	 this	 study,	 NSG-A2	 mice	 (NOD.Cg-
PrkdcscidIl2rgtm1WjlTg	(HLA-A2.1)	1Enge/SzJ)	were	humanised	to	provide	a	model	for	studying	
the	 antigenicity	 of	 DFEBV	 in	 vivo.	 Newborn	 NSG-2A	 mice	 were	 irradiated	 with	 1	 Gy	 and	
injected	 intrahepatically	 with	 2	 x	 105	 CD34+	 hematopoietic	 progenitor	 cells	 (HPCs).	 The	
CD34+	 HPCs	were	 isolated	 from	 human	 fetal	 liver	 tissue	 (Advanced	 Bioscience	 Resources,	
USA)	using	a	human	CD34	MicroBead	kit	(Miltenyi	Biotec).	Humanisation	was	determined	12	
weeks	after	engraftment	by	assessing	the	presence	of	huCD45+	cells	in	the	peripheral	blood	
of	mice	via	flow	cytometry.		
5.2.16.2.	Vaccination	and	challenge	of	humanised	NSG-A2	mice	
In	total	20	Humanised	NSG-A2	(huNSG-A2)	mice	were	randomly	sorted	into	three	groups	so	
that	each	group	contained	similar	humanisation	percentages.	Thereafter,	mice	were	injected	
in	a	 single	blind	 fashion	with	PBS,	1	 x	106	particles	of	 DFEBV,	or	1	 x	106	particles	of	 DFEBV-
EBNA1RI+RII.	In	all	cases,	50	μg	of	poly	(I:C)	was	used	as	adjuvant.	Animals	were	boosted	one	
month	 after	 vaccination	using	 the	 same	 treatments	 and	 adjuvant.	One	 and	 a	 half	months	
after	 the	boost,	mice	were	 infected	 intraperitoneally	with	B95-8	 (1	 x	105	GRU).	Mice	were	
euthanised	after	8	weeks	and	their	spleen	and	blood	analysed	for	evidence	of	EBV	infection	
as	previously	described	[194].	
5.2.17.	Statistical	analysis	
A	two-tailed	student	T-test	was	performed	to	compare	the	ability	of	CD19-	PBMCs,	gp350-	or	
DFEBV-EBNA1RI+RII-specific	T	cells	to	control	B	cells	infected	with	B95-8	or	M81.	A	One-tailed	
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Chi-square	 test	was	used	 to	analyse	 the	 incidence	of	EBV	 infection	 in	humanised	mice.	All	
statistical	analyses	were	performed	using	GraphPad	Prism	6	software.		
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